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 1 
Abstract 
Chronic Obstructive Pulmonary Disease (COPD) is a chronic 
inflammatory disease involving both innate and adaptive 
immune responses. Abnormal numbers of inflammatory cells 
have been examined in COPD subjects, as well as the effects 
of cigarette smoking on immune cells and molecules. Killer 
cells, including CD8+ T cells, NKT-like cells and NK cells, are 
thought to play a role in the development of COPD through 
their cytotoxic functions. In this project, we report ex vivo, 
activation levels of these cell types in COPD patients, as well 
as effects induced by cigarette smoke extract in vitro.  
PBMCs were collected from healthy non-smokers (HNS), 
current healthy smokers (HS), current smokers with COPD 
(cuS-COPD) and ex-smokers with COPD (exS-COPD). 
Activation levels of interest and CSE effects on them were 
analysed by flow cytometry. 
Killer cells, including CD8+ T cells, NKT-like cells and NK cells, 
were significantly activated in current smokers with or without 
COPD compared to healthy non-smokers. Furthermore, KIR 
(CD158e1) expression was dramatically lower in smokers with 
or without COPD in comparison with healthy non-smokers. The 
cytotoxicity of CD8+ T cells from both current smokers and ex-
smokers with COPD patients were significantly less than that 
in healthy volunteers. Also, in vitro, CSE markedly decreased 
 2 
IL-15 treated NK cell activation in current smokers with COPD 
compared to other three groups. The expression of granzyme 
B was also significantly inhibited on IL-15 stimulated NK cells 
when CSE was added. 
We conclude systemic ex vivo killer cell activation is smoking 
rather than disease related. Cigrette smoking has 
immunosuppressive effects on killer cell activation and 
granzyme B expression in PBMCs from current smokers with 
COPD. 
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Introduction 
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1.1 Chronic Obstructive Pulmonary Disease 
1.1.1 Definition, Prevalence and Global burden 
COPD, as a common, preventable and treatable disease, is 
characterised as a chronic inflammatory disease causing 
airway limitation that is usually progressive but not completely 
reversible (Celli and MacNee, 2004). It is the fourth leading 
worldwide cause of morbidity and mortality, and is predicted 
to become the third most frequent burden of disease in the 
world by 2030, after heart disease and stroke (Rabe et al., 
2007). The estimated death rate of COPD shows geographical 
differences. In the US, according to updated statistics from 
the Centre for Disease Control (CDC), 0.04% of people died 
from COPD in 2009. Compared with the decreasing mortality 
in some diseases, such as heart disease and stroke, COPD is 
the only major disease with an increasing death rate. In 
European countries, mortality from COPD varies from 0.025% 
to 0.075% of the adult population. In Japan, the reported 
mortality from COPD is 0.04%, whereas nearly 1.3% of 
deaths result from COPD in China(Buist et al., 2007, Fukuchi 
et al., 2004, Halbert et al., 2006). Gender differences are also 
seen: morbidity from COPD is higher in men than in women in 
the UK (Soriano et al., 2000). Nevertheless, some studies 
indicate that the prevalence of COPD seems almost equal in 
men and women and that women are more susceptible to 
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COPD than men (Xu et al., 1994, Silverman et al., 2000). 
Medical costs of COPD are an economic burden in both 
developed countries and developing countries (Chapman et al., 
2006). There is a positive correlation between the severity of 
COPD and the cost of care (Jansson et al., 2002), although 
costs per patient for COPD are variable across countries due to 
how health care is provided and paid .  
 
1.1.2 Risk factors 
Prevalence estimates of the disorder show considerable 
variability across populations, suggesting that risk factors can 
affect populations differently. Although only 15% to 20% of 
smokers develop clinical COPD (Brown et al., 1994), cigarette 
smoking is still the common and key pathological driver in the 
development and progression of COPD (Burrows et al., 1977). 
The Fletcher curve (Figure 1.1) shows the importance of 
smoking cession in patients with COPD.  
 
Besides, other factors are involved. Genetic predisposition now 
also seems to play an important role in the development of 
COPD. 1-antitrypsin (AAT), a major circulating inhibitor of 
serine proteases, is the best established antiprotese 
associated with COPD (Hill et al., 1999, Ishii et al., 2000, 
Sandhaus, 2009, Zielinski and Kuca, 2004). It has been 
 6 
 
 
 
 
 
 
observed that AAT deficiency can lead to early onset 
emphysema in COPD patients (Ekeowa et al., 2009, Eriksson, 
1965, Ranes and Stoller, 2005, Strange, 2013). 
Metalloproteases, proinflammatory cytokines, various 
antioxidant enzymes and detoxifying enzymes are also linked 
to COPD (Wood and Stockley, 2006). Occupational exposure 
to biomass smoke, environmental pollution with noxious 
particles and gases, chronic asthma, history of pulmonary 
tuberculosis and poor socioeconomic status can all result in 
COPD (Balmes et al., 2003, Barker et al., 1991, Ezzati, 2005, 
Figure 1.1 Age-related decline in FEV1 with different smoking 
history. (Adapted from Fletcher et al. Definitions of emphysema, 
chronic bronchitis, asthma, and airflow obstruction: 25 years on from 
the Ciba symposium. Thorax 1984; 39: 81-85) 
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Orozco-Levi et al., 2006, Prescott and Vestbo, 1999, Viegi and 
Di Pede, 2002). These may explain why there are around one-
third of COPD patients who have never smoked (Salvi and 
Barnes, 2009).  
 
Cigarette Smoke 
Cigarette smoking has been implicated as an etiological risk 
factor resulting in various chronic diseases with high morbidity 
and mortality, including cancers, heart diseases, variety of 
infections and chronic lung diseases (Almirall et al., 1999, 
Arcavi and Benowitz, 2004, Sopori, 2002).  
 
The smoke from a cigarette contains thousands of chemicals 
which have various toxic, mutagenic and carcinogenic 
activities (Hoffmann and Wynder, 1986, Stedman, 1968). The 
concentrations of chemical ingredients also vary widely in the 
different cigarette brands. Studies show that various 
components of cigarette smoke can affect the immune 
response in different cell types (Lee et al., 2007b, McCue et 
al., 2000, Ouyang et al., 2000). Two major components of 
smoke that leads to many of deleterious effects are nicotine 
and tar (Hoffmann and Wynder, 1986, Stedman, 1968). Holt 
et al has shown that cigarette smoke containing high levels of 
tar and nicotine is more immunosuppressive than the smoke 
 8 
from low-tar low-nicotine cigarettes (Holt et al., 1976). 
However, effects of cigarette smoke on the immune system 
are biphasic, which is mainly determined by the components 
and duration of exposure. For example, unlike nicotine and tar, 
tobacco glycoprotein and metals present in cigarette smoke 
are generally immunostimulatory (Brooks et al., 1990, 
Francus et al., 1992).  
 
Previous studies have demonstrated that cigarette smoke 
causes structural and functional changes in the respiratory 
ciliary epithelium (Cantin et al., 2006, Mio et al., 1997, Wyatt 
et al., 1999), lung surfactant and immune cells (Mohan, 
2002a). In COPD patients, abnormal cell numbers of different 
cell types have been observed, including CD8+ T cells, alveolar 
macrophages, dendritic cells (DCs), neutrophils and NK cells in 
bronchoalveolar lavage (BAL) fluid, epithelium and adventitia 
of small airways, sputum or peripheral blood samples 
(O'Shaughnessy et al., 1997, Saetta et al., 1998, Baraldo et 
al., 2004, Barnes, 2004b, Demedts et al., 2007, Urbanowicz et 
al., 2009). Therefore, accumulating data suggested that 
chronic inhalation of cigarette smoke alters a wide range of 
immunologic function, including both innate and adaptive 
immune responses.   
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1.1.3 Systemic effects of COPD  
Studies have shown that COPD is associated with both 
pulmonary and systemic inflammation. Weight loss, skeletal 
muscle dysfunction, cardiovascular disease, cancer, nutritional 
abnormalities and other organ effects all contribute the high 
burden of COPD together with respiratory symptoms protein 
(Agusti, 2007, Gosker et al., 2000, Pryor and Stone, 1993, 
Schols et al., 1996, Skillrud et al., 1986, Van den Heuvel et al., 
1999), which result in a pronounced deterioration in health 
status of life.  
 
1.1.4 Comparison of COPD with asthma and tuberculosis  
COPD, asthma and tuberculosis (TB) are three main public 
health problems related to lung worldwide. Studies have 
shown that these diseases have common risk factors, such as 
cigarette smoking, low socioeconomic status and 
dysregulation of host defence functions. Also, they can co-
exist, which result in co-morbid conditons. Table 1.1 lists the 
common charasteristics and differences of among these 
diseases. 
 
1.1.5 Pathology of COPD 
Chronic obstructive bronchiolitis (swelling and inflammation of 
the lining of the airways that results in narrowing and  
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Table 1.1 Comparison of COPD with asthma and TB 
 
 
COPD Asthma TB 
Common Features 
 Pulmonary diseases 
 All carry a significant burden in terms of morbidity and mortality 
worldwide 
 Induce inflammatory responses 
Differences 
Epidemiology 
Worldwide prevalence; 
Not infectious 
 
High prevalence in the 
developed countries; 
Not infectious 
Over 95% of TB cases in 
developing countries; 
Infectious 
Patients group 
Mainly adults 40 years 
old 
Mainly young children Mainly young adults 
Symptoms 
Chronic cough ; 
Dyspnea; Large 
amounts of mucus 
production; Wheezing; 
Chest tightness 
 
Cough (specially at 
night); Wheezing; 
Shortness of breath; 
Chest tightness, pain or 
pressure; Fatigue 
 
Cough (usually cough up 
mucus); Coughing up 
blood; Fatigue; Fever; 
Excessive sweating, 
especially at night; 
Unintentional weight loss 
Burden of mortality 
The fourth leading 
worldwide cause of 
morbidity and mortality 
Most cases are managed 
at a primary care level. 
Second only to HIV/AIDS 
as the greatest  
infectious killer worldwide 
Disease development 
Airway limitation is not 
reversible; 
Have features of 
asthma 
Airway limitation is 
reversible;  
Co-exist with COPD 
 
Not all patients develop 
airway limitation;  
COPD as a sequel to 
active TB 
Immune cells mainly involved 
Neutrophils, 
macrophages, CD8+ T 
cells, NK cells and NKT 
cells; 
Both Th1 and Th2 cell-
induced immunity 
Eosinophils, CD4+ T cells; 
Mainly Th1 cells-mediated 
immunity 
CD4+ T cells play a 
crucial role; 
Mainly Th1 cell-induced 
immunity 
References 
(Sciurba, 2004) (Braman, 2006).. 
 
(Chakrabarti et al., 
2007) 
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obstruction of the airways), emphysema (permanent 
destructive enlargement of airspaces distal to the terminal 
bronchioles, caused by loss of lung elastic recoil) and mucus 
hypersecretion (productively coughing and bringing up sputum 
for >3 months for at least two consecutive years) are 
recognized as three distinct pathological features of most 
COPD patients (Barnes, 2000, Kim et al., 1991). They affect 
all parts of the lungs including parenchyma and airways and 
increase the resistance of the conducting airways and lung 
compliance. The severity of COPD is related to the remodelling 
of the small airways, especially of the terminal bronchioles 
including increased airway smooth muscle and goblet cell 
hyperplasia, submucosal gland hypertrophy and epithelial 
metaplasia (Hogg et al., 2004). 
 
1.1.6 Classification of COPD 
Currently, two staging systems have been applied to COPD. 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
has confirmed the classification of COPD with spirometry. 
According to the two values of the postbronchodilator 
spirometric measurement, namely, forced expiratory volume 
in one second (FEV1) and forced vital capacity (FVC), COPD is 
c la ss i f i ed  f rom s tage  0  to  s tage  I I I  (Tab le  1 .2 ) 
(www.goldcopd.org., 2011). However, COPD patients carry  
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Table 1.2 GOLD classification of COPD 
 
 
 
 
Stage Spirometry Symptoms 
0: At risk Normal spirometry 
 
Chronic symptoms 
(cough, sputum 
production) 
I: Mild 
COPD 
FEV1/FVC<70% 
 
FEV1 greater than or equal to 
80% predicted 
With or without 
chronic symptoms 
(cough, sputum 
production) 
II:Moderate 
COPD 
FEV1/FVC<70% 
 
FEV1 greater than or equal to 
30% to 80% predicted 
IIa: FEV1 greater than or equal 
to 50% to 80% predicted 
IIb: FEV1 greater than or equal 
to 30% to 50% predicted 
With or without 
chronic symptoms 
(cough, sputum 
production, dyspnea) 
III: Severe 
COPD 
 
FEV1/FVC<70% 
 
FEV1<30% predicted or FEV1<50% plus respiratory 
failure or clinical signs of right heart failure 
Respiratory failure: arterial partial pressure of oxygen<60mm Hg with or 
without arterial partial pressure of carbon dioxide greater than or equal 
to 50mm Hg while breathing air at sea level 
Source: The GOLD Workshop level 
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both physical impairment and mental burden related to their 
disease and its symptoms, such as anxiety and depression 
(Gudmundsson et al., 2005, Wagena et al., 2005); the 
classification of COPD based on GOLD stages is not sufficient 
for explaining those mental symptoms (Dahlen and Janson, 
2002, Hill et al., 2008, Celli et al., 2004). The BODE index 
(Body Mass-Index, Airflow Obstruction, Dyspnea and Exercise 
Capacity) is a multidimensional scoring system for COPD. It 
comprises an assessment of symptoms, a surrogate of the 
nutritional state, and exercise capacity together with the 
spirometric measure of airflow (FEV1) (Celli et al., 2004). It 
has been shown to be superior in predicting hospitalization 
and the mortality risk of COPD patients and better correlates 
to health status (Celli et al., 2004, Ong et al., 2005, Ong et al., 
2006). Table 1.3 shows the BODE index classification. 
 
To detect COPD early, the disease should be suspected when a 
patient has with chronic cough and sputum production and a 
history of COPD risk factors. 
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Table 1.3 BODE index for COPD  
BODE index point 
Variable 0 1 2 3 
FEV1% 
predicted 
≥65 50-64 36-49 ≤35 
Distance 
walked in 6 
minutes (m) 
 
≥349 
 
250-349 
 
150-249 
 
≤149 
MRC 
dyspnoea 
scale 
 
0-1 
 
2 
 
3 
 
4 
BMI (Kg/m2) >21 ≤21 
 
 
Modified MRC Dyspnoea Scale 
0. Breathless only with strenuous exercise 
1. Short of breath when hurrying on the level or walking up a slight hill 
2. Slower than most people of the same age on the level because of 
breathlessness or have to stop for breath when walking atown pace on 
the level 
3. Stop for breath after walking about 100 meters or after a few minutes 
at own pace on the level 
4. Too breathless to leave the house or breathless when dressing 
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1.2 Pathological hallmarks in COPD 
 
In the last decade, there have been many studies performed 
on bronchial biopsies, lung parenchyma and peripheral blood 
obtained from COPD patients compared with healthy non-
smokers and smokers with normal lung function. They provide 
new insights on the role of the different inflammatory and 
structural cells, mediators and signalling pathways, 
contributing to a better knowledge of the pathogenesis of 
COPD. Immunological cells, such as neutrophils, macrophages, 
DCs, T lymphocytes, epithelial cells, NK cells, NKT-like cells 
and so on, are mostly involved in the abnormal inflammatory 
response that occurs in COPD. These cells play different roles 
in producing structural changes in the airways including loss of 
respiratory bronchioles, alveolar ducts and alveoli, which 
further lead to smooth muscle hypertrophy, epithelial 
disruption, fibrosis, mucociliary dysfunction and lung 
destruction. This section summarizes how these immune cells 
work in COPD patients. 
 
1.2.1 Immune cells in COPD 
1.2.1.1 Neutrophils 
Neutrophils are the only cell type in mammals permitted to 
migrate to any part of the body (Nathan, 2006). As one of the 
front line defensive cells of the immune system, they 
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contribute to both tissue repair and tissue damage (Henson et 
al., 2006, Weiss, 1989). Once injury happens, activated 
neutrophils accumulate to infected tissues and release 
proteases, such as neutrophil elastase, cathepasin G, matrix 
metalloproteinases (MMPs), and reactive oxygen intermediate 
including superoxide, onzone, hydroxyl radical that contribute 
to tissue damage (Nathan, 2006). On the other hand, 
neutrophils produce destructive oxidizing agents and attempts 
at blocking neutrophil function that have resulted in 
significantly diminished early tissue destruction (Brickson et 
al., 2003). According to this unique capacity and without the 
serious side effects of increasing the host’s risk of infection 
(Nathan, 2002), targeting neutrophils can be considered as an 
anti-inflammatory therapeutic in many diseases. Neutrophils 
are also life-saving decision-markers that trigger and maintain 
an immune response by producing molecular signals. 
Generated signals can activate epithelial cells, macrophages, 
mast cells, endothelial cells, T cells, B cells, and also 
neutrophils themselves. For instance, tumour-necrosis factor 
(TNF) produced by neutrophils drives DC and macrophage 
differentiation and activation (Bennouna et al., 2003, van 
Gisbergen et al., 2005). TNF-related ligand B-lymphocyte 
stimulator (BLyS), also secreted by neutrophils, helps to elicit 
the proliferation and maturation of B cells (Scapini et al., 
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2005). Neutrophil activated pro-chemerin, such as chemerin, 
can attract both immature DCs and plasmacytoid DCs, and 
monocytes (Chertov et al., 1997, Wittamer et al., 2005). IL-
12 activated neutrophils produce IFN- that helps to drive T 
cell differentiation and macrophage activation (Ethuin et al., 
2004).  
 
There is a homeostatic feedback loop among neutrophils, 
macrophages and T cells regarding neutrophil production in 
the bone marrow. Granulocyte colony-stimulating factor (G-
CSF) is a necessary regulator of neutrophil proliferation and 
production. Its secretion is regulated by IL-17 produced by 
regulatory T cells. Extravascular macrophages release IL-23 
as the major factor governing IL-17 production. However, 
apoptosis of neutrophils by macrophage ingestion can 
suppress IL-23 production. 
 
Many acute and chronic lung diseases including asthma, COPD, 
bronchiectasis, cystic fibrosis, acute bronchitis, and lung 
cancer are associated with neutrophilic inflammation. There is 
abundant evidence showing neutrophils as primary effector 
cells in COPD (Barnes, 2007). Studies on BAL, sputum, 
bronchial epithelium and lamina proparia indicated that 
smokers with or without COPD have increased numbers of 
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activated neutrophils compared with non-smokers (Dragonieri 
et al., 2009, Janoff et al., 1983, Keatings et al., 1996, Lacoste 
et al., 1993, Pesci et al., 1998). However, neutrophil numbers 
are only higher in sputum, BAL and small airways than lung 
parenchyma large airways (Battaglia et al., 2007), which 
indicate rapid transit through the airways and parenchyma. 
Also, the percentage of sputum neutrophils was increased with 
GOLD stage in COPD patients (Singh et al., 2010).  
 
After maturation in the bone marrow, neutrophils are released 
into the circulation. When lung inflammation occurs, 
neutrophils migrate from the pulmonary circulation to 
postcapillary venules and adhere to endothelial cells in the 
alveolar wall before passing into the alveolar space (Hogg and 
Walker, 1995). The recruitment of neutrophils from bronchial 
circulation to the bronchial submucosa is coordinated by the 
interaction of adhesion molecules on the surface of neutrophils 
and proteins released by the bronchial endothelial cells. B2-
integrin (CD18) is a neutrophil adhesion molecule that 
facilitates neutrophil adhesion to endothelium via its 
endothelial counter receptor intercellular adhesion molecule 1 
(ICAM-1) (Diamond et al., 1990, Woolhouse et al., 2005). 
Increased expression of macrophage antigen (MAC)-1 
(CD11b/CD18) has been found in COPD patients (Noguera et 
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al., 1998). Also, IL-8, produced by neutrophils, monocytes, 
alveolar macrophages, pulmonary epithelium, smooth muscle 
airway cells, eosinophils and fibroblasts, can cause rapid 
mobilization of MAC-1 to the neutrophil surface (Huber et al., 
1991). Increased levels of IL-8 have been detected in BAL and 
sputum of patients with COPD (Donaldson et al., 2009, Pesci 
et al., 1998). E-selectin, which is essential to slow down the 
circulating neutrophils to increase neutrophilic uptake, is 
upregulated on endothelial cells in the airways of COPD 
patients (Di Stefano et al., 1994).  
 
Trafficking neutrophils into the respiratory tract from 
postcapillary venules is predominantly regulated by the 
epithelial cells that form a barrier lining the airway of the lung 
(Hogg and Walker, 1995). Chemotactic signals attract 
neutrophils accumulation near mucosal epithelial cells and in 
the lumen of the airway (Tanino et al., 2002, Traves et al., 
2002). These signals including IL-8 (Tanino et al., 2002), TNF-
(Higham et al., 2000), granulocyte-macrophage colony 
stimulating factor (GM-CSF) (Aaron et al., 2001), leukotriene 
B4 (LTB4) (Crooks et al., 2000), nuclear factor-B (NF-B) (Di 
Stefano et al., 2002), and ENA-78 (epithelial neutrophils 
activating protein of 78 kDa) (Papi et al., 2006b) have all been 
found increased in COPD airways. Above chemotactic factors 
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may derive from alveolar macrophages and epithelial cells, 
however, IL-8 and leukotriene B4 (LTB4) are also produced by 
neutrophils themselves (Profita et al., 2005). Recently, 
Blidberg and colleague have shown that chemotaxis of 
circulating neutrophils towards IL-8 and partly towards LTB4 
was increased in both smokers with or without COPD (Blidberg 
et al., 2012).  
 
In the respiratory tract of COPD patients, recruited neutrophils 
have been shown to infiltrate the airway epithelium and 
submucosal glands from the proximal to the distal part 
(Saetta et al., 1997), causing these cells to act as producers 
of potent secretagogues that result in mucus hypersecretion 
and emphysema (Damiano et al., 1986, Nadel, 1991). Also, 
increased numbers of neutrophils and CD8+ T cells infiltrate 
the smooth muscle in the peripheral airways of COPD patients 
compared to smokers and non-smokers, which affects the 
structure and contractility of airway smooth muscle, 
contributing to peripheral airways obstruction (Baraldo et al., 
2004).  
 
Activated neutrophils produce serine proteases including 
neutrophil elastase (NE), cathepsin G, proteinase-3, 
macrophage-derived matrix metalloproteinase (MMP)-8, MMP-
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9 and myeloperoxidase (MPO) (Borregaard et al., 2007), 
which promote the bronchial inflammation, alveolar 
destruction and also potent mucus stimulants (Ilumets et al., 
2008, Weiss, 1989). NE has been demonstrated in 
emphysematous tissue of COPD patients and there is a 
correlation between emphysema severity and elastase levels 
in peripheral blood neutrophils (Damiano et al., 1986, 
Galdston et al., 1977). Higher concentratioin of NE-specific 
fibrinogen degradation product A-Val has been observed in 
sputum in exacerbations of COPD compared to stable COPD 
patients (Carter et al., 2012). MMP-9 and MMP-12, which are 
secreted by macrophages, determine the neutrophils influx 
(Russell and Ley, 2002). They are also increased in COPD 
patients (Russell et al., 2002).  
 
Once neutrophils arrive in airways, they generate great 
amount of O2
- and reactive oxygen species (ROS), which are 
also produced by activated neutrophils, eosinophils, 
macrophages and epithelial cells in the airways of COPD 
patients (MacNee, 2001b). ROS can damage the epithelium, 
reduce ciliary beat frequency, stimulate mucus production by 
goblet cells, and increase the permeability of the bronchial 
mucosa (Rusznak et al., 1996). All of them lead to airway 
edema and protein exudation in the airway (Gompertz et al., 
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2001). Studies on systemic neutrophils have shown that there 
is an increase in ROS production in COPD patients compared 
to healthy smokers and healthy nonsmokers (Gustafsson et al., 
2000, Rahman et al., 1996).  
 
Apoptosis of neutrophils is the way to terminate inflammation 
and further prevent any permanent damage. During apoptosis, 
neutrophils lose their ability to produce granule contents and 
undertake phagocytosis (Haslett, 1999). Mucociliary escalator 
can also remove activated neutrophils if apoptosis is not 
efficiently performed. However, this removal leads to the 
production of proteases and chemoattractants that 
continuously destroy the lung tissue (Nathan, 2006). 
Increased levels of chemotactic factors, such as IL-8, LTB4 
and GM-CSF, have shown their capacities of delaying 
neutrophils apoptosis in COPD patents, which leads to 
secondary necrosis and increases inflammation (Haslett, 
1999). Also, delayed apoptosis by neutrophils from COPD 
patients is related to the expression of bak, bcl-xl and mcl-1 
mRNA (Zhang et al., 2012). Interestingly, reduced 
spontaneous apoptosis only occurs at exacerbation but not 
stable COPD patients (Pletz et al., 2004). 
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In contrast to T lymphocytes, particularly CD8+ T cells, and 
macrophages that are predominant inflammatory cells in the 
lung of patients with mild COPD, neutrophils is more potent in 
severe COPD patients (Di Stefano et al., 2004). Studies on 
BAL and sputum from COPD patients indicate that the 
concentration of neutrophils is positively correlated with 
airflow limitation (Di Stefano et al., 1998, Stanescu et al., 
1996). It has also been found that there are increased 
numbers of neutrophils in bronchial biopsy specimens and 
peripheral blood during COPD exacerbations (Papi et al., 
2006a, Saetta et al., 1994, Zhu et al., 2001). Furthermore, 
the percentage of apoptotic blood neutrophils at COPD 
exacerbations is reduced (Schmidt-Ioanas et al., 2006).  
 
To sum up, neutrophils play an important role in the pathology 
in COPD, especially at exacerbations. Modulation of neutrophil 
recruitment and apoptosis in the lungs of patients with COPD 
may provide potential targets of this disease. 
 
1.2.1.2 Dendritic Cells (DCs) 
DCs are potent antigen-presenting cells (APCs) and play a 
crucial role in the initiation of adaptive immune responses 
(Banchereau et al., 2000). The first defined pulmonary DCs 
were Langerhans cells (LCs). They are now recognized by their 
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immunohistochemical expression of CD1a, langerin (CD207) 
and by electron microscopy the presence of Birbeck granules 
(Sertl et al., 1986). Recently, three phenotypically and 
functionally different pulmonary DC subsets have been 
classified including type 1 myeloid DCs (mDCs, BDCA1, 
CD1c+), type 2 myeloid DCs (mDCs BDCA3, CD141+) and 
plasmacytoid DCs (pDCs, BDCA2, CD303+/CD123+). Myeloid 
and plasmacytoid DCs perform different functions in both 
innate and adaptive immunity. They have functional plasticity 
to induce one of three T-cell responses depending on the type 
of stimuli, including Th1, Th2, or regulatory T (Treg) cells 
(Vermaelen and Pauwels, 2005).  
 
The role of DCs in the pathogenesis of asthma has been well 
studied (Lambrecht and Hammad, 2003). However, studies on 
the involvement of DCs in the development of smokers with 
COPD are fairly rare. In vitro human studies indicate that DC 
maturation, their capacity to secrete cytokines and expression 
of adhesion molecules are affected by nicotine. Mahyar and his 
colleagues have shown that in a nicotinic environment 
(200ug/ml), both endocytic and phagocytic abilities of 
monocyte-derived DCs are reduced. Nicotine has no effects on 
DC maturation in response to bacterial antigen 
lipopolysaccharide (LPS). Nevertheless, they secrete 
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dramatically lower levels of pro-inflammatory cytokines, such 
as IL-12, IL-10, and TNF-. IL-12 is a principal cytokine that 
bridges innate and specific immune response by activation of 
NK and T cells and biases the differentiation of CD4 T cells 
towards IFN--producing Th1 cells (Macatonia et al., 1995). 
Low level production of IL-12 by nicotine treated DCs indicates 
that in a nicotinic environment, the ability of DCs to prime 
type 1 T-cell polarization is diminished. Moreover, T cells co-
cultured with DCs in the presence of nicotine produced 
significantly lower levels of IFN- than in the absence of 
nicotine (Nouri-Shirazi and Guinet, 2003). Another study 
performed by Alexandra et al has shown that nicotine 
increases the DC expression of adhesion molecules such as 
the 2-intergrin lymphocyte function-associated antigen 1 
(LFA-1, CD11aCD18) and its ligand CD54 (ICAM-1). 
Furthermore, the expression of HLA-DR and the DC 
maturation marker CD83 are also increased in the presence of 
nicotine (Aicher et al., 2003).  
 
In vivo human studies, the number of CD1a+ immature DCs 
were increased in the alveoli and in the BAL of smokers 
compared to non-smokers (Casolaro et al., 1988, Soler et al., 
1989). However, unlike the airway epithelium that contains 
exclusive CD1a+ DCs, there are normally relatively few CD1a+ 
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DCs in human alveoli and BAL (Demedts et al., 2005). In 
COPD patients, the number of langerin (CD207+) immature 
LCs in the epithelium and the adventitia of small airways is 
significantly higher compared to never smokers and 
asymptomatic smokers. This accumulation of DCs is positively 
correlated to the disease severity. Nevertheless, there is no 
significant difference in DC numbers in the epithelial layers 
between current smokers with COPD and ex-smokers with 
COPD. Also, there is no difference in DC numbers in the 
lamina propria among groups (Demedts et al., 2007).. 
Recently, abnormal numbers of DCs subsets were detected in 
PBMCs from COPD patients. The absolute number of pDCs was 
significantly reduced along with a marked increase of the 
mDC/pDC ratio in COPD patients comparied to non-smokers 
(Malta et al., 2013).  
 
CCL20 (also known as MIP3) is a chemokine that attracts 
DCs toward sites of inflammation via interaction with its 
receptor CCR6 (Reibman et al., 2003). Its mRNA expression is 
significantly higher in lung tissue from COPD patients 
compared to healthy non-smokers and healthy smokers. There 
is an inverse correlation between the FEV1% and CCL20 mRNA 
expression. Nevertheless, there is no significant difference in 
CCR6 mRNA expression in lung tissue between controls and 
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COPD patients. Similar results have also been found in sputum 
samples (Demedts et al., 2007). In large airways, current 
smoking appears to markedly reduce the number of DCs both 
in the bronchial mucosa and in induced sputum (Reibman et 
al., 2003). Expression of receptors for antigen recognition, for 
example, BDCA-1 or Langerin, are significantly increased in 
mDCs from current smokers with COPD but also markedly 
decreased in mDCs from ex-smokers with COPD, compared 
with non-smokers (Stoll et al., 2014). 
 
Overall, investigations on DCs in the pathogenesis of COPD 
indicate that chronic exposure to cigarette smoking impairs 
the normal maturation process of DCs and subsequently alters 
their normal function and interaction with naive lymphocytes, 
leading to an imbalance of immunity that may increase 
susceptibility of patients with COPD to respiratory infections. 
 
1.2.1.3 Macrophages 
Monocytes, DCs and macrophages, along with neutrophils and 
mast cells, are all phagocytic cells that are strategically 
located throughout the body’s tissues, where they ingest and 
process foreign molecules, apoptose cells and debris, 
maintaining homeostasis, as well as producing multiple 
mediators to recruit other immune cells (Erwig and Henson, 
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2008, Mantovani et al., 1972). Macrophages account for the 
majority of inflammatory cells recovered by airway lavage, 
regardless of subject status, such as whether or not they are 
smokers or suffering from airway diseases (Kuschner et al., 
1996, Linden et al., 1993). Studies on macrophages have 
shown that macrophages play a potent role in the 
pathophysiology of COPD (Barnes, 2004a, Shapiro, 1999).  
 
Numbers of macrophages in BAL fluid, sputum, small airway 
epithelium, lung parenchyma, bronchial submucosal and 
bronchial glands are all increased in COPD patients (Barnes, 
2004d, Saetta et al., 1993, Saetta et al., 1997, Wallace et al., 
1992). In particular, compared to healthy smokers, the 
number of macrophages is significantly increased by up to 25-
fold in the alveolar spaces and tissue in patients with 
emphysema (Wallace et al., 1992). Also, there is a positive 
correlation between macrophage numbers in the alveolar walls 
and the presence of mild-to-moderate emphysema as well as 
the degree of small airways disease in COPD patients (Di 
Stefano et al., 1998, Finkelstein et al., 1995, Meshi et al., 
2002). 
 
Increased recruitment of monocytes from the circulation in 
response to monocyte-selective chemokines may be one of 
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the reasons to account for the increased numbers of 
macrophages in the lungs of smokers and patients with COPD. 
Expression of C-C chemokine receptor 2 (CCR2) is thought to 
be particularly important for macrophage differentiation and 
recruitment to the airways (Lee et al., 1999), which is 1.4-fold 
higher levels in macrophages in COPD patients compared to 
subjects without COPD. Macrophages have a very low 
proliferation rate in the lungs, however, increased proliferation 
has been reported to be responsible for the increased 
numbers of macrophages detected in smokers (de Boer et al., 
2000, Barbers et al., 1991, Bitterman et al., 1984). The life 
span of tissue macropahges ranges from 6 to 16 days. Tissue 
macrophages are renewed by local proliferation of progenitor 
cells rather than by monocyte influx into tissue (Sawyer, 1986, 
Tarling et al., 1987). This feature protects patients from an 
overwhelming risk of fatal infection when neutrophil 
production is transiently interrupted. Particles from cigarette 
smoke can be found within the cytoplasm of alveolar 
macrophages in smokers for more than two years after 
smoking cessation (Marques et al., 1997). Therefore, smoking 
may contribute to the prolonged cellular activation of 
macrophages.  In smokers and patients with COPD, markedly 
increased expression of the anti-apoptotic protein Bcl-XL and 
expression of cyclin-dependent kinase inhibitor p21CIP/WAF1 in 
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the cytoplasm are detected in macrophages (Tomita et al., 
2002). These findings suggest that apoptosis of alveolar 
macrophages may be defective in smokers and in COPD 
patients, which may be another explanation for the 
accumulation of macrophages in the lung. In COPD patients 
and healthy smokers, the expression of apoptosis inhibitor of 
macrophages in alveolar macrophages is significantly 
increased in the lung of COPD patients and healthy smokers. 
Likewise, apoptosis inhibitor of macrophages expression was 
enhanced in response to CSE exposure (Kojima et al., 2013).  
 
Macrophages tend to display polarized phenotypes by which 
they can be divided into two major subpopulations, namely, 
M1 and M2. M1 are classically activated macrophages that 
exhibit pro-inflammatory properties. These cells play 
important effector functions including the production of 
reactive nitrogen species and they secrete high amounts of 
pro-inflammatory cytokines, such as TNF-, IL-12 and IL-1 
that regulate antigen presentation to T cells and promote Th1 
immunity. In contrast, M2 macrophages have poor antigen 
presenting capacity but a better clearance of apoptotic cells. 
They produce anti-inflammatory cytokines, such as IL-10 and 
TGF-. Mannose receptor (CD206) and the scavenger receptor 
CD163 are two representative markers to distinguish M1 and 
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M2. In vitro, GM-CSF can generate M1 macrophages whereas 
M-CSF can activate M2 macrophages from human peripheral 
blood monocytes (Murray and Wynn, 2011, Verreck et al., 
2006). In the lung, alveolar macrophages predominantly show 
anti-inflammatory M2 features that have highly phagocytic 
capacity (Blumenthal et al., 2001, Van den Heuvel et al., 
1999). Figure 1.2 shows the macrophage polarization and 
their features.  
 
 
 
 
 
 
 
 
 
Figure 1.2 Macrophage polarizations. Diversity and plasticity are two 
hallmarks of macrophages. M1 macrophages (classically activated 
macrophages) are pro-inflammatory and have a central role in host 
defense against infection, while M2 macrophages (alternatively activated 
macrophages) are associated with responses to anti-inflammatory 
reactions and tissue remodeling, and they represent two terminals of the 
full spectrum of macrophage activation.  Adapted from: M.C. Schmid & 
J.A. Varner, J Oncol. 2010:201026 
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Decreased phagocytosis of alveolar macrophages has been 
detected in smokers with COPD and smoking cession 
contributes to improvement (Berenson et al., 2006, Hodge et 
al., 2007, Taylor et al., 2010). This finding suggests that there 
may be a regulation of macrophage polarization in COPD 
patients. Kunz and colleagues recently showed that the 
percentage of macrophages with M2 characteristics is 
markedly higher in BAL from ex-smokers with COPD compared 
to current smoking COPD patients. Also, the percentage of M2 
in BAL is higher than in induced sputum, which indicates that 
the M2 macrophage subpopulation is mainly present in the 
periphery of the lung. In addition, there is no significant 
difference in the percentage and number of M2 macrophages 
in BAL between ex-smokers and current smokers suffering 
from COPD. Although there are other studies to show the shift 
of macrophage polarization in COPD (Kunz et al., 2011, 
Frankenberger et al., 2004, Hogger et al., 1998, Kollert et al., 
2009), disease severity may be a possible explanation for 
these controversial findings. Impaired phagocytosis of alveolar 
macrophages for Haemophilus influenzae and Moraxella 
catarrhalis has been detected to be correlated with the 
severity of COPD (FEV1% predicted) in COPD patients 
(Berenson et al., 2013). Moreover, Metcalfe and colleague 
showed that cigaretter smoke extract significantly reduced 
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innate immune response of alveolar macrophages from COPD 
patients (Metcalfe et al., 2014).  
 
Macrophages induce mucus hypersecretion and lung 
emphysema via production of LTB4, IL-1 and matrix 
metalloprotease enzymes (MMPS). In vitro, alveolar 
macrophages from COPD patients express increased levels of 
MMP-1 and MMP-9 (Finlay et al., 1997a, Segura-Valdez et al., 
2000), and, in vivo, expression of MMP-2, MMP-9 and MMP-12 
are enhanced in COPD patients (Molet et al., 2005, Montano et 
al., 2004).  
 
1.2.1.4 T cells 
T cells in the lung make up a significant proportion of the total 
T cell population of the body (Pabst and Tschernig, 1995). 
They are derived from the progenitor cells that begin 
recombination of four gene segments, namely,  and , or  
and , which build up the T cell receptor (TCR) genes (La 
Motte-Mohs et al., 2005, Lauritsen et al., 2006). The TCR is 
composed of two disulfide-linked chains, either  or . TCR-
/ cells comprise 95% of the T cell population and regulate 
the immune response by production of cytokines and 
chemokines. TCR-/ cells play key functions in mucosal 
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homeostasis and in response to tissue damage at the 
epithelial surface (Jameson et al., 2003). 
 
/ T cells 
Cytotoxic T cells (Tc cells, CD8+) and helper T cells (Th cells, 
CD4+) are  T cell subsets. Tc cells consist of 30-40% of the 
total / T cell population and recognize intracellular antigens, 
such as viral or tumour proteins, presented by MHC class I 
molecules. Th cells constitute 60-70% of the total / T cells 
and recognize extracellular antigens, such as bacterial 
peptides, presented by MHC class II molecules (Alam and 
Gorska, 2003, Parkin and Cohen, 2001). The predominant 
function of Tc cells is to kill infected cells via producing 
cytokines such as IFN- and toxic molecules like perforin and 
granzymes (Henkart, 1985, Zagury, 1982). Perforin is a pore-
forming protein that helps granule proteins of Tc cells to be 
transported into target cells (Froelich et al., 1996, Shresta et 
al., 1999). Granzymes and T-cell intra-cytoplasmic antigen-1 
(TLA-1) are two main Tc granule proteins that have the 
capacity to activate caspase mediated DNA fragmentation 
resulting in apoptosis of the target cells (Kojima et al., 1994). 
In addition, binding of Fas-ligand presented by Tc cells to Fas 
expressed by target cells can also induce apoptosis of infected 
cells (Nagata and Golstein, 1995). Th cells are coordinating 
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cells of the immune response. They play a major part in 
activation of B cells. 
 
Tc cells include two subsets, namely, Tc1 cells and Tc2 cells. 
Tc1 cells produce IFN- whereas Tc2 cells release IL-4 and IL-
5 (Mosmann et al., 1997). Th cells are also divided into two 
main groups, namely, Th1 cells and Th2 cells. Th1 subset 
secretes IL-2 and IFN- and is associated with cell-mediated 
functions, such as activating Tc cells and delayed 
hypersensitivity. Although both Th1 and Th2 subset can 
activate B cells and induce antibody production, the main 
difference is in the profile of isotype switching- Th1 induce 
mainly IgG1-3; Th2 induce IgG1-4, IgG3 and IgG A (Mosmann 
et al., 1997).  
 
Besides CD8+ cytotoxic T cells and CD4+ helper T cells, Treg 
cells are a special subpopulation of T cells with the major 
function of suppressing activation of the immune system by 
producing suppressor molecules, such as IL-10 or TGF- 
(Cederbom et al., 2000, Liu et al., 2003).. CD4+ cells 
expressing high levels of CD25 (CD25 bright) are thought to 
be Treg cells that represent between 1 and 3% of total CD4+ T 
cells (Dejaco et al., 2006). Besides CD4 and CD25, FoxP3 is 
mostly restricted to CD4+ Treg cells, although some CD8+ T 
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cells do express it (Fontenot and Rudensky, 2004, Tang and 
Bluestone, 2008). Recently, CD127 has been identified as a 
unique cell surface marker for Treg cells (Liu et al., 2006, 
Shen et al., 2009). In particular, CD127dim has been shown to 
be a specific marker for Treg cells, whereas CD127bright is 
expressed by non-regulatory T cells. 
 
/ T cells 
/T cells are preferentially associated with epithelial tissue. 
They are abundant in the gastrointestinal mucosa and skin, 
which have a potent role in epithelial repair.  Unlike / T cells, 
/T cells do not recognize antigen as peptides presented by 
MHC molecules. They directly distinguish a great amount of 
diverse antigens, such as the non-classcial MHC class I 
molecules T10 and T22, without clonal expression (Hayday 
and Tigelaar, 2003, Holtmeier and Kabelitz, 2005). 
 
In 1995, Finkelstein et al showed an increase of CD3+ T cells 
in the lung parenchyma in smokers and there was a positive 
correlation between the number of T cells of the lung tissue 
and the extent of emphysema (Finkelstein et al., 1995). 
Further studies have also shown that numbers of CD4+ T cells 
and CD8+ T cells are both increased in the lung parenchyma 
and airways in COPD patients compared to asymptomatic 
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smokers and healthy non-smokers, with a predominance of 
CD8+ T cells. This is in contrast to the findings in asthma, in 
which the predominantly increased cells are CD4+ T cells and 
eosinophils. Abnormal numbers of CD8+ T cells in smokers 
with COPD is not tissue specific. They are detectable in 
different tissue compartments, such as large airways sub-
epithelium (Lams et al., 2000, O'Shaughnessy et al., 1997), 
peripheral airway (Saetta et al., 1998), parenchyma (Saetta 
et al., 1999), smooth muscle (Baraldo et al., 2004), bronchial 
arteries (Peinado et al., 1999, Saetta et al., 1999, Turato et 
al., 2002), peripheral blood (Urbanowicz et al., 2009), sputum 
samples (Urbanowicz et al., 2010), and small airways such as 
BAL (Saetta et al., 2003, Saetta et al., 2002). Some studies 
demonstrate the correlation between the number of CD8+ T 
cells and lung function (Di Stefano et al., 2001, 
O'Shaughnessy et al., 1997, Turato et al., 2002). However, 
recently one study demonstrated that the distribution of T-cell 
subsets in BAL of patients with mild to moderate COPD is 
smoking pe se but not correlated with airway obstruction 
(Forsslund et al., 2014). Smokers with or without COPD show 
higher percentages of CD8+ T cells and NKT-like cells than 
those never smokers and ex-smokers with COPD. Altough toll-
like receptors (TLRs) are expressed at low levels in the lung 
tissue, the percentage of CD8+ T cells expressing TLRs 
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including TLR1, 2, 4, 6 and 2/1 is significantly elevated in 
smokers with COPD compared to smokers with normal lung 
functions (Freeman et al., 2013). Activated CD8+ T cells in 
COPD secrete Th1 predominant cytokine pattern that includes 
increased production of IFN-, interferon-inducible protein-10 
(IP-10), and monokine induced by interferon-gamma (MIG). 
In turn, these mediators can cause tissue destruction through 
the up-regulation of MMP production by macrophages and 
other immune cells (Grumelli et al., 2004, Maeno et al., 2007). 
Enzymes released by CD8+ T cells, such as granzymes and 
perforin, as well as binding of Fas-ligand to Fas between CD8+ 
T cells and target cells, can also cause cell apoptosis (Henkart, 
1994, Kojima et al., 1994). 
 
Although studies of CD4+ T cells are less extensive than CD8+ 
T cell infiltrates, CD4+ T cells have also been shown to be 
increased in airways, lung parenchyma and peripheral blood in 
COPD patients (O'Shaughnessy et al., 1997, Saetta et al., 
1999), particularly in proximity to bronchus associated 
lymphoid tissue (Hogg et al., 2004). Decreased number of 
CD4+ helper T cells is detectable in BAL from smokers with or 
without COPD in comparion with non-smoking participants 
(Forsslund et al., 2014). CD4+ helper T cells are mainly 
responsible for orchestrating downstream immune process by 
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producing cytokines. They are essential for the full 
development of adaptive immune cytotoxicity by priming and 
promoting the long-term survival of CD8+ T cells. They also 
help activation and differentiation of antibody elaborating B-
cells (Wan, 2010).  
 
Treg cells (CD4+CD25+ T cells) are a subpopulation of CD4+ T 
lymphoctyes with significant anti-inflammatory and 
immunomodulatory effects (Bluestone and Tang, 2005, Jiang 
and Chess, 2006). Recently, more studies have shown 
interests in the Treg cells in the pathogenesis of COPD. 
However, the findings are conflicting. Smyth et al 
demonstrated the up-regulation of Treg cells in BAL fluid in 
healthy smokers and COPD patients, compared to healthy 
non-smokers, and there is a positive correlation between 
FoxP3 expression and the number of pack-years (Smyth et al., 
2007). Nevertheless, Barcelo et al found increased levels of 
Treg cells only in BAL from smokers but not in COPD patients 
and healthy non-smoking participants. Also, the number of 
Treg cells were higher in BAL than in the peripheral blood in 
the three groups of individuals studied (Barcelo et al., 2008). 
Human Treg cells are classifed into three subsets including 
CD25(++)CD45RA(+) resting Tregs (rTregs), 
CD25(+++)CD45RA(-) activated Tregs (aTregs), which play 
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suppressive functions, and CD25(++)CD45RA(-) cytokine 
secreting (Fr III) cells. Decreased proportions of rTregs and 
aTregs, and increased proportion of F III cells among CD4+ T 
cells were found in COPD compared to normal smokers (Hou 
et al., 2013).  
 
/ T cells play a potent role in tissue repair and mucosal 
homeostasis. However, only a few studies address the 
potential role of / T cells in COPD. Richmond et al showed 
the number of / T cells was increased in the bronchial glands 
of healthy smokers compared to healthy non-smokers 
(Richmond et al., 1993). Likewise Majo et al also found 
increased / T cells in the lung parenchyma of healthy 
smokers (Majo et al., 2001). Recently, two studies both 
confirmed that the number of / T cells are also increased in 
both peripheral blood and BAL fluid from healthy smokers, 
compared to COPD patients and healthy non-smokers, 
particularly in BAL (Ekberg-Jansson et al., 2000, Pons et al., 
2005). Also, current smokers with normal lung function 
showed a significant up-regulation of / T cells compared to 
ex-smokers with normal lung function (Pons et al., 2005). 
Importantly, the active smoking inducing up-regulation of / 
T cells was blunted in current smokers with COPD, which 
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indicates the capacity for tissue repair involving / T cells 
might be postponed in COPD patients. 
 
Cytokines, chemokines and enzymes producing by T cells 
perform different roles in cell recruitment, cell activation, cell 
differentiation as well as killing infected cells. Molecular 
mechanisms of these molecules in COPD will be demonstrated 
individually in later sections. 
 
1.2.1.5 NKT cells 
NKT cells share receptor structure and function with both T 
cells and NK cells (Kronenberg and Gapin, 2002). They 
express T cell membrane proteins, such as CD3, CD4 and CD8, 
as well as NK cell markers including CD56, CD161 and 
inhibitory natural killer cell receptors (Emoto and Kaufmann, 
2003). The most widely studied subset of NKT cells is 
invariant NKT (iNKT), which express both an invariant TCR 
consisting of the -chain (V24/JQ in humans and 
V14/J281 in mice) paired with a -chain (V11 in human 
and V2, V7 or V8 in mice) and NK cells markers, such as 
NK1.1 and Ly-49 (Berzins et al., 2004, Stenstrom et al., 2004). 
The unique invariant TCR of NKT cells recognizes glycolipid 
antigens, such as the synthetic glycolipids -
galactosylceramide (-Galcer) and the endogenous 
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isoglobotrihexosylceramide (iGb3) by interaction with the MHC 
class I-like molecule CD1d presented by antigen presenting 
cells (Burdin and Kronenberg, 1999, Crowe et al., 2003, Zhou 
et al., 2004). However, recognition of CD1d by NKT cells 
appears to be tissue specific (Hong et al., 1999).-Galcers 
has stronger immunostimulatory activities and has been used 
as a powerful tool for analyzing NKT cell function in vivo 
because conventional T cells do not recognize this molecule 
(Crowe et al., 2003). There is an overwhelming body of 
evidence showing that most NKT cells are thymus-dependent, 
however, some argue for an extrathymic origin (Bendelac, 
1995, Bendelac et al., 1997, Crowe et al., 2003, MacDonald, 
1995). 
 
In humans, most studies on NKT cells have been limited in 
peripheral blood. However, one study has shown that NKT 
cells are clearly detectable in human liver at approximately 
4% of hepatic T cells (Doherty et al., 1999). Recently, it has 
been shown that iNKT cells are found in low numbers in the 
BAL fluid (less than 2% of total CD3+ T cells), induced-sputum 
(less than 1.3% of CD3+ T cells) and bronchial biopsy (less 
than 1.7% of CD3+ T cells) in subjects with mild or moderately 
severe asthma, subjects with stable or exacerbated COPD and 
healthy volunteers (Vijayanand et al., 2007). Furthermore, 
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there are no significant differences among those three groups. 
The distribution of NKT cells in other human tissues remains to 
be determined. 
 
According to the expression of CD4 or CD8 surface molecules 
on NKT cells, they are classified into three subpopulations, 
namely, CD4+CD8- NKT cells (CD4 NKT cells), CD4-CD8+ NKT 
cells (CD8 NKT cells) and CD4-CD8- NKT cells (DN NKT cells). 
Recent studies have highlighted the distinct Th1- and Th2- 
type cytokine profiles of these subsets of NKT cells (Gumperz 
et al., 2002, Takahashi et al., 2002, Takahashi et al., 2000). 
Upon stimulation, the CD4 NKT cells produce Th1 cytokines 
(e.g. IFN-) and Th2 type cytokines (e.g. IL-4), plus IL-2, IL-
10 and granulocyte-macrophage colony-stimulating factor 
(GM-CSF). By contrast, CD8 NKT cells and DN NKT cells 
predominantly secrete Th1 cytokines (e.g. IFN-) but not IL-2, 
GM-CSF or Th2 cytokines (Kim et al., 2002, Lee et al., 2002). 
The different cytokine production of NKT cell subpopulations 
has different actions on immune effector cells in adaptive 
immune responses. For example, CD4 NKT cells induce the 
greatest activation of NK cells, CD4+ T cells and B cells but 
have no effect on CD8+ T cells. These observed stimulatory 
activities might be involved in both Th1- and Th2-type 
immunity. Compared with the other two NKT cell subsets, CD8 
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NKT cells have substantially greater stimulatory activities on 
CD8+ T cells while producing less IFN-. 
 
One of the interesting features of the NKT cells is its 
paradoxical function in different diseases including 
malignancies and autoimmune dysfunctions. It is hard to 
conclude which kind of NKT cell subset performs more 
important roles in immune response. This is dependent on the 
distribution of NKT cell subsets in different tissues. For 
example, DN NKT cells are at greater frequency than CD4 NKT 
cells and CD8 NKT cells in human liver (Kenna et al., 2003). 
Moreover, activation of NKT cells can be either beneficial or 
detrimental (Duarte et al., 2004, Kikuchi et al., 2001, Kim et 
al., 2005, Sharif et al., 2002, Terabe et al., 2000). Previous 
studies have raised the prospect of manipulating NKT cells for 
therapeutic benefits (Parekh et al., 2004, Yu et al., 2005). 
Phase I cancer clinical trials revealed that soluble -GalCer 
treatment is safe, but exerts moderate immunostimulatory 
effects (Major et al., 2004, Nakai et al., 2004, Tupin et al., 
2004). Depending on differences in cytokine profiles in NKT 
cell subsets, non-selective activation of all NKT cell subsets 
could likely result in unexpected immunological outcomes for 
the intended therapeutic use. This suggests that clinical trials 
to develop the therapeutic potential of NKT cells should 
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probably utilize strategies that activate or bias toward specific 
NKT cell subpopulations rather than the whole NKT cell 
population. For examples, the numbers of NKT cells were 
reduced significantly in smokers with COPD compared with 
non-smoking healthy volunteers and healthy smokers whereas 
the relative proportion of CD8+ NKT cells was increase in 
peripheral blood from COPD patients (Urbanowicz et al., 2009).  
 
In addition, cytokine release by NKT cells is always rapid and 
transient, with a peak of activity within 24 hours. After 24 
hours, the production of these cytokines, for example IFN-, 
quickly returns to baseline levels (Lin et al., 2006). Thus, the 
timing of activation of NKT cells is also an important factor to 
achieve therapeutic efficacy. 
 
Besides cytokine production, NKT cells also exhibit potent 
cytotoxic functions. They can induce cell apoptosis by 
constitutively expressing Fas-L that interacts with Fas+ target 
cells (Arase et al., 1994). They also kill tumor targets in a 
perforin-dependent manner (Smyth et al., 2000). 
 
The capacity of rapidly producing high levels of 
immunoregulatory cytokines may allow NKT cells to regulate 
adaptive immunity and autoimmune diseases. Previous studies 
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have shown that NKT cells are critical in both innate and 
adaptive immune responses against viral and bacterial 
infections (Grubor-Bauk et al., 2003, Hansen and Schofield, 
2004, Kakimi et al., 2000, Skold and Behar, 2003), as well as 
in tumour immunity and certain autoimmune and allergic 
diseases such as type 1 diabetes and allergic asthma 
(Lisbonne et al., 2003, Smyth et al., 2000). 
 
Recently, Kim et al introduced a new mouse model to detect 
invariant NKT cell function in both asthma and COPD (Kim et 
al., 2008). They found that, in mouse lung tissue, the chronic 
pulmonary symptoms required interactions between CD4- NKT 
cells and macrophages via CD1d molecules. IL-13, derived 
from iNKT cells, also served as a source of early anti-
inflammatory cytokine with great activity on activation of 
macrophages. This activation resulted in an autocrine 
signalling loop due to more IL-13 produced by activated 
macrophages (Martinez et al., 2009). Similar results were 
seen in the COPD group. Increased numbers of macrophages 
expressing high levels of IL-13 were observed in COPD 
affected lungs removed from transplant recipients compared 
with normal lungs (Kim et al., 2008). 
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To date, a number of studies have shown differences of 
distribution and function of NKT cells in peripheral blood, 
induced sputum and tissues. For instance, Urbanowicz et al 
have demonstrated remarkable findings on NKT cell features 
in peripheral blood from COPD patients (Urbanowicz et al., 
2009). The numbers of NKT cells were reduced significantly in 
smokers with COPD compared with non-smoking healthy 
volunteers and healthy smokers whereas the relative 
proportion of CD8+ NKT cells was increased. The expression of 
cytotoxic effector molecules, namely, perforin and granzyme B, 
were both markedly lower in COPD subjects. In contrast to 
smoking-free healthy participants and healthy smokers, NKT 
cells isolated from peripheral blood of COPD patients also 
showed less cytotoxic activity. Su et al further confirmed and 
extend these findings (Chi et al., 2011). The number of iNKT 
cells was significantly reduced in peripheral blood from COPD 
patients compared to healthy smokers. Furthermore, the 
frequency of iNKT cells is lower in peripheral blood from 
patients with exacerbations of COPD compared to stable COPD 
patients. Interestingly, the proportion of NKT cells is 
dramatically higher in induced sputum from smokers with 
COPD compared to healthy smokers and healthy non-smokers 
(Urbanowicz et al., 2010). Also, the expression of both 
perforin and granzyme B by NKT cells is also increased in 
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COPD patients compared to the other two groups, which 
means that NKT cells from COPD patients are more cytotoxic 
than those from healthy smokers and non-smoking subjects. 
 
NKT cells, as a unique lymphocyte population sharing 
characteristics with both conventional T cells and NK cells, are 
involved in immediate immune responses through their 
efficient cytokine secretion and lytic activity. Therefore, it is 
necessary to investigate their roles in health and disease. 
Previous studies on NKT cell performance in COPD highlight 
that it is important to design clinical studies aiming to modify 
NKT cell activity for therapeutic benefit. 
 
1.2.1.6 Natural killer (NK) cells 
NK cells, as a critical innate immune effector cell type, are an 
important source of immunoregulatory cytokines and play 
potent roles in early host defence by interaction with other 
immune cells. They are equipped with a great number of 
receptors that can be either inhibitory or stimulatory and also 
possess certain adhesion molecules that facilitate NK cell 
homing and trafficking (Gregoire et al., 2007, Lanier, 1998, 
Lanier et al., 1998). Upon activation, NK cells release a 
number of cytokines including myeloid-differentiation or 
activation factors (IL-3, TNF-, GM-CSF), IFN- and type 2 
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cytokines (IL-4, IL-5, IL-10 and IL-13) and cytotoxic 
molecules, such as granzymes and perforin (Cooper et al., 
2001a, Cooper et al., 2001b, Loza et al., 2002). These 
important properties warrant NK cells multiple functions in 
both innate and adaptive immune system. Killing infected cells 
by cytotoxic molecules, inducing adaptive immunity through 
cytokine and chemokine secretion, and providing co-
stimulatory molecules to T cells and B cells are main 
immunological functions of NK cells. 
 
CD56 is an isoform of the human neural cell adhesion 
molecule and widely used as a cell surface marker to identify 
NK cells (CD3-CD56+). Although its function in NK cells is still 
unexplored, early studies suggest that CD56 may function as 
an adhesion protein mediating interactions between NK cells 
and target cells (Lanier et al., 1989, Nitta et al., 1989, Suzuki 
et al., 1991). CD16 (FcRIII), as a receptor of IgG, is also 
detectable on NK cells (Dall'Ozzo et al., 2004, Lanier et al., 
1986). According to the intensity of CD56 and CD16 
expression, NK cells have been classified into two subsets 
including CD56bright and CD56dim NK cells (Cooper et al., 
2001a). In peripheral blood, CD56bright NK cells that rarely 
express CD16 molecule only comprise of approximately 10% 
of total NK cells and function as cytokine-producing cells with 
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low level expression of perforin (Konjevic et al., 1995, Nagler 
et al., 1989). CD56dim NK cells expressing high density of 
CD16, however, are a majority (~90%) of NK cells and 
defined as killers due to their high cytotoxicity. The perforin 
levels of these cells are also high (Nagler et al., 1989). 
Besides CD56 and CD16, cytokine receptors, such as receptors 
for IL-2 and IL-15, and other activation or inhibitory receptors 
are also expressed on NK cells. They can selectively recognize 
MHC class I ligands, MHC class-I related ligands and host-
encoded non-MHC ligands (Lanier, 1998).  
 
Adhesion molecules are thought to play functions in cell-cell 
interactions, trafficking and homing. Two subpopulations of NK 
cells have distinct expression patterns of these molecules that 
result in their functional diversity. In contrast to CD56dim NK 
cells that express high levels of LFA-1 and PEN5 (a sulfated 
polylactosamine carbohydrate epitope), CD56bright NK cells 
highly express CC-chemokine receptor 7 (CCR7) and L-
selectin that both are important for homing immune cells to 
secondary lymphoid organs (Frey et al., 1998), which also 
may be a reason to explain why CD56bright NK cells are highly 
presented in lymph node in contrast to CD56dim NK cells 
(Ferlazzo et al., 2004). Figure 1.3 presents the phenotypes of 
NK cells with their functional molecules. 
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Figure 1.3 Properties of human NK cell subsets. CD56bright NK cells (left in the figure) express high levels of inhibitory receptor 
CD94/NKG2A, cytokine receptors IL-2/15Rand adhesion molecules including L-selectin and CCR7. However, CD16 and KIRs are 
rarely expressed on these cells. Upon activation, these cells can release high levels of cytokines. Thus, the predominant function of 
CD56bright NK cells is immunoregulatory. By contrast, CD56dim NK cells express high levels of CD16 and KIRs. They can secrete a great 
amount of cytotoxic proteins including perforin and granzyme B but release few cytokines after stimulation. Therefore, they mainly 
perform as killer cells in the immune system. (Adapted from Megan et al. The biology of human natural kill-cell subsets. 2001. TRENDS 
in Immunology. 22: 633-640) 
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T cells, B cells and NK cells all develop from haematopoietic 
progenitor cells that reside in the CD34+ cell compartment 
(Lotzova et al., 1993). Figure 1.4 shows the Origins of NK and 
NKT-like cells in hematopoiesis. Recent studies indicate that 
bone marrow and lymph nodes are two major physiological 
sites for NK cell development. IL-2 has been detected as an 
Figure 1.4 Origins of NK and NKT cells. Hematopoietic stem cells 
give rise to all blood lineages. NK cells are innate immune effector 
cells. They are derivate from either lymphoid or myeloid progenitor 
cells, and CD3-CD56+. NKT cells are a distinct lineage of T 
lymphocytes that are derivate from lymphoid progenitor, and 
CD3+CD56+.   
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effective promoter to support the differentiation of NK cells 
from CD34+CD38- hematopoietic progenitors (Lotzova et al., 
1993, Shibuya et al., 1995). Exogenous IL-2 can also expand 
NK cell proportions (Caligiuri et al., 1993, Piguet et al., 1986, 
Rosenberg et al., 1987). IL-15 is another necessary promoter 
for NK cell development. It has structural similarities with IL-2 
and they both share several functions, such as inducing T cell 
proliferation, generation and activation of NK cells. Studies 
focusing on the NK cell progenitor in bone marrow have shown 
that IL-15 plays a critical roles in both the development and 
the maturation of NK cells (Fehniger and Caligiuri, 2001, 
Williams et al., 1999). It can induce human CD34+ 
haematopoietic progenitor cell differentiation into NK cells in 
the absence of other cytokines (Mrozek et al., 1996). However, 
differentiation based on IL-15 is not able to enhance NK cell 
expansion (Mrozek et al., 1996), unless two additional bone 
marrow stromal factors, namely, ligands of the receptor 
tyrosine kinases c-kit and flt-3, act synergistically with IL-15 
(Lyman and Jacobsen, 1998, Yu et al., 1998). Besides bone 
marrow, lymph node is another important site for NK cell 
development. CD56bright NK cells have been found in peripheral 
blood when CD34+ progenitor cells are treated with 
recombinant IL-15 (Lyman and Jacobsen, 1998). Although 
CD56bright NK cells only comprise around 10% of circulating NK 
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cells, they are a majority of NK cells (~90%) in lymph nodes. 
Interestingly, in lymph node, addition of IL-2 can functionally 
differentiate CD56bright NK cells to CD56dim NK cells through 
increasing their cytotoxicity (Ferlazzo et al., 2004). Collectively, 
lymph nodes may serve as a harbour for NK precursor cells 
that more frequently develop into CD56bright NK cells.  
 
NK cell receptors 
NK cell receptors can be classified into three families including 
receptors recognizing MHC class I ligands, receptors 
interacting with MHC class I related ligands, and receptors for 
host-encoded non-MHC ligands. NK receptors for MHC class I 
refer to those with capacities to recognize either classical or 
non-classical class I molecules encoded by genes within the 
MHC. In human two representative receptors in this family 
have been investigated, namely, human killer cell 
immunoglobulin-like receptors (KIRs) and conserved 
CD94/NKG2 receptors. These receptors are suggested to play 
predominant functions in monitoring cells for aberrant 
expression of MHC class I molecules in immune surveillance. 
 
KIRs, belonging to the Ig superfamily, are also referred to as 
the CD158 family. They are type I transmembrane 
glycoproteins that contain two  (D1 and D2) or three (D0, D1 
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and D2) Ig-like domains (designated KIR2D and KIR3D 
respectively) in the extracellular region (Colonna and 
Samaridis, 1995, Wagtmann et al., 1995), a short stalk region 
separating the Ig-like domains from the transmembrane 
segment, and cytoplasmic domains which characteristics are 
variable in length, for instance, some receptors possess long 
(L) cytoplasmic domains containing at least one intracellular 
immunotyrosine-based inhibitory motif (ITIM) sequence, they 
are named as KIR2DL or KIR3DL. While other receptors with 
short (S) cytoplasmic domains possess no ITIM sequence, 
which are called KIR2DS or KIR3DS. There are also five 
different types of cytoplasmic tails in the structure of KIRs.  
Numbers (1-5) designating to which cytoplasmic tail group 
each KIR belongs are also used to label KIRs, such as 
KIR2DL1, KIR2DS2 and so on. In humans, 14 different KIR 
genes have been detected, they are KIR2DL (1-5), KIR2DS (1-
5), KIR3DL (1-3) and KIR3DS1 (Raulet et al., 2001). Unlike 
the ITIM-induced signalling pathway in KIR2DL and KIR3DL, 
KIR2DS and KIR3DS lacking ITIMs possess a Lys residue in 
their transmembrane domains. This charged residue 
associates with an immunoreceptor tyrosine-based activation 
motif (ITAM)-bearing DAP12 adapter protein to transmit 
signals. In other words, KIRs with long cytoplasmic domains 
perform as inhibitory receptors, whereas KIRs possessing 
 56 
 
 
 
 
 
 
 
 
 
 
 
short cytoplasmic domains are assumed to be activating 
receptors. Figure 1.5 shows representative structures of KIRs. 
 
In humans, ligands for KIRs are mainly HLA subfamily, such 
as HLA-A, HLA-B and HLA-C. KIR2DL can recognize HLA-C 
Figure 1.5 Representative structures of KIRs (KIR2DL, 
KIR3DL, KIR2DS and KIR3DS). KIRs contain long (L) cytoplasmic 
domains possessing at least one ITIM sequence. Thus their major 
function is inhibitory. Whereas KIRs with short (S) cytoplasmic 
domains lack ITIMs, they possess a Lys residue in their 
transmembrane domains. This charged residue associates with an 
ITAM-bearing DAP12 adapter protein to transmit signals. KIR(S) 
function as activating receptors. (Adapted from Jordan et al. Natural 
killer cells in human disease. 2006. Clinical Immunology. 118: 1-10) 
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proteins (Colonna et al., 1992), whereas KIR3DL shows the 
capacity of ligation with HLA-B and certain HLA-A (Gumperz et 
al., 1997, Gumperz et al., 1995). To date, ligands for KIR2DS 
and KIR3DS are not known; all studies show that these 
activation KIRs either do not interact with HLA class I 
molecules or bind them with much weaker affinity than that of 
the paired inhibitory KIRs (Valiante et al., 1997, Winter et al., 
1998).  
 
KIR2DL4 is a unique gene in KIR family with remarkable 
structural features. HLA-G is suggested to be KIR2DL ligand in 
some studies (Boyson et al., 2002, Cantoni et al., 1998, 
Rajagopalan and Long, 1999).  
 
Most human KIR genes are expressed by subsets of NK cells, 
memory and effector CD8+ T cells, some CD4+ T cells and  
TCR+ T cells except KIR2DL4 (Ferrini et al., 1994, Phillips et 
al., 1995). Once they are expressed, they are stably 
maintained on the cell surface. However, KIR2DL4 again as an 
exception – it is expressed constitutively on the surface of 
CD56bright NK cells and on only activated CD56dim NK cells 
(Goodridge et al., 2003).  
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Interaction of inhibitory KIRs with their MHC class I ligands 
expressed on target cells can lead to suppression of cytokine 
production and cytotoxicity of KIR-bearing NK cells and T cells. 
Although several studies have speculated that lacking an 
inhibitory receptor for self MHC class I molecule can elicit 
autoimmune disorders (Namekawa et al., 2000, Snyder et al., 
2003, Suzuki et al., 2004, Yen et al., 2001), which is 
detrimental, KIRs can also be beneficial in immune responses 
to tumours or viral pathogens (Flores-Villanueva et al., 2001).  
 
CD94/NKG2 receptors are type II transmembrane proteins of 
the C-type lectin family. They contain two C-lectin domains in 
the extracellular region, a transmembrane region and a 
cytoplasmic domain (Lazetic et al., 1996). In humans a single 
CD94 gene is genetically linked to four NKG2 family genes 
(NKG2A-, -C, -E, and -F) (Glienke et al., 1998, Houchins et al., 
1991). CD94 does not bind ligands of CD94/NKG2 complex 
and also plays no function on signal transduction (Lazetic et 
al., 1996, Lohwasser et al., 1999). Unlike KIRs, in humans, 
CD94/NKG2 receptors recognize non-conventional MHC class I 
molecules (HLA-E) (Braud et al., 1998).  
 
Although NKG2A and NKG2C share the same ligand HLA-E, 
their immunological functions are different. Vales-Gomez et al 
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has found that inhibitory receptor CD94/NKG2A shows 
stronger affinity than the activating receptor CD94/NKG2C. In 
addition, peptides bound to HLA-E can also affect binding 
selection between the two receptors (Llano et al., 1998, Vales-
Gomez et al., 1999). To date, ligands and functions of 
CD94/NKG2E and CD94/NKG2F have not been well 
characterised. 
 
Nearly same as KIRs, CD94/NKG2 receptors are also 
expressed on most NK cells, memory and effector CD8+ T cells 
and  TCR+ T cells. However, their expression on CD4+ T cells 
is undetectable (Lazetic et al., 1996). Also, CD94/NKG2 
expression is not constitutively stable and is regulated by 
surrounding cytokines, such as IL-12, IL-15 and TGF- 
(Bertone et al., 1999, Derre et al., 2002, Mingari et al., 1998).  
 
Besides KIRs and CD94/NKG2 receptors, leukocyte 
immunoglobulin (Ig)-like receptors (LILRs) are another type of 
receptors for MHC class I molecules. One representative 
member of LILRs family is LILRB1 that has the inhibitory 
activity. LILRB1 are expressed on a subset of T cells, B cells 
and monocytes. They can also be found on NK cells from 
peripheral blood with variable frequency (undetectable to 75%) 
(Colonna et al., 1997, Cosman et al., 1997). However, its 
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affinity of ligation with all HLA molecules seems very low 
(Chapman et al., 1999, Lepin et al., 2000). U18 has been 
investigated as a ligand with higher affinity to LILRB1 and can 
elicit their inhibitory activity during viral infection (Beck and 
Barrell, 1988, Cosman et al., 1997, Chapman et al., 1999).  
 
There is a kind of glycoprotein which is not encoded by genes 
in the MHC complex but structurally related to MHC class I 
molecule. It does not serve as a peptide-binding molecule to 
present antigens to T cells. However, this MHC class I-related 
protein can be recognized by NK receptor NKG2D (Raulet, 
2003). NKG2D, as a type II transmembrane-anchored 
glycoprotein, is a unique activating receptor which both 
structurally and functionally differ from other NKG2 receptors 
(Bauer et al., 1999, Jamieson et al., 2002). It is encoded by a 
single gene without polymorphism and does not need to form 
dimers with CD94 (Wu et al., 1999). In human, NKG2D is 
expressed on the surface of NK cells,  TCR+ T cells, and 
especially, it is constitutively present on all CD8+ T cells (Wu 
et al., 1999). The expression of NKG2D can be regulated by 
cytokines. For example, IL-15 and TNF- can enhance the 
NKG2D expression whereas TGF- causes downregulated 
effects on it (Castriconi et al., 2003, Lee et al., 2004). Unlike 
two isoforms of NKG2D (NKG2D-L and NKG2D-S, “L” and “S” 
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represent long or short protein respectively) found in mouse, 
humans only express NKG2D-L that transmit signals through 
transmembrane segment associating with adaptor protein 
DAP10 (Diefenbach et al., 2002, Wu et al., 1999). Studies 
demonstrate that in the absence of DAP10, NKG2D is not able 
to be presented on cell surface and only retained in the 
cytoplasm (Wu et al., 1999). Human ligands for NKG2D have 
been identified, such as MICA, MICB, ULBP1, ULBP2, ULBP3 
and ULBP4 (Bauer et al., 1999, Cosman et al., 2001). Figure 
1.6 presents the interactions of the NKG2D and CD94 family 
with target cells. 
 
Besides receptors for recognition of MHC class I and MHC class 
I-like molecules, NK cells also possess additional receptors 
that can encounter targets lacking expression of MHC class I 
or MHC class I-related proteins. However, this type of 
receptors is supposed to be costimulatory receptors because 
they are unable to individually initiate an immune response. In 
human, this kind of receptors mainly includes 2B4 receptor 
(CD244), DNAM-1 receptor (CD226) and CD16 (FcRIII). 
 
2B4 (CD244) and its ligand CD48 are both members of the 
CD2 family of Ig-related proteins. In human, they are 
expressed by all NK cells, most  TCR+ T cells, memory and  
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effector CD8+ T cells, monocytes and basophils (Nakajima et 
al., 1999, Speiser et al., 2001, Tangye et al., 2000). Although 
signalling pathways of 2B4 receptor is still unresolved, studies 
Figure 1.6 Interactions of NKG2D and CD94 family with target 
cells. CD94 receptors are type II transmembrane proteins of the C-type 
lectin family. In humans a single CD94 gene is genetically liked to four 
NKG2 family gens (NKG2A-,-C,-E and -F). CD94 receptors recognize 
non-conventinal MHC class I molecules (HLA-E). NKG2D is a type II 
transmembrane-anchored glycoprotein. Human only expresses NKG2D-L 
that transmits signals through transmembrane segment associating with 
adaptor protein DAP10. Human ligands for NKG2D are MICA, MICB, 
ULBP1-4. 
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in human suggest that 2B4 may serve as a multifunctional 
receptor that can cause either inhibitory or activating 
responses depending on the stage of NK cell differentiation 
and activation (Namekawa et al., 2000, Parolini et al., 2000). 
 
DNAX accessory molecule-1 (DNAM-1, also called CD226) is a 
member of the Ig superfamily and ligated with CD112 and 
CD155 that are broadly distributed on many tissues (Tahara-
Hanaoka et al., 2004). Expression of DNAM-1 is detectable in 
human NK cells, a majority of T cells, a subset of B cells, 
monocytes and platelets (Castriconi et al., 2004, Pende et al., 
2006, Reymond et al., 2004, Scott et al., 1989, Shibuya et al., 
1996). 
 
CD16 is a low affinity receptor for IgG. It binds the lower 
hinge region of IgG and induces activation signals through 
FceRI -chain and CD3z, which enable NK cells to mediate 
antibody-dependent cellular cytotoxicity (ADCC) (Dall'Ozzo et 
al., 2004, Radaev et al., 2001). Expressions of ICAM-1 
together with IgG on infected cells are required to induce 
efficient ADCC (Bryceson et al., 2005). CD16 shows high 
expression on CD56dim cells. 
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In conclusion, since NK cells are defined as non-MHC-
restricted cells according to their capacities of recognizing 
target cells that either express or lack MHC class I molecules, 
missing-self hypothesis demonstrates that self-MHC molecules 
engages inhibitory receptors on the surface of NK cells, which 
can prevent attack against normal cells (Ljunggren and Karre, 
1990). Actually, rather than absolutely saying that interaction 
between MHC-I molecules and inhibitory receptors are 
terminated, responses of NK cells to target cells are regulated 
by a balance of signals from inhibitory and activating 
receptors (Figure 1.7). Either lack of the ligands for inhibitory 
receptors or signals from activating receptors that are 
stronger than inhibitory signals can both induce NK cell 
stimulation. On the other hand, NK cells display their 
inhibitory functions if there are no activating ligands presented 
in target cells or much stronger inhibitory signals are avaiable. 
Several experimental lines of evidence have confirmed this 
corollary. When activating receptors are sufficiently stimulated 
or multiple activating receptors are engaged, NK cells still can 
eliminate infected cells, although MHC class I molecules on 
these infected cells are still ligated with inhibitory receptors 
(Cerwenka et al., 2001, Diefenbach et al., 2001, Lanier et al., 
1997). Also, Fc-receptors (FcRs) have similar scenarios in 
immune response. By vitue of coexpression of activating and  
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Figure 1.7 Regulation of NK cell responses by inhibitory or 
activating receptors. NK cell activation can be induced in two 
manners. Either lack of the ligands for inhibitory receptors or 
signals from activating receptors that are stronger than inhibitory 
signals can both induce NK cell stimulation. On the other hand, NK 
cells display their inhibitory functions if there are no activating 
ligands presented in target cells or much stronger inhibitory signals 
are available. (Adapted from Lewis L. Lanier. NK cell recognition. 
2005. Annu. Rev. Immunol. 23: 225-274) 
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inihibitory signalling FcRs on the same cells, they set a 
threshold for immune cell activation by immune complexes. 
Loss of the balanced signalling leads to uncontrolled response 
that can result in the damage of healty tissues and ultimately 
to the initiation of autoimmune processes (Abes et al., 2009).  
 
So far, several major types of NK cell receptors presented in 
human cells have been introduced with respect to their ligands 
specificity and signalling properties. However, other receptors 
expressed on NK cells, such as natural cytotoxicity receptors 
and cytokine receptors, are also important for generating 
various NK cell functions in response to target ligands. 
Although many features and functions of NK cells have been 
well studied in tumour, viral infection and autoimmune 
diseases, their immunological properties in COPD patients are 
still unexplored. Since the predominant risk factor of COPD is 
cigarette smoking, several studies have successfully detected 
the effects of cigarette smoke in humans. In vivo, previous 
studies have shown that NK cell numbers and their phagocytic 
activities are suppressed in both asymptomatic smokers and 
COPD patients (Ferson et al., 1979, Prieto et al., 2001). Our 
group further demonstrated that decreased numbers of NK 
cells are present in peripheral blood from COPD patients 
compared to healthy non-smokers and healthy smokers 
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(Urbanowicz et al., 2009). Also, their cytotoxic function is 
defective. Nevertheless, NK cell proportions and their 
cytotoxicity are increased in induced sputum from COPD 
patients in contrast to healthy non-smokers and healthy 
smokers (Urbanowicz et al., 2010). In addition, cigarette 
smoke treated NK cells from non-smoking healthy subjects 
show defective cytotoxicity and their capacity for cytokine 
secretion is also impaired upon poly I:C activation (Mian et al., 
2008). In conclusion, investigation of NK cells’ properties in 
COPD may provide new insights for understanding the 
development of COPD as well as indicate more beneficial 
therapeutic approaches for the disease.  
 
1.2.1.7 Epithelial cells 
The surface of airway epithelium consists of ciliated cells, 
goblet cells, ciliated cells and basal cells. These cells work 
together as an efficient barrier against pathogens through 
intercellular epithelial junctions. They also exert important 
roles in airway defence mechanisms, such as clearance of the 
mucus, water transport, antioxidant, antiprotease functions 
and cell apoptosis (Puchelle et al., 2006). 
 
Cigarette smoking is the key risk factor in the development of 
COPD. Injury in airway epithelium caused by cigarette 
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smoking can result in increased proliferation of airway 
epithelial cells, which further lead to the squamous metaplasia. 
Likewise, squamous metaplasia can decrease mucociliary 
clearance and contribute to the increased risk of squamous 
cell carcinoma in COPD patients (Cosio et al., 1978, Papi et al., 
2004). 
 
A series of studies have shown that cigarette smoking can not 
only cause the increased expression of IL-8 and mucin in 
epithelial cells but also reduce the function of trans-epithelial 
electric resistance (TEER), which reflects a breakdown of the 
epithelial integrity that can affect the defence mechanisms of 
the airway (Glader et al., 2006a, Rusznak et al., 1999, Richter 
et al., 2002, Takeyama et al., 2001). Also, up-regulation of 
early growth response gene 1 (Egr-1) was detectable when 
epithelial cells were exposed to cigarette smoke. Egr-1 
mediates the production of pro-inflammatory cytokines, such 
as IL-1, TNF-, which have shown increased levels in 
smoking conditions (Reynolds et al., 2006). Furthermore, in 
vitro, epithelial cells from small airways of healthy smokers 
and COPD patients secrete more TGF- than do those from 
healthy non-smokers (Takizawa et al., 2001). Increased levels 
of fibroblast growth factors (FGF) 1 and 2 are also observed in 
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the bronchial epithelium of COPD patients (Kranenburg et al., 
2005). 
 
Pathogens including bacteria and viruses can exacerbate 
COPD and accelerate deterioration of lung function (Rohde et 
al., 2003, Seemungal et al., 2001). Previous studies have 
shown that rhinovirus (RV) is the dominant viral pathogen in 
exacerbation of COPD. RV infection can cause secretion of a 
variety of pro-inflammatory chemokines, such as ENA-78, IL-8 
and IP-10, as well as cytokines, for example, IL-1, IL-6, IL-11, 
IL-16, TNF- and GM-CSF, by epithelial cells (Proud and Chow, 
2006). These inflammatory mediators play different functions 
on recruitment and activation of inflammatory cells including 
neutrophils, macrophages, T cells and NK cells that can induce 
pulmonary and systemic inflammatory responses, mucus 
hypersecretion and airway remodelling, which result in the 
exacerbation of COPD. Beside viruses, bacteria can also cause 
exacerbation of COPD by colonizing and infecting the lower 
respiratory tract (Murphy, 2006). Although M. catarrhalis and 
H. influenza can trigger immune response in airway epithelial 
cells (Shuto et al., 2001, Slevogt et al., 2006, Watanabe et al., 
2004), a study performed by Sethi et al. has shown that 
alteration in bacterial load was not an important mechanism 
for exacerbation of COPD (Sethi et al., 2007).  
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Airway epithelial cells are the initial targets of reactive oxygen 
species (ROS). Pierrou et al. have investigated extensive 
changes in oxidant response gene expression in the airway 
epithelial cells that are related to cigarette smoking and the 
presence of COPD (Pierrou et al., 2007). Furthermore, the 
levels of 4-hydroxy-2-nonenal-modified (4-HNE) proteins were 
increased in airway epithelial cells of COPD patients (Rahman 
et al., 2002). 4-HNE is a diffusible and highly reactive lipid 
peroxidation end-product. The modification of 4-HNE can lead 
to abnormal regulation of cell proliferation and inhibition, T 
cells apoptosis and activation of signalling pathways.  
 
Hypersecretion of mucus and reduction of mucociliary 
clearance are two main mechanisms inducing mucus 
accumulation (Danahay and Jackson, 2005, Stannard and 
O'Callaghan, 2006). The epithelial goblet cells are a main 
source of secretory gel-forming mucins in the airway. The 
number of goblet cells has shown increased level in COPD 
patients compared to healthy smokers (Innes et al., 2006). 
Mucociliary clearance is dependent on the interactions 
between the ciliated epithelium, the height of the periciliary 
fluid and mucus (Stannard and O'Callaghan, 2006). It has 
been shown that there is significant reduction (nearly no 
presence) of ciliated cells in COPD patients, compared to 
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healthy non-smokers and healthy smokers (Rusznak et al., 
2000). 
 
Apoptosis is a potent mechanism for elimination of damaged 
or infected cells. There are abundant studies showing that 
numbers of apoptotic cells, including bronchial and alveolar 
epithelial cells and endothelial cells, are increased in the 
parenchyma in COPD patients (Henson et al., 2006, Hodge et 
al., 2005b, Hodge et al., 2003a, Park et al., 2007). The 
apoptosis of airway epithelial cells is disease related rather 
than smoking status. Hodge S et al. have shown that there is 
no significant difference in apoptosis of airway epithelial cells 
between ex-smokers with COPD and current smoking COPD 
patients (Hodge et al., 2005b), which implies that apoptosis 
exists after smoking cession. 
 
1.2.1.8 Mast cells 
Since neutrophils, macrophages and CD8+ T cells are 
commonly considered the predominant cells in the 
pathogenesis of COPD (Chung and Adcock, 2008), the role of 
mast cells in COPD is just beginning to become unravelled.  
 
Mast cells are highly heterogeneous cells and originate from 
myeloid stem cells (Anderson et al., 1990). Their maturation 
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and differentiation are influenced by many cytokines and 
chemokines, such as IL-3, 4, 9 and 10 (Brown et al., 2008). 
They are normally classified into two subsets, namely, 
mucosal mast cells (MCT) and connective tissue mast cells 
(MCTC). The MCT mainly exist in the respiratory tract and gut, 
and their number can be modulated in different inflammatory 
conditions, such as allergy and inflammatory bowel disease. 
The MCTC are predominantly present in connective tissue, such 
as the skin, and their number is constant (Irani et al., 1986). 
 
Studies related to the mast cell functions in lung diseases are 
mostly performed in animal models (Galli et al., 2005, 
Sekizawa et al., 1989, Thomas et al., 1992). However, 
recently studies have shown the number, the density and 
mediators released by mast cells are altered in airways of 
smokers, even in COPD patients. Wen et al have explored that 
the numbers of mast cells were significantly increased in 
sputum of smokers compared to ex-smokers (Wen et al., 
2010). In the lung and skin of smokers, there is also an 
increase in absolute numbers of mast cells (Kalenderian et al., 
1988). Furthermore, elevated histamine and tryptase levels in 
BAL fluid from smokers have also been demonstrated (Bessa 
et al., 2008, Kalenderian et al., 1988). Gosman et al have 
investigated the distribution and the numbers of tryptase- and 
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chymase- positive mast cells in the airways (Gosman et al., 
2008). There was no significant difference in the distribution 
of these cells in the airways between COPD patients and 
healthy volunteers. In central airways, the concentration of 
these mast cells was significantly higher in the subepithelial 
area, whereas in the peripheral airways, the highest 
concentration of these cells existed in the adventitia. However, 
numbers of these mast cells differed between COPD patients 
and controls. The number of chymase- positive mast cells was 
significantly higher in both subepithelial areas and smooth 
muscle of peripheral airways in COPD patients than in controls. 
Whereas the number of tryptase- positive mast cells in the 
subepithelial area of central airways was lower in COPD 
patents than in controls. Moreover, higher percentages of both 
tryptase- and chymase- positive mast cells were detected in 
the peripheral airways and positively correlated with FEV1% 
predicted, which was compatible with the issue that peripheral 
airways are the main site of airflow limitation in COPD (Hogg 
et al., 2004, Hogg et al., 1968).  
 
Besides population and distribution, the density of mast cells 
in the lung of COPD patients has been investigated lately 
(Hogg et al., 1968). In the small airways, there were 
significant decreases in total mast cell density in both patients 
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with severe COPD and patients with moderate to severe COPD 
compared to healthy non-smokers and healthy smokers. In 
the pulmonary vessel walls, the reduction of mast cell density 
was only shown in severe COPD subjects but not other groups. 
In addition, the balance of MCTC and MCT was shifted. The 
population of MCT was deceased in all anatomical 
compartments of the lung, whereas the density of MCTC was 
markedly higher in the walls of small airways and in alveolar 
parenchyma in severe COPD groups than other groups. 
Recently, Soltani and colleague have shown that in COPD 
airways, both reticular basement membrane and lamina 
propria mast cells were increased (Soltani et al., 2012) 
 
Taken together, although alternation of mast cell numbers, 
density and distribution has been identified in several studies, 
the mechanisms about the signalling pathway and by which 
mast cells can be activated in the airways of COPD patients 
are still not well explored. Mast cells express many receptors, 
such as abundant TLRs, and can release leukotrienes, 
cytokines and chemokines after activation (Kumar and 
Sharma, 2010). Therefore, evaluation of expression of key 
mast cell associated molecules can contribute to more 
understanding of the role of mast cells in COPD. 
 
 75 
1.2.1.9 Eosinophils  
Eosinophils are end-stage cells derived from the bone marrow. 
Their maturation and proliferation are regulated by GM-CSF, 
IL-3 and IL-5 (Denburg, 1999). Eosinophil cationic protein 
(ECP) and eosinophil peroxidase (EPO) are two eosinophil 
specific proteins. They are toxic to bronchial epithelial cells 
(Blanchard and Rothenberg, 2009). Eosinophils, together with 
mast cells and basophils, are the predominant source of 
cysteinyl-leukotrienes (Bozza et al., 1997). Eosinophilic 
inflammation is mostly studied in allergic airway inflammation 
(Walsh et al., 2010). Recently, studies on its role in COPD 
have started to be investigated. Some groups have 
demonstrated increased numbers of inactive eosinophils in the 
airways and lavage of stable COPD patients, whereas others 
have failed to present differences in eosinophil numbers in 
airway biopsies, BAL, or induced sputum (Lacoste et al., 1993, 
Turato et al., 2001). Interestingly, the levels of ECP is higher 
in induced sputum from moderate to severe COPD in the 
absence of eosinophils (Brightling et al., 2005, Brightling et al., 
2000, Gibson et al., 1998, Takahashi et al., 2006), which 
indicates that eosinophils may have degranulated during 
disease development (Keatings and Barnes, 1997). A negative 
correlation between FEV1 and the ratio of activated eosinophils 
to total eosinophils in endobronchial biopsies has been 
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reported in COPD patients (Lams et al., 2000). Furthermore, 
levels of sputum eosinophils and ECP concentration are also 
negatively correlated with FEV1 (Balzano et al., 1999). 
Eosinophil function has been accepted to be important in 
severe COPD. Greater numbers of eosinophils have been 
detected in bronchial biopsies and BAL fluid during acute 
exacerbation of COPD compared with stable COPD and 
controls (Saetta et al., 1996, Saetta et al., 1994). 
 
1.2.2 Cytokines in COPD 
The potential roles of cytokines in COPD have been explored in 
many studies. Over 50 cytokines have now been identified in 
COPD (Barnes, 2004d). However, cytokines work in a complex 
manner. They may have different or even opposing actions in 
different cell types or in different inflammatory process.  
 
Proinflammatory cytokines in COPD 
1.2.2.1   Tumour necrosis factor- (TNF- 
TNF- is a member of peptide ligands that stimulate a 
corresponding series of structurally related receptors (Bazzoni 
and Beutler, 1996). It plays important roles in many 
inflammatory diseases. Proinflammatory cells, such as 
macrophages, monocytes, dendritic cells, B cells, CD4+ T cells, 
neutrophils, mast cells and eosinophils, and structural cells 
 77 
including fibroblasts, epithelial cells and smooth muscle cells, 
are all good sourses for TNF- production (Russo and Polosa, 
2005). Increased levels of TNF- have been found in induced 
sputum from COPD patients, pariticularly during exacerbations 
(Aaron et al., 2001). Soluble TNF- receptors are also 
increased in sputum of COPD patients (Vernooy et al., 2002). 
Serum concentrations of TNF- are elevated in COPD patients 
with weight loss, particularly during exacerbations (Calikoglu 
et al., 2004), which indicates that TNF- may have functions 
in the cachexia of severe COPD (de Godoy et al., 1996, Di 
Francia et al., 1994, Pitsiou et al., 2002). There is a significant 
increase in TNF- released from circulating cells in COPD 
patients compared to normal controls. Plasma concentrations 
of TNF- are also increased slightly in COPD patients 
compared to normal subjects during exercise (Rabinovich et 
al., 2003). 
 
TNF- activates NF-B pathway and p38 mitogen-activated 
protein kinase (MAPK) that switch on the transcription of 
inflammatory genes including cytokines, chemokines and 
proteases released by epithelial cells and macrophages, which 
indicates that TNF- play a role in amplifying the inflammation 
of COPD, such as activation of neutrophils, monocytes, 
macrophages, epithelium, mucus secretion and destruction of 
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lung parenchyma (Aggarwal, 2003). Furthermore, TNF- 
accounts for 70% of cigarette smoke-induced emphysema in 
mice (Churg et al., 2004).  
 
1.2.2.2   Interleukin-1 (IL-1 
IL-1 is a proinflammatory cytokine with similar functions as 
TNF- (Watkins et al., 1999). It markedly stimulates alveolar 
macrophages to produce inflammatory cytokines, chemokines 
and MMPs in COPD patients (Culpitt et al., 2003). The 
concentration of IL-1 is increased in induced sputum of COPD 
patients and is correlated with disease severity. However, 
concentrations of IL-1 receptor antagonist and soluble IL-1 
receptor are reduced in same COPD groups (Sapey et al., 
2009). 
 
1.2.2.3   IL-6 
IL-6 is a marker of inflammation and plays functions on both 
proinflammatory response and anti-inflammatory response. 
Its effects are determined by the presence of other cytokines 
(Barnes et al., 2011). Therefore, it provides a link between 
innate and acquired immunity. Increased concentrations of IL-
6 are detected in induced sputum, exhaled breath and plasma 
of COPD patients, especially during exacerbation (Bucchioni et 
al., 2003, Grubek-Jaworska et al., 2012, Hageman et al., 
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2003, Wedzicha et al., 2000). Levels of IL-6 released by 
monocytes are higher in COPD patients compared to normal 
subjects (Aldonyte et al., 2003). 
 
1.2.2.4   Granulocyte-Macrophage Colony Stimulating 
Factor (GM-CSF) 
GM-CSF is a monomeric protein and is secreted by T cells and 
macrophages. It is a strong chemoattractant for neutrophils. 
It also has the ability of enhancing oxidative metabolism and 
phagocytotic activity of neutrophils and macrophages 
(Hamilton, 2002). There is a higher concentration of GM-CSF 
in BAL fluid from stable COPD patients, particularly during 
exacerbation (Balbi et al., 1997). 
 
1.2.2.5   IL-32 
Recently, IL-32, as a newly explored proinflammatory cytokine, 
has been shown to be induced by IFN-. Upon activation of 
NF-B and p38 MAPK, IL-32 stimulates the production of TNF-
 and IL-1(Joosten et al., 2013). Increased expressioin of IL-
32 has been found in epithelial cells, macrophages and CD8+ T 
cells in COPD patients, and is correlated with disease severity 
(Calabrese et al., 2008). 
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1.2.2.6   Thymic stromal lymphopoietin (TSLP) 
TSLP is a cytokine belonging to IL-7 family. It regulates the 
secretion of chemokine ligand by dendritic cells including CCL-
17, CCL-22 and CXCL-10, which attract T lymphocytes to the 
airways (Liu et al., 2007). Increased expression of TSLP has 
been detected in airway epithelium of COPD patients (Ying et 
al., 2008). In addition, elevated levels of TSLP can be found in 
airway smooth muscle of COPD patients (Zhang et al., 2007). 
 
 
T cell cytokines 
1.2.2.7   IL-12 family 
IL-12, secreted by macrophages, DCs and airway epithelial 
cells, plays a potent role in Th1 cell differentiation and 
activation (Watford et al., 2003). It also up-regulates the IFN-
 production (Trinchieri and Scott, 1995). Its effects are 
mostly mediated by activation of STAT4. IL-23, shared p40 
subunit with IL-12, plays an important role in regulation of 
Th17 cells (Qu et al., 2013). It also activates STAT4. IL-27 is 
another member of the IL-12 family (Bosmann and Ward, 
2013, Gee et al., 2009). It has effects on Th1 cell 
differentiation via a STAT1-dependent mechanism. Increased 
levels of IL-12 have been detected in bronchial biopsies of 
COPD patients (Di Stefano et al., 2004). There is also elevated 
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expression of IL-23 in the bronchial mucosa of COPD subjects 
(Di Stefano et al., 2009b). A study performed by Huang et al 
has mentioned that polymorphisms of the IL-27 gene are 
linked to increased risk of COPD (Huang et al., 2008). 
 
1.2.2.8   Th17 cytokines 
Th17 cells are a subset of CD4+ T cells. Their differentiation is 
regulated by IL-1, IL-6, and IL-23 (Manel et al., 2008). IL-
17A, IL-21 and IL-22 are major cytokines secreted by Th17 
cells (Chen and O'Shea, 2008). Traves et al have shown 
increased levels of IL-17A in the sputum of COPD patients 
(Traves and Donnelly, 2008). Furthermore, the expression of 
IL-17A, IL-22 and IL-23 are all markedly elevated in the 
bronchial mucosa of stable COPD patients (Di Stefano et al., 
2009b). Interestingly, IL-17A levels are also increased in 
smokers with normal lung function, which indicates that the 
secretion of IL-17A is mediated by smoking per se rather than 
disease itself. Increased expression of IL-22 is also observed 
in the bronchial epithelium and submucosa of COPD patients 
compared to healthy smokers and healthy non-smokers. 
 
1.2.2.9   Other T cell cytokines 
IL-2, IL-4, IL-9, IL-13, IL-15, IL-18 and IFN- are all produced 
by either Tc cells or Th cells (Mosmann and Coffman, 1989).  
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Higher IL-2 levels have been found in lung plasma samples 
from stable COPD patients compared to participants with 
rapidly progressive COPD (D'Armiento et al., 2009). Also, 
corticosteroid (dexamethasone) has shown less inhibiton of IL-
2 production in COPD patients compared to healthy volunteers 
although these numerical differences between groups did not 
reach statistical significance (Kaur et al., 2012).  
 
Levels of both IL-4 released by CD8+ T cells and IFN- 
released by CD4+ T cells are increased in the BAL fluid from 
COPD patients (Barczyk et al., 2006). There is also an 
increase in the expression of IFN- in bronchial biopsies of 
COPD patients (Di Stefano et al., 2004a).  
 
IL-9 is normally released by Th2 cells and has functions in 
allergic inflammation (Shimbara et al., 2000). It increases the 
expression of MUC5AC and therefore, is a potent inducer of 
mucus production (Reader et al., 2003). Interestingly, there is 
a significant increase in the expression of IL-9 in T 
lymphocytes from bronchial biopsies of COPD patients 
(Panzner et al., 2003). 
 
IL-13 is another inducer of mucus production and plays a role 
in the differentiation of goblet cells through activation of EGFR 
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(Shim et al., 2001). Although there is no significant difference 
in the expression of IL-13 between COPD and controls 
(Grubek-Jaworska et al., 2012), smokers with mucus 
hypersecretion show a higher concentration of IL-13 in 
bronchial biopsies compared to non-smokers (Miotto et al., 
2003). 
 
IL-15 shares several similar functions with IL-2. Details of 
their features will be indicated in the later chapter. Recently, 
in vitro, it has been found that IL-15 stimulation by itself had 
no effect on IFN- protein expression in COPD patients at 
GOLD stages 2, 3, and 4. However, IL-15 primed CD8+ lung T 
cells to have greater cytotoxic potential by expressing higher 
levels of intracellular perforin when they encounter a target 
cells in COPD (Freeman et al., 2010). Furthermore, CSE 
treated NK cells were less activated after poly I:C stimulation, 
and this suppression was IL-15 mediated (Mian et al., 2009). 
 
IL-18 is not only secreted by T cells but also activated 
macrophages (Nakanishi et al., 2001). IL-18 protein is highly 
expressed by alveolar macrophages, CD8+ T cells and both the 
bronchiolar and alveolar epithelia in the lung of COPD patients. 
Its serum levels are also elevated in smokers with or without 
COPD compared to non-smokers (Imaoka et al., 2008). IL-18 
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concentrations are also increased in the induced sputum of 
COPD patients and correlated with disease severity (Rovina et 
al., 2009). Higher IL-18 gene expression has been found in 
plasma and in skeletal muscle of COPD patients (Petersen et 
al., 2007), which indicates that IL-18 may function in systemic 
manifestations of COPD.  
 
1.2.2.10   IL-10 
IL-10 is an anti-inflammatory cytokine secreted by monocytes, 
alveolar macrophages and Treg cells. Decreased concentration 
of IL-10 has been detected in induced sputum of COPD 
patients (Barnes, 2001). However, its production seems to be 
elevated in macrophages from normal smokers (Lim et al., 
2000). Interestingly, increased expression of IL-10 is found in 
bronchial biopsies from COPD patients (Panzner et al., 2003). 
 
To sum up, although many cytokines are abnormally 
expressed in COPD patients, overlapping effects of them mean 
therapeutic benefits may be trivial. Neverthelss, exploring the 
cytokine network in COPD provides a new insight for 
understanding the pathogenesis of disease development. 
 
1.2.3 Chemokines in COPD 
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COPD involves chronic inflammation of small airways and lung 
parenchyma, with the recruitment of inflammatory cells. 
Trafficking inflammatory cells to infected areas is orchestrated 
by multiple chemokines and cytokines. There are over 50 
different chemokines that have been indentified. They can 
selectively activate 19 different surface receptors expressed 
by target inflammatory cells (Locati et al., 2005). Unlike 
classical cytokine receptors, receptors for chemokines belong 
to the 7 transmembrane receptor super family of G-protein-
coupled receptors (GPCRs), which makes it possible to 
discover small molecule inhibitors (Proudfoot, 2002). Four 
different families of chemokines are now categorized, namely 
CC, CXC, Cm and CX3C chemokines, based on their 
differences in the position of critical cysteine residues. Binding 
of chemokines to their corresponding receptors results in the 
activation of signal transduction pathways, which further 
induces chemotaxis or other cellular activities (Gutierrez-
Ramos et al., 2000). Currently, several chemokines and their 
receptors seem to be involved in the pathogenesis of COPD 
(de Boer, 2005).  
 
1.2.3.1   Interleukin-8 
Interleukin-8 (IL-8, CXCL8) is a CXC chemokine and a 
predominant chemoattractant of neutrophils (Hammond et al., 
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1995) . It activates two chemokine receptors, namely, CXCR1 
and CXCR2. CXCR1 is a low affinity receptor that is almost 
specific for IL-8, whereas CXCR2 is a high affinity receptor and 
is shared by other related CXC chemokines (Premack and 
Schall, 1996). Binding of IL-8 to these two receptors can 
activate protein kinase B and GTPases, which consequencely 
enhances the neutrophil adherence to endothelial cells and 
directs cell migration. Activated protein kinase B can also 
stimulate the phosphoinositide 3 kinase that induces F-actin 
polymerization, leading to pseudopod formation and 
chemotaxis (Chodniewicz and Zhelev, 2003). In addition, Ras 
and MAP kinases in neutrophils are activated when IL-8 binds 
to its receptors, which induces their degranulation (Bowman et 
al., 1998). 
 
IL-8 is synthesized in several cell types, predominantly 
macrophages, epithelial cells and neutrophils (Mukaida, 2003), 
up on activation by several stimuli including TNF-, IL-1, 
bacterial products including LPS, certain viruses, oxidative 
stress and cigarette smoke extract (DeForge et al., 1993, 
Johnston et al., 1998, Kwon et al., 1994, Nakamura et al., 
1991, Schulz et al., 2004). Release of IL-8 is regulated 
transcriptionally by several transcription factors, such as NF-
B, p38MAP kinase and ERK pathways (Waugh and Wilson, 
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2008). NF-B is the predominant transcription factor for IL-8 
secretion (Carter et al., 1998). Therefore, inhibition of the NF-
B activating kinase IKK2 results in the reduction of IL-8 
production (Hacker and Karin, 2006, Tang et al., 2001). 
 
Previous studies have confirmed that IL-8 is a major 
chemokine that plays key roles in the neutrophilic 
inflammation in COPD. The concentration of IL-8 is markedly 
increased and correlated with increased numbers of 
neutrophils in both induced sputum and BAL fluid from COPD 
patients (Keatings et al., 1996, Nocker et al., 1996, Soler et 
al., 1999, Yamamoto et al., 1997). Unsuprisingly, neutrophils 
themselves release IL-8 that attracts more neutrophils. 
Therefore, a self-perpetuating inflammation may be 
established in COPD patients (Bazzoni et al., 1991). In 
induced sputum, IL-8 levels are elevated during acute 
exacerbation and are positively correlated with the bacterial 
colony count, which indicates that bacterial infection may at 
least in part induce neutrophilc inflammation through 
induction of IL-8 secretion in the airways (Hill et al., 2000, 
Patel et al., 2002). In BAL, IL-8 is the only chemokine with 
higher concentration in smokers with emphysema, compared 
to healthy smokers (Tanino et al., 2002). Furthermore, IL-8 
concentrations are also increased in hospitalized COPD 
 88 
patients and are correlated with skeletal muscle weakness 
(Spruit et al., 2003).  
 
More IL-8 production has been observed in cultured airway 
epithelial cells and alveolar macrophages from COPD patients 
than smokers with normal lung function, which also indicates 
an amplified response (Culpitt et al., 2003, Schulz et al., 
2004). Alveolar macrophages provide a great source of IL-8 in 
response to stimuli. Cells derived from COPD patients release 
more IL-8 than those from health smokers (Culpitt et al., 
2003). IL-8 protein and mRNA are increased in bronchiolar 
epithelial cells from COPD patients (de Boer et al., 2000). Also, 
there is elevated basal release of IL-8 from airway epithelial 
cells of COPD patients (Profita et al., 2003, Schulz et al., 
2003). 
 
In clinical trials, anti-IL-8 antibodies decreased only 
approximately 30% of the neutrophil chemotactic activity of 
sputum from COPD patients (Beeh et al., 2003, Crooks et al., 
2000). This is because other neutrophil chemotactic factors, 
such as LTB4 and C5a, are also involved. Therefore, blocking 
IL-8 alone is not sufficient as a therapeutic strategy to reduce 
neutrophil inflammation in the respiratory tract. CXCR2 is a 
receptor of IL-8 and is also shared by other chemokines. 
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Small antagonists of CXCR2 are now in clinical development 
for the treatment of COPD (Chapman et al., 2009).  
 
1.2.3.2   CXCL1 (growth-related oncogene-, GRO-) 
CXCL1 is another CXC chemokine that is involved in COPD. It 
is released by alveolar macrophages and airway epithelial cells 
upon TNF- and IL-17 activation (Jones and Chan, 2002, 
Prause et al., 2003, Schulz et al., 2004). It also binds to 
CXCR2 expressed by neutrophils and monocytes (Premack and 
Schall, 1996). CXCL1 concentration is significantly increased in 
both induced sputum and BAL fluid from COPD patients 
compared to healthy smokers and healthy non-smokers 
(Traves et al., 2002). There are greater amounts of CXCL1 
released by epithelial cells from COPD patients compared to 
healthy smokers (Schulz et al., 2004), and by BAL cells from 
normal smokers compared to non-smokers (Morrison et al., 
1998). In COPD patients, monocyte chemotactic activity is 
increased in response to CXCL1, which may account for the 
higher amount of alveolar macrophages in the lungs of COPD 
patients (Traves et al., 2004). 
 
1.2.3.3   CXCL5 (epithelial-cell-derived neutrophil 
activating peptide-78, ENA-78) 
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CXCL5 is mainly released by epithelial cells and also binds to 
CXCR2 (Imaizumi et al., 1997). Unlike IL-8 and CXCL1, CXCL5 
does not induce an increased chemotactic activity on 
monocytes (Traves et al., 2004).  The concentration of CXCL5 
is increased in the BAL fluid from COPD patients compared to 
healthy non-smokers (Tanino et al., 2002). However, there is 
no significant difference between patients with emphysema 
and healthy smokers. Similarly to CXCL1, the amount of 
CXCL5 derived from BAL cells is higher in COPD patients 
compared to healthy non-smokers (Morrison et al., 1998). 
Furthermore, CXCL5 expression is significantly increased in 
epithelial cells during exacerbations of COPD (Qiu et al., 2003). 
Recently, Stefano and colleague showed that the numbers of 
CXCL5+ endothelial cells in the bronchial submucosa is 
negatively correlated with COPD severity (Di Stefano et al., 
2009a). 
 
1.2.3.4   CXCL7 (neutrophil-activating peptide-2) 
CXCL7 is released by -granules of platelets but is required to 
be activated by proteolytic cleavage by enzymes, for example, 
cathepsin-G (Walz, 1992). It also binds to CXCR2, therefore, it 
has chemotactic functions for both neutrophils and monocytes. 
There is an enhanced chemotactic activity of monocytes in 
response to CXCL7 in COPD patients (Traves et al., 2004). The 
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number of CXCL7+ cells, including endothelial cells, fibroblasts 
and submucosal glands in the bronchial submucosa are 
significantly higher in patients suffering from severe or very 
severe COPD compared to healthy non-smokers (Di Stefano et 
al., 2009a). 
 
1.2.3.5   Other CXC related chemokines 
Previous studies have shown that T cells, predominantly CD8+ 
T cells, play a potent role in the pathogenesis of COPD. 
Homing of T cells to the infected organs depends on initial 
activation followed by adhesion and selective chemotaxis. 
CXCL9 (monokine induced by interferon (IFN-), CXCL10 (IFN-
-inducible protein of 10kDa, IP-10), and CXCL11 (IFN-
inducible T-cell- chemoattractant) are three chemokines 
released by IFN- activated bronchiolar epithelial cells and 
macropahges. They all can activate CXCR3 expressed by T 
cells and B cells (Devora, 2000). Studies have shown that 
CXCL10 expression is increased in bronchiolar epithelial cells 
and airway smooth muscle cells in COPD patients (Hardaker et 
al., 2004, Saetta et al., 2002), which leads to the 
accumulation of CXCR3+ CD8+ T cells (Tc1) and CD4+ T cells 
(Th1) in the epithelium and submucosa. CXCL11 has the 
highest affinity for CXCR3 (Clark-Lewis et al., 2003). Its 
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concentration is also increased in induced sputum of COPD 
patients. 
 
CXCL12 (stromal-cell-derived factor-1) and CXCL13 (B-cell-
attracting chemokine-1) are other two CXC chemokines 
binding to CXCR4 and CXCR5 respectively (Lapidot et al., 
2005). CXCR4 is expressed by T cells, moncytes, immature B 
cells and airway epithelial cells upon activation. CXCR5 is 
predominantly expressed by mature B cells, T follicular helper 
cells (a subset of CD4+ helper T cells) and memory CD4+ T 
cells (Forster et al., 1996, Kim et al., 2001, Schaerli et al., 
2000). Although their roles in COPD have not been explored 
yet, because their levels are increased in B cells and T cells 
associated with severe COPD, antagonists of CXCR4 and 
CXCR5 might be novel treatments for severe COPD. 
 
CXCL16 (scavenger receptor for phosphatidylserine and 
oxidized low-density lipoprotein) is a transmembrane 
chemokine expressed by DCs, macrophages and B cells. It 
binds to CXCR6 expressed by Th1 cells (Kim et al., 2001a). 
Therefore, it could be relevant to COPD. 
 
1.2.3.6   CCL2 (monocyte chemotactic protein-1, MCP-1) 
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CCL2 is a CC-chemokine and expressed by alveolar 
macrophages, T lymphocytes and epithelial cells. It is also 
released by type II pneumocytes in culture. Its secretion is 
triggered by LPS but inhibited by CSE. CCL2 activates CCR2 
on monocytes and lymphocytes (Rose et al., 2003). Previous 
studies have shown that CCL2 levels are enhanced in induced 
sputum, BAL fluid and lungs of COPD patients (Capelli et al., 
1999, de Boer et al., 2000, Traves et al., 2002). Recently, 
CCL2 expression has also been detected in small macrophages 
in induced sputum from COPD patients. Interestingly, there is 
a significantly increased level of mRNA expression of CCL2 in 
COPD patients compared to healthy non-smokers. Similar 
results are also seen in healthy smokers, although it is less 
pronounced (Frankenberger et al., 2010). TLR-2 and TLR-4 
can down-regulate CCR2 expression (Parker et al., 2004). 
Blocking CCR2 induces the termination of the chemoattractant 
effect of induced sputum from COPD patients (Monzon et al., 
2011), which indicates that antagonism of CCR2 may be a 
useful therapeutic strategy in COPD. 
 
1.2.3.7   Other CC-chemokines 
CCL3 (Macrophage inflammatory protein, MIP-1) and CCL4 
(MIP-1) are secreted by macrophages, taken together with 
CCL5 (released by activated normal T cells expressed and 
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secreted, RANTES), they all not only activate CCR1 expressed 
by monocytes and neutrophils, but also bind to CCR5 
expressed on Th1 and Tc1 cells (Devora, 2000). The levels of 
CCL3, CCL4 and CCL5 are all increased in COPD patients 
(Barnes, 2009). Numbers of CCR5+ T lymphocyte are elevated 
in induced sputum of COPD patients and in the airways of 
mild-moderate COPD patients but is decreased in severe 
disease (Costa et al., 2008, Di Stefano et al., 2001, Grumelli 
et al., 2004). CCL5 expression is increased in the airways and 
sputum of COPD patients during exacerbations, which 
indicates a role of CCR5 in the recruitment of T cells and 
macropahges during exacerbations (Fujimoto et al., 2005, Zhu 
et al., 2001a). In addition, CCL5 also activates CCR3 
predominantly expressed by eosinophils. 
 
CCL7 (MCP-3) and CCL13 (MCP-4) are CC-related chemokines 
and bind to CCR2 and CCR3 respectively. CCL17 (thymus- and 
activation-dependent chemokine, TARC), CCL20 (MIP-3) and 
CCL22 (macrophage-derived chemokine) are members of CC- 
chemokines and recruit target cells by interaction with CCR8, 
CCR6 and CCR4 respectively (Devora, 2000). Similar to CCL2, 
mRNA expression of CCL7, CCL13 and CCL22 are all markedly 
increased in small macrophages from induced sputum of COPD 
patients and healthy smokers compared to healthy non-
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smoking subjects, although less pronounced in smokers 
(Frankenberger et al., 2010). CCL20 is a potent 
chemoattractant of dendritic cells and is mainly expressed by 
airway epithelial cells in response to IFN- (Reibman et al., 
2003). Levels of CCL20 protein are increased in induced 
sputum from COPD patients compared to never smokers and 
smokers without COPD, and are negatively correlated with 
FEV1% function. There is also a significant inverse correlation 
between CCL20 mRNA expression in total lung and FEV1% 
(Demedts et al., 2007).  
 
1.2.3.8   CX3C chemokines 
CX3CL1 (fractalkine) is a unique CX3C chemokine that is 
expressed on cell surfaces. Its expression is enhanced in 
human airway epithelial cells after IFN- induced stimulation. 
It is involved in the recruitment and adhesion of monocytes, T 
lymphocytes and natural killer cells to epithelial cells (Fujimoto 
et al., 2001). However, its role in COPD is unexplored. 
Recently it has been implicated in the function of CX3CL1 in 
dendritic cell recruitment, which might be relevant to antigen 
presentation in COPD (Niess et al., 2005). 
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To sum up, cytokines and chemokine play potent roles in the 
pathogenesis of COPD. Figure 1.8 shows the pathological 
hallmarks of COPD. 
 
 
 
 
 
 
 
 
Figure 1.8 Pathological hall marks of COPD. The three main 
pathological hallmarks of COPD are chronic obstructive bronchiolitis, 
emphysema and mucus hypersecretion. 
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1.2.4 Oxidative stress in COPD 
Excessively production of ROS can generate oxidative stress, 
which results in damage to lipids, proteins and DNA (Finkel, 
2003). Oxidative stress can also lead to the oxidation of 
arachidonic acid and the formation of isoprostanes (a new 
series of prostanoid meidators), which have functional effects 
including bronchoconstriction and plasma exudation. Activated 
neutrophils, eosinophils, macrophages and epithelial cells are 
all good sources for ROS production in the airways (MacNee, 
2001a). For examples, in neutrophils, hydrogen peroxide 
(H2O2) generated from superoxide anions (O2 ·
-) is 
metabolized to hypocholorous acid in the presence of chloride 
ions, which is strong endogenous oxidant in the lung (Eiserich 
et al., 1998). Cigarette smoke, nitrogen dioxide, and ozone 
are exogenous oxidants that have the capacity to enhance the 
oxidative stress in the lungs (Pryor and Stone, 1993, Sunyer, 
2001). In human airways, the production of oxidants is 
controlled by several antioxidant mechanisms (Cantin et al., 
1990). However, the major antioxidants are extracellular, 
such as glutathione peroxidase that is significantly up-
regulated in response to cigarette smoking and oxidative 
stress (Avissar et al., 1996).  
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There are abundant studies showing increased oxidative stress 
in COPD (MacNee, 2001b, Repine et al., 1997). Increased 
xanthine/xanthine oxidase activity has been observed in BAL 
fluid from COPD patients (Pinamonti et al., 1998). 4-hydoxy-
2-nonenal is a specific marker for lipid peroxidation that is 
detectable in lungs of COPD patients and is location specific 
(Rahman et al., 2002). Ethane formed through lipid 
peroxidation is elevated in the breath of COPD patients and its 
concentration is correlated with disease severity (Paredi et al., 
2000). Concentrations of H2O2, 8-isoprostaglandin F2, 
malondialdehyde and thiobarbituric acid reactive substances 
are all increased in exhaled breath condensate of COPD 
patients (Montuschi et al., 2000). Formation of ROS can 
activate NF-B and activator protein-1 transcription factors, 
which induce a neutrophilic inflammation through increased 
expression of IL-8 and other chemokines, TNF- and MMP-9 
(Rusznak et al., 1996). Therefore, this evidence indicates that 
increased oxidative stress in the respiratory tract plays a 
potent role in the disease by amplifying the inflammatory and 
the destructive responses in COPD. 
 
1.2.5 Nitric oxide in COPD 
Peroxynitrite is an oxidant and nitrating agent. It can damage 
a wide array of molecules in cells, including DNA and proteins 
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(Pacher et al., 2007). Increased oxidative stress leads to the 
formation of peroxynitrite via combination of nitric oxide (NO) 
with superoxide anions and then nitrate, which both change 
the gaseous phase of NO. This may explain why the NO levels 
are reduced in normal smokers (Kharitonov et al., 1995). 
However, in COPD patients, the NO levels are increased and 
are positively correlated with eosinophil numbers and 
bronchodilator response (Papi et al., 2000). The enzyme 
inducible NO synthase (iNOS) that generates NO is expressed 
in macrophages and lung parenchyma of patients with COPD, 
especially in severe COPD (Ichinose et al., 2000, Maestrelli et 
al., 2003). Furthermore, concentrations of nitrate are also 
elevated in breath condensate and sputum of smokers with or 
without COPD (Corradi et al., 2001, Kanazawa et al., 2003). 
Increased levels of NO are detected in the alveolar 
compartment of COPD patients and correlates with disease 
severity (Brindicci et al., 2005). This corresponds to the 
finding of increased inducible NO synthase in the periphery of 
lungs in COPD subjects (Maestrelli et al., 2003). Therefore, 
the peripheral NO may be a useful non-invasive biomarker of 
COPD inflammation (Barnes et al., 2006). 
 
1.2.6 Peptide mediators in COPD 
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Endothelin-1 (ET-1) and bradykinin are two kinds of peptide 
related to COPD development (Barnes, 2004d). ET-1 is a 
potent vasoconstrictor with the ability to cause vascular 
smooth muscle hyperplasia (Bouallegue et al., 2007). Giaid et 
al have shown that expression of ET-1 is increased in 
pulmonary endothelial cells of COPD patients who have 
secondary pulmonary hypertension (Giaid et al., 1993). ET-1 
concentrations are also increased in induced sputum and BAL 
fluid in COPD patients (Bacakoglu et al., 2003, Chalmers et al., 
1999). All these findings indicate that ET-1 secretion may play 
an important role in pulmonary vasoconstriction and 
pulmonary hypertension in COPD. Bradykinin is a potent 
bronchoconstrictor of huma airways, particulary small airways 
(Hulsmann et al., 1994). It can stimulate mucus secretion and 
potentiates cough in airways (Nagaki et al., 1996). Although 
its function in COPD is not fully explored, proinflammatory 
cytokines produced in COPD increase the expression of 
bradykinin receptors in pulmonary cells (Tsukagoshi et al., 
1995). 
 
1.2.7 Lipid mediators in COPD 
1.2.7.1   Prostaglandin E2 (PGE2) and Prostaglandin F2 
(PGF2) 
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PGE2 is a bronchodilator of human airways (Pavord and 
Tattersfield, 1995). It inhibits the release of proinflammatory 
cytokines from monocytes and of acetylcholine from airway 
cholinergic nerves (Meja et al., 1997, Spicuzza et al., 1998). 
Therefore, PGE2 may have beneficial effects in COPD. However, 
it can also stimulate mucus secretion and expression of mucin 
genes (Borchers et al., 1999), and activate airway sensory 
nerves to enhance coughing (Stone et al., 1992). PGF2 is a 
bronchoconstrictor and has the ability of activating airway 
sensory nerves to produce cough (Nichol et al., 1990). 
Increased concentrations of both PGE2 and PGF2 are detected 
in exhaled breath of COPD patients (Montuschi et al., 2003).  
 
1.2.7.2   Leukotriene B4 (LTB4) 
LTB4 is mainly released from activated alveolar macrophages 
and neutrophils in the airways (Shamsuddin et al., 1997). It is 
a potent chemoattractant of neutrophils and binds to its 
receptors, namely, BLT1 and BLT2, expressed on neutrophils 
and T lymphocytes respectively (Yokomizo et al., 2000). 
Increased levels of LTB4 have been demonstrated in both 
exhaled breath condensate and induced sputum from patients 
with stable COPD (Beeh et al., 2003, Woolhouse et al., 2002), 
and particularly enhanced during exacerbations (Biernacki et 
al., 2003). 
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1.2.8 Growth Factors in COPD  
The release of growth factors can induce fibrosis and cell 
proliferation and further cause structural changes in small 
airways and lung parenchyma.  
 
1.2.8.1   Transforming growth factor- (TGF-) 
TGF- is a multifunctional growth factor with the ability to 
induce proliferation of fibroblasts and airway smooth muscle 
cells, deposition of extracellular matrix and epithelial repair. It 
also has immuno-suppressive effects on Th1, Th2 and Th17 
cells (Yoshimura and Muto, 2011). Increased expression of 
TGF- has been detected in airway epithelial cells and 
macrophages from small airways of COPD subjects (Takizawa 
et al., 2001). TGF- levels are also elevated in peripheral 
blood monocytes from COPD patients (Hodge et al., 2003b). 
In peripheral lung tissue from COPD patients, TGF- 
expression is increased and is correlated with 
immunoreactivity for 4-hydroxy-4-nonenal that is a marker of 
oxidative stress (Rahman et al., 2002).  
 
1.2.8.2   Epidermal growth factor (EGF) 
EGF, together with TNF-, activates EGF receptor (EGFR) 
(Argast et al., 2004, Lee et al., 2007a). It plays a critical role 
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in regulation of mucus secretion, differentiation of mucus-
secreting cells and expression of mucin genes (Burgel and 
Nadel, 2004). Increased levels of EGF, EGFR and the related 
cytokine, heregulin, have been detected in airway epithelial 
cells of COPD patients (Ganesan et al., 2012).  
 
1.2.8.3   Vascular endothelial growth factor (VEGF) 
VEGF is a regulator for the growth of new vessels and vascular 
leakage (Ho and Kuo, 2007). Its expression is increased in 
pulmonary vascular smooth muscle of patients with mild and 
moderate COPD but is reduced in severe COPD with 
emphysema (Santos et al., 2003). The level of VEGF is also 
reduced in induced sputum and the lung of COPD patients 
(Kanazawa and Yoshikawa, 2005). 
 
1.2.8.4   Fibroblast growth factors (FGF) 
FGF is related to vascular remodelling. Increased expression of 
FGF-1 and FGF-1 receptor, and FGF-2 have been investigated 
in large pulmonary vessels and small pulmonary vessels 
respectively (Kranenburg et al., 2005). 
 
1.2.9 Proteases in COPD 
1.2.9.1   Matrix metalloproteases (MMPs) 
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MMPs are a large family of up to 26 homologous 
endopeptidases, which can not only degrade protein 
components of the extracellular matrix but also has a potent 
function as regulating secretion of cytokines, chemokines and 
growth factors (Verma and Hansch, 2007). They are secreted 
by stromal cells and two major inflammatory cells including 
neutrophils and alveolar macropahges (Betsuyaku et al., 1999, 
Finlay et al., 1997a). Imbalance between proteinase and 
antiproteinase can lead to extracellular matrix destruction in 
the airways and contributing to airway remodelling and to 
decreased lung function in patients (Abboud and Vimalanathan, 
2008). Therefore, the balance between MMPs and tissue 
inhibitors of MMPs (TIMPs) is thought to be crucial in disease 
pathogenesis (Barnes, 2002).  
 
There are abundant studies showing the role of MMPs in COPD 
patients. MMP-9 is released by bronchial epithelial cells, 
neutrophils, alveolar macrophages and eosinophils (Atkinson 
and Senior, 2003). Its expression is induced by IL-13 and 
inhibited by TNF- and IL-1. There are feedback loops 
between MMP-9 and TGF- and bewteen MMP-9 and IL-8 (Fini 
et al., 1998). The expression of MMP-9 on alveolar 
macrophages is elevated in the BAL fluid from patients with 
emphysema (Finlay et al., 1997b). Increased levels of MMP-9 
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and its inhibitor TIMP-1 are also detected in induced sputum 
from stable COPD patients, which correlates with both 
neutrophilia and FEV1, compared to controls (Cataldo et al., 
2000, Culpitt et al., 2005, Vernooy et al., 2004). In COPD 
exacerbations, levels of MMP-9 are markedly increased in 
induced sputum and are positively correlated with numbers of 
neutrophils and lymphocytes, but not macrophages (Mercer et 
al., 2005). Moreover, higher expression of MMP-9 is found in 
alveolar macrophages from healthy smokers than healthy 
non-smokers (Russell et al., 2002a).  
 
A variety of experimental models of COPD have been 
established to detect effects of MMP-12 in COPD. Emphysema 
induced by cigarette exposure is prevented in MMP-12 
knockout mice (Hautamaki et al., 1997). Also, MMP-12 -/- 
mice do not develop to the lavage neutrophilia as seen after 
smoke exposure. However, the neutrophil influx can be 
restored by instillation of wild type alveolar macrophages 
(Churg et al., 2003). Unlike findings in mice, studies on MMP-
12 expression in human are controversial. Some studies 
demonstrate that MMP-12 mRNA is hardly detected in the lung 
(Gosselink et al., 2010, Imai et al., 2001, Lee et al., 2010), 
whereas others do show its difference between COPD patients 
and controls. For example, MMP-12 levels are higher in 
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induced sputum from stable COPD patients, no matter 
whether they are current smokers or ex-smokers, compared 
to healthy smokers and healthy non-smokers (Demedts et al., 
2006, Ilumets et al., 2007). Its enzymatic activity is also 
significantly higher in COPD subjects. These data indicate that 
MMP-12 in sputum is not induced by cigarette smoking per se 
but by the disease itself. Babusyte et al show that the number 
of MMP-12 positive macrophages is higher in BAL fluid from 
current smokers with COPD than ex-smokers with COPD and 
controls (Babusyte et al., 2007). Another group also found the 
MMP-12 levels are higher in the macrophages from current 
smokers compared to ex-smokers (Wallace et al., 2008). 
 
MMP-1 is also called interstitial collagenase-1. It is produced 
by bronchial epithelial cells, type II pneumocytes and alveolar 
macrophages in the lung (Verma and Hansch, 2007). 
Increased levels of MMP-1 mRNA and protein are detected in 
the lung of COPD patients (Gosselink et al., 2010, Lappalainen 
et al., 2005, Selman et al., 2003). 
 
In addition, levels of MMP-2 are elevated in induced sputum, 
lung parenchyma and lung tissue of COPD patients (Gueders 
et al., 2006, Ramos et al., 2009, Segura-Valdez et al., 2000). 
Also, increased levels of MMP-8 are detected in induced 
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sputum, particlularly during exacerbations in COPD patients 
(Ilumets et al., 2007, Skillrud et al., 1986, Vernooy et al., 
2004). 
 
Taken together, MMPs account for most of the elastolytic 
activity released from alveolar macrophages and neutrophils in 
COPD patients. They not only contribute to the destruction of 
extracellular matrix but also play important roles in small 
airway remodelling and emphysema. 
 
 
1.2.9.2   Neutrophil elastase (NE) 
NE is a serine protease that is inhibited by anti-protease 1-
antitrypsin in the lung parenchyma. It is stored in neutrophils 
and expressed on the cell surface when cells are activated by 
cytokines (Owen et al., 1997). NE is a potent mucus 
secretagogue of submucosal gland cells and goblet cells 
(Sommerhoff et al., 1990). It induces the expression of 
MUC5AC (Fischer and Voynow, 2002, Voynow et al., 1999). It 
also induces secretion of cytokines and chemokines, such as 
IL-8 (Nakamura et al., 1992). The apoptosis induced by 
macrophages are also impaired by NE (Vandivier et al., 2002).  
The amount of NE/1-AT complexes is increased in BAL fluid 
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from current smokers with COPD and is negatively correlated 
with FEV1 (Betsuyaku et al., 2000, Yoshioka et al., 1995). 
 
1.3 Role of apoptosis in the pathogenesis of 
COPD  
Unlike necrosis that is an uncontrolled process, apoptosis, 
programmed cell death, plays a key function in the elimination 
of unwanted damaged or infected cells (Baetu and Hiscott, 
2002). Three major pathways have been involved in the 
regulation of apoptosis, namely, ligand-death receptor 
pathway (e.g, TNF- and Fas ligand), cytolytic effector cell 
pathway (e.g, perforin and granzymes) and the mitochondrial 
intrinsic pathway (e.g. bcl-2). All pathways finally converge at 
the level of caspase-3 activation. Caspase activation leads to 
DNA fragmentation, characteristic of apoptotic cells and the 
cleavage of cytoskeletal proteins (Plataki et al., 2006). Figure 
1.9 shows the different mechanisms of apoptosis induced by 
cytotoxic cells. 
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Figure 1.9 Different mechanisms of apoptosis induced by cytotoxic 
cells. Infected cells (Target cells) present antigen peptides to cytotoxic cells 
by binding to their TCRs. Activated cytotoxic cells then release granule 
killing molecules, such as perforin and granzymes. The former one is 
traditionally considered to form pores on the cytoplasm of target cells which 
facilitates granzymes passage. However, others indicate the granzyme B 
can still be endocytosised independently of perforin by mannose-6 
phosphate receptors. Besides granule molecules, Fas-L and TNF-
expressed by cytotoxic cells interact with Fas and TNF receptor expressed 
by target cells respecitively. Grznzyme A and granzyme B induce cell 
apoptosis in different manners. 
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Studies on apoptosis in COPD are well established. Segura-
Valdez et al were the first to show increased apoptosis in lung 
tissue sections of COPD patients compared to controls 
(Segura-Valdez et al., 2000). Both apoptosis and proliferation 
of cells (alveolar epithelial cells, endothelial cells and 
mesenchymal cells) have been elevated in the lung tissue of 
patients with emphysema compared to healthy subjects with 
or without smoking history (Imai et al., 2005, Yokohori et al., 
2004). VEGF is a growth factor that induces the expression of 
anti-apoptotic proteins and is a survival factor of endothelial 
cells (Alon et al., 1995, Gerber et al., 1998). Its levels are 
decreased in induced sputum of COPD patients and correlated 
with disease severity. Moreover, both the percentage and 
absolute number of apoptotic bronchial epithelial cells were 
significantly higher in COPD patients, with increased 
expression of Fas, p53 and activated caspases (Hodge et al., 
2005a). Reduced apoptosis of neutrophils was found in 
hospitalized patients with an acute exacerbation of COPD 
(Pletz et al., 2004).  
 
In peripheral blood studies, several mediators involved in the 
induction of T cell apoptosis, such as TNF- and Fas, are 
upregulated in COPD patients (Hodge et al., 2003b). There is 
a marked increase in soluble Fas in plasma from severe COPD 
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patients but not in mild or moderate COPD and healthy 
controls (Yasuda et al., 1998). Since COPD is a complex lung 
disease with systemic consequences, skeletal muscle 
apoptosis has been studied. Interestingly, the skeletal muscle 
apoptosis is elevated in COPD patients who have a low BMI 
(Agusti et al., 2002). 
 
The major mechanism of cytotoxic cell-mediated killing is 
performed by cytotoxic granules and Fas-FasL (Russell and 
Ley, 2002). After recognition of target cells by effector cells, 
granules released by cytotoxic cells move to the 
immunological synapse by exocytosis. Then their membrane 
fuses with the killer cell plasma membrane and release 
contents into target cells by endocytosis (Hayes et al., 1989, 
Stinchcombe et al., 2001). A pore forming protein perforin and 
a group of serine proteases named as granzymes are two 
representative types of granules related to granule-mediated 
cytolysis (Pasternack et al., 1986, Podack et al., 1985). 
 
1.3.1 Perforin  
Perforin is homologous to the complement protein C9. It is 
expressed by all cytolytic cells including cytotoxic T cells, NK 
cells and NKT cells. Traditionally, perforin is thought to form 
pores in the target cell plasma membrane in a Ca2+-dependent 
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manner that help granzymes to pass through (Tschopp et al., 
1986). Indeed, pores are not big enough to allow passage of 
globular molecules as big as granzymes. Sublytic 
concentrations are required to deliver granzymes (Kawasaki et 
al., 2000, Metkar et al., 2002). Increased expression of 
perforin and granzyme B has been detected on CD8+ T cells 
from BAL fluid in COPD patients and healthy smokers 
compared non-smokers (Hodge et al., 2006). Percentages of 
killer cells expressing both perforin and granzyme B were also 
markedly higher in induced sputum of COPD groups 
(Chrysofakis et al., 2004, Urbanowicz et al., 2010). Morissette 
et al have shown that there is no significant difference in the 
percentage of CD8+ or CD4+ T lymphocytes and NK cells 
expressing perforin from peripheral blood between 
emphysematous smoking COPD patients and control groups 
(Morissette et al., 2007). Whereas Urbanowicz et al have 
demonstrated proportions of killer cells expressing both 
perforin and granzyme B are lower in the peripheral blood 
from COPD patients (Urbanowicz et al., 2009).  
 
1.3.2 Granzymes 
Granzymes are a family of highly homologous serine proteases. 
Their main function is to induce cell death to eliminate 
infected cells. Also, they play a role in immune regulation 
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(Regner and Mullbacher, 2004). Five human granzymes have 
been identified, namely, A, B, H, K, M (Barry and Bleackley, 
2002). However, the most abundant granzymes are granzyme 
A and B, which induce cell death through alternate and 
nonoverlapping pathways. 
 
Granzyme A 
Granzyme A is the most abundant protease in the cytotoxic 
granules (Garcia-Sanz et al., 1990, Gershenfeld and 
Weissman, 1986). It is mainly expressed by NK cells and 
activated cytotoxic T lymphocytes. Unlike perforin and other 
granzymes, granzyme A is continuously expressed after T cell 
activation, perhaps even in long-term memory cells (Chen et 
al., 2001, Zhang et al., 2003). Although it is also delivered 
into target cells via perforin, it initiates innate immune 
response via a granzyme B and caspase independent pathway 
and has the extracellular matrix cleavage capacities including 
degradation of type IV collagen (Chowdhury and Lieberman, 
2008, Shresta et al., 1999). Interestingly, a recent study 
shows that, rather than its cytotoxic ability, the major role of 
granzyme A is promoting inflammation through inducing 
production of pro-inflammatory cytokines in monocytic cells 
(Metkar et al., 2008). Increased expression of granzyme A, 
but not granzyme B, has been detected in type II 
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pneumocytes in patients with severe COPD (Vernooy et al., 
2007).  
 
Granzyme B 
Granzyme B is a serine protease and is classically considered 
to be expressed by cytotoxic T lymphocytes and NK cells 
(Fairclough et al., 2008). Recently, it has also been found in 
many different types of myeloid cells that are noncytotoxic, 
such as Treg cells, type II pneumocytes, basophils, 
macrophages, DCs, smooth muscle cells and so on, generally 
without perforin (Gondek et al., 2005, Grossman et al., 2004). 
Therefore, besides the major function in inducing cell death, 
granzymes also have additional non-cytolytic functions, for 
examples, regulating lymphocyte survival and immune 
tolerance, promoting inflammation and potentially enhancing 
lymphocyte migration (Chowdhury and Lieberman, 2008). 
Tranditionally, perforin is thought to be essential in mediating 
the action of granzyme B against target cells. Perforin forms a 
multimeric transmembrane pore in the target cell, which 
facilitates granzyme B passing into the target cells (Bossi and 
Griffiths, 2005). Recently, another perforin-independent model 
of this process has been established. Granzyme B is 
endocytosed in complex with the mannose-6 phosphate 
receptor while perforin has not been expressed by effector 
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cells (Froelich et al., 1996, Metkar et al., 2002, Shi et al., 
1997). Granzyme B mediated apoptosis is caspase-dependent. 
Caspase 3 is a central execution caspase and is directly 
processed by granzyme B (Talanian et al., 1997, Yang et al., 
1998). In addition, activation of T cells induces the expression 
of perforin and granzymes. IL-2 is the only stimulus that 
consistently upregulates the expression of granzyme A, 
granzyme B and perforin (Liu et al., 1989). IL-15 and IL-21 
also activate granzyme B and perforin expression in CD8+ T 
lymphocytes from human peripheral blood samples (White et 
al., 2007). 
 
The specific role of granzyme B in COPD is much more studied 
than other granzymes. Hodge et al have shown increased 
expression of granzyme B and perforin by CD8+ T cells from 
BAL fluid in COPD patients and healthy smokers compared to 
non-smokers (Hodge et al., 2006), and there was a correlation 
between the percentage of granzyme B expressing T cells and 
bronchial epithelial cell apoptosis. In the same study, both 
soluble granzyme B and the percentage of T cells with 
intracellular granzyme B have been observed to be increased 
in COPD patients. Percentages of CD8+ T lymphocytes, NK 
cells and NKT-like cells expressing both perforin and granzyme 
B were markedly higher in induced sputum of COPD groups 
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(Urbanowicz et al., 2010). Nevertheless, findings produced 
using peripheral blood samples are complicated. Morissette et 
al have reported that there is no significant difference in the 
percentage of CD8+ or CD4+ T lymphocytes and NK cells 
expressing granzyme B between emphysematous smoking 
COPD patients and control groups including healthy non-
smokers and healthy smokers (Morissette et al., 2007). 
Conversely, intracellular granzyme B has been investigated in 
a greater percentage of T cells from the peripheral blood of 
COPD patients (Hodge et al., 2006). Studies performed in our 
group have shown that the percentage CD8+ T lymphocytes, 
CD6dimCD16+ NK cells and NKT-like cells that expressed both 
perforin and granzyme B were significantly lower in COPD 
patients compared with the healthy smokers and non-smokers 
(Urbanowicz et al., 2009). 
 
Granzyme K 
Granzyme K is another tryptase and causes cell death in a 
capase-independent manner similar to granzyme A. However, 
it is expressed much less than granzyme A. Granzyme K is 
mainly expressed by activated killer cells and a small 
population of CD4+ T cells (Bratke et al., 2008, Hameed et al., 
1988). Although there is no difference in granzyme K 
expression in BAL fluid from COPD patients and allergic 
 117 
asthma (without allergen provocation), it is indeed 
upregulated in cases of acute airway inflammation (Bratke et 
al., 2008). These findings suggest that granzyme K release is 
a specific event in acute airway inflammation, and chronic 
inflammation, such as stable COPD, does not equate to a pan-
granzyme effect and that there may be inter-granzyme 
variability regarding activity and leves in different diseases. 
 
Other human granzymes  
Up to date, there are no studies on the role of granzyme H 
and granzyme M in COPD.  
 
1.3.3 Fas and Fas-ligand 
Fas is a transmembrance receptor belonging to the TNF 
receptor family. It is widely expressed on normal cells and 
malignant cells (Leithauser et al., 1993, Nagata and Golstein, 
1995, Smith et al., 1994). Fas ligand (Fas-L) is a membrane-
bound cytokine belonging to the TNF family. It is mainly 
expressed on activated T cells and induces cell apopotosis by 
binding to Fas (Suda et al., 1995, Suda et al., 1993). Unlike 
levels of TNF- that are significantly higher in peripheral blood 
from COPD patients, there is no significant difference in the 
serum level of soluble Fas-L and the plasma level of soluble 
Fas among groups (Takabatake et al., 2000). Interestingly, 
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another study has shown that the proportion of Fas positive T 
lymphocytes is dramatically higher in peripheral blood from 
COPD patients compared to healthy non-smokers and smokers. 
Moveover, the proportion of CD8+ T cells expressing Fas is 
correlated with disease severity (Domagala-Kulawik et al., 
2007). Increased expression of Fas is also detected in 
bronchial epithelial cells in COPD subjects (Hodge et al., 
2005a). 
 
1.3.4 Granulysin  
Granulysin is a proinflammatory molecule expressed by 
activated cytotoxic T cells and natural killer cells (Krensky and 
Clayberger, 2005). It is also a chemoattaractant for 
monocytes, T lymphocytes, and activates the expression of 
many cytokines, such as IL-1, IL-6 and IL-10 (Deng et al., 
2005). Studies have shown that granulysin has broad clinical 
relevance to a myriad disease including cancers (Kishi et al., 
2002), skin afflictions (Ammar et al., 2008), infections 
(Sahiratmadja et al., 2007) and reproductive complications 
(King et al., 2003). However, it is still to be studied in COPD.   
 
1.4 Hypothesis of this project 
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Chronic Obstructive Pulmonary Disease (COPD) is a chronic 
inflammatory disease involving both innate and adaptive 
immune responses. Activated inflammatory cells can release 
inflammatory mediators, such as TNF-, IFN-, matrix-
metalloproteinase and IL-8, that sustain the inflammatory 
process and finally lead to airway remodelling (Chung, 2005), 
parenchymal destruction and mucocilialary dysfunction 
(Danahay and Jackson, 2005). Activated neutrophils (Damiano 
et al., 1986, Galdston et al., 1977), macropahges (Molet et al., 
2005, Montano et al., 2004) and DCs (Demedts et al., 2007) 
have been observed in the airways or sputum of COPD groups. 
CD8+ T-lymphocytes, NKT-like cells and NK cells are the three 
main types of killer cells in the immune system and have been 
implicated in the pathogenesis of COPD (Fairclough et al., 
2008).  Abnormal numbers of CD8+ T-lymphocytes have been 
found in large airways sub-epithelium (O'Shaughnessy et al., 
1997, Lams et al., 2000), peripheral airway (Saetta et al., 
1998), parenchyma (Saetta et al., 1999), smooth muscle 
(Baraldo et al., 2004), bronchial arteries (Peinado et al., 1999, 
Saetta et al., 1999, Turato et al., 2002), peripheral blood 
(Urbanowicz et al., 2009), sputum samples (Urbanowicz et al., 
2010), and small airways such as broncheoalveolar lavage 
(BAL) (Saetta et al., 2002, Saetta et al., 2003). Abnormal 
proportions of NKT-like cells have also been detected in 
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peripheral blood (Urbanowicz et al., 2009), and induced 
sputum (Urbanowicz et al., 2010) from smokers with COPD. 
The frequency of iNKT cells is lower in peripheral blood from 
patients with exacerbations of COPD compared to stable COPD 
patients (Chi et al., 2011). Reduced numbers of NK cells and 
their phagocytic activities have been observed in peripheral 
blood from both asymptomatic smokers and COPD patients 
(Ferson et al., 1979, Prieto et al., 2001). However, NK cell 
proportion and their cytotoxicity are increased in induced 
sputum from COPD patients in contrast to healthy non-
smokers and healthy smokers (Urbanowicz et al., 2010). 
Taken together, all these findings indicate that killer cells may 
be much more activated in COPD groups and play an 
important role in pathogenesis of disease. Figure 1.10 shows 
how NK cells interact with other leucocytes and epithelims to 
become activated. 
 
This project we are aiming to explore immunological features 
of killer cells in COPD, especially under the condition of 
cigarette smoking induced activation. Main approaches of this 
project are as followed. Firstly, we compared the activation 
status of killer cells ex vivo in both healthy participants and  
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COPD patients. Cigarette smoking is still the predominant risk 
factor in COPD, we hypothesis that cigarette smoke extract 
may induce immunological changes on killer cell functions. 
Therefore, in vitro, effects of cigarette smoke extract on killer 
cell activation upon different stimulation were investigated 
between study groups. Expression levels of effoctor molecules, 
such as granzymes, perforin and Fas-ligand, by killer cells 
Figure 1.10 Interaction between NK cells and other 
lymphocytes. NK cells are the innate immune cells expressing multiple 
receptors. Activation of NK cells can be induced either by interaction of 
ligands to functional receptors, such as MICA to NKG2D; or by 
cytokines, for example, IL-2, 15, 18, 23, INF- and TNF-, produced by 
other lymphocytes. Epithelial cell is a big source of producing IL-15. 
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were also tested. Furthermore, cytotoxicity of CD8+ T cells in 
each study group was also investigated. All above research 
were performed in peripheral blood samples. Finally, we 
compared the activation levels of killer cells in BAL from COPD 
patients. 
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2.1 Study population and procedures 
 
The study population consisted of 16 healthy non-smoking 
volunteers, 12 healthy smokers, and 21 COPD patients who 
were either current smokers or ex-smokers. The diagnosis of 
COPD was made according to the ATS guidelines. Healthy non-
smokers and current healthy smokers were with an FEV1>80% 
of predicted normal and had normal lung function. COPD 
patients had irreversible airflow limitations on spirometry 
(FEV1<80% of predicted with FEV1/FVC ratio of <70%) and 
were reversibility to an inhaled beta-2 agonist of<10% or 
<200 mls absolute improvement. Smokers suffering from 
COPD accrued at least a 20-pack year smoking history and 
healthy smokers had a similar smoking history to them. All 
participants were age-matched and met the following inclusion 
criteria. Firstly, they were nonatopic (negative skin prick test 
response to common allergen extracts including grass pollen, 
house dust mite, cat dander and dog hair). Secondly, there 
was also no personal or family history of allergic diseases with 
them, such as allergic rhinitis. Thirdly, these subjects did not 
have any history of systemic or other pulmonary diseases, for 
example, TB, asthma, lung cancer, bronchiectasis or 1-anti-
trypsin deficient. In addition, they should also not be infected 
by acute viruses or bacteria. Finally, all COPD patients had 
been free of an acute exacerbation of COPD for at least 6 
 125 
weeks preceding the study and none had received antibiotics 
or corticosteroids (oral and inhaled) over the same period.  
 
Other four COPD patients were recruited for the BAL study. 
The inclusion/exclusion criteria were the same as mentioned 
above. 
 
The study protocol was approved by the Nottingham Research 
Ethics Committee (REC reference 04/Q2403/102) and 
informed consent was obtained from all participants before 
entering the blinded study.  
 
2.2 Peripheral Blood Mononuclear Cell (PBMCs) 
isolation 
Peripheral venous blood (50mls) from each participant was 
diluted in warm RPMI 1640 (Sigma, Poole, UK) with 100U/ml 
penicillin and 100ug/ml streptomycin (RPMI-1640 medium) at 
2:1 ratio and then layered over a discontinuous Histopaque 
density gradient (Sigma, Poole, UK). PBMCs were removed 
from the surface of Histopaque after centrifugation at 800g for 
22 minutes and washed twice in RPMI medium at 300g, 4°C 
for 5 minutes. Isolated PBMCs were resuspended in 
appropriate medium. Prior to experiments, cells were counted 
with a Hemocytometer using standard protocol. Cell viability 
 126 
was assessed with 0.5% Trypan Blue (Sigma, Poole, UK) 
staining. 
 
2.3 CD56+ and CD8+ cell separation 
Isolated PBMCs were incubated with anti-CD56 MicroBeads 
(Miltenyi Biotech Ltd, Surrey, UK) in MACS buffer containing 
sterile D-PBS (Sigma), 1% heat-inactivated fetal calf serum 
(FCS) (QB-Perbio, UK) and 0.4% EDTA (Sigma, Poole, UK) for 
15 minutes at 4°C. CD56- cell fractions were obtained by cell 
suspension passing through a cold MS column attached to a 
magnet. After washing three times, the column was removed 
from the magnet and 1ml MACS buffer was added and quickly 
plunged through the MS column into sterile tube for collection 
of CD56+ cells. To obtain NKT-like cells (CD3+CD56+) and NK 
cells (CD3-CD56+), CD56+ cells were incubated with Multisort 
Release Reagent for 10 minutes at 4°C, washed and then 
incubated with MultiSort Stop Reagent and -CD3 microbeads 
for 15 minutes at 4°C. Finally the labelled cells were separated 
on a refrigerated LS column. CD8+ T lymphocytes were 
positively selected from CD56 negative fraction after 
incubated with anti-CD8 MicroBeads (Miltenyi Biotech Ltd, 
Surrey, UK) by using the same method of NKT-like cell 
separation. All isolated fractions were washed and counted. 
Detailed protocol for cell separation was shown on 
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manufacturer’s instructions. The purity of CD3+CD56+, CD3-
CD56+ cells or CD8+ CD56- cells was over 90%, as verified by 
flow cytometry.  
 
2.4 Cigarette smoke extract (CSE) preparation 
It should be noted that there are more than four thousand 
components in cigarettes that contribute to the diversity of 
cigarette brands. Choosing Marlboro to produce cigarette 
smoke extract in this project is because, of all menthol and 
non-menthol cigarettes, Marlboro is the brand used most often 
by 42.4% of smokers (Ref, office of applied studies. The 
NSDUH report Cigarette Brand Preferences in 2005. 2007).  
 
A CSE collection apparatus is set up prior to 30 minutes of cell 
culture for each experiment in fume hood. As shown in Figure 
2.1, the chemicals and equipment for the apparatus are as 
followed. (1) 10ml of Phenol-red free RPMI-1640 (GIBCO, 
Invitrogen, Paisley, UK) in a 30ml steralin; (2) cigarette 
(Marlboro, EU; Tar 10mg, Nicotine 0.8mg, carbon monoxide 
10mg) with filter cut off; (3) 3-way tap; (4) two sections of 
flexible tubing; (5) steralin lid with hole cut in, for tubing to fit 
through; (6) 50ml syringe to aspirate the smoke; (7) two 
clapmps and one clamp stand. 
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Figure 2.1 Apparatus of CSE preparation 
 
 
To collect CSE, firstly, the tap should be switched to the 
position that keep the tubing leading to the seralin is off. CSE 
from single lit commercial cigarette were aspirated to the 
50ml syringe at rate of 125ml in 60s. Then, switch the tap so 
that the route to the steralin containing 10ml of Phenol-red 
free RPMI-1640 is ON. Slowly bubble the entire 50ml of smoke 
into the medium. Repeat this process until the cigarette is 
finished. The crude CSE was filtered through a 0.45um pore 
filter to remove bacteria and/or large particles and 
subsequently adjusted with medium to an absorbace reading 
of 0.15 at 320nm.  This solution was taken as 100% CSE.  
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2.5 Cell culture and treatments 
Isolated PBMCs, NKT-like cells, NK cells or CD8+CD56- T 
lymphocytes cells were resuspended in RPMI-1640 medium 
supplemented with 10% FCS at a density of 1x106 cells/ml. 
Cell suspension was loaded to a 96-well flat bottom tissue 
culture plate at 200ul of each well. To detect the cell 
activation, receptor expression and cytokine secretion, cells 
were stimulated with anti-CD3 (R&D System, Abingdon, UK), 
recombined human IL-2 (rhIL-2; PeproTech, EC, London, UK), 
recombined human IL-15 (rhIL-15; PeproTech, EC, London, 
UK), and CSE and incubated at 37°C in 5% CO2. The time 
period of incubation and concentrations of these stimulators 
were determined by each experiment protocol. Specially, anti-
CD3 was pre-coated in the plate for 90 minutes at 37°C in 5% 
CO2 and wash in cold sterile D-PBS twice to remove the 
unbound antibody.  
 
For cytotoxicity assay, isolated CD8+CD56- cells were only 
incubated for 24 hours at 37°C in 5% CO2. Before cell 
incubation, the plate was coated with 2µg/ml anti-CD3 (in 
50ul D-PBS solution each well) for a minimum of 2 hours at 
37°C in 5% CO2. Target cells (P815 cells) were grown in 
RPMI-1640 medium supplemented with 10% FCS at 37°C in 
5% CO2 and ready for use when they reached confluence. 
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2.6 Extracellular staining and Intracellular 
staining 
To harvest maximal cells for analysis, cells in each well were 
flushed with 200ul PBA (PBS; 1% BSA; and 0.1% sodium 
azide; Sigma, Poole, UK) twice and washed with 1ml PBA in a 
FACS tube (Elkay, Hampshire, UK). For extracellular staining, 
cells were incubated with fluorescently conjugated antibodies 
at the recommended concentrations for 30 minutes at 4°C. 
Unlabeled antibodies were removed with 1ml PBA washing up 
twice. Control tubes with single colour fluorescently 
conjugated antibody were used for setting compensation on 
flow cytometer by technician. Additional tubes with 
fluorescence minus one (FMO) were set up for quadrant 
setting in data presentation.  
 
To detect the intracellular protein secretion, prior to 10 hours 
of harvesting, cells were treated with 10ug/ml brefeldin A 
(Sigma, Poole, UK). After washed with 1ml PBA solution, cell 
pellets were fixed in 3% formaldehyde in isotonic azide free 
solution, incubated for 5 minutes at 4ºC, centrifuged, washed 
with 1ml PBA, 1ml PBA with 0.04% saponin (Sigma, Poole, UK) 
and 1ml PBA with 0.04% saponin and 10% FCS orderly. 
Interested labeled antibodies were mixed to cells at 
recommended concentrations and cells were incubated on a 
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rocker at 4°C for 2 hours (see table 1). Unbound antibodies 
were removed by 1ml PBA with 0.04% saponin washing up 
twice. 
 
All centrifugations were performed at 300g for 5 minutes. 
Finally, cell pellets were fixed in 0.5% formaldehyde in 
isotonic azide free solution and stored at 4°C for flow 
cytometry analysis.  
 
2.7 CD8+ T lymphocytes Redirected Cytotoxicity 
Assay 
The cytotoxicity of CD8+ T lymphocyte was measured with 
colorimetric quantification of lactate dehydrogenase LDH 
released from lysed target cells (P815 cells). Harvested CD8+ 
CD56- T cells were counted in a standard manner and 
resuspended at 4x106 cells/ml in RPMI-1640 medium without 
phenol red and FCS. P815 target cells were treated with 
10ug/ml of anti-CD3 and incubated at 37°C. After 30 minutes 
incubation, P815 cells were washed twice and resuspened in 
RPMI-1640 without phenol red supplement with 10% FCS at a 
density of 1x105 cells/ml. A U-bottom 96-well culture plate 
was used in this protocol. 
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RPMI-1640 without phenol red supplement with 5% FCS was 
loaded to two triplicate sets of wells at 100ul/well. The top 
three wells, called as Culture Medium Background, were 
established to correct for contributions caused by phenol red 
and LDH activity that may be present in serum containing 
culture medium. The bottom three wells, called as Volume 
Correction Control, were used for correcting for the volume 
increase caused by addition of Lysis Solution (10X).  
 
Target cells were added at 50ul/well to two triplicate sets of 
wells each containing 50ul RPMI-1640 without phenol red. The 
top three wells were used for measurement of target cell 
spontaneous LDH release, the bottom three was for the 
detection of target cell maximum LDH release. 
 
Four effector to target (E:T) ratios were tested in this assay, 
namely, 40, 20, 10 and 5. Diluted effector cells at 50ul were 
loaded to each well containing 50ul of RPMI-1640 without 
phenol red supplement with 10% FCS. Target cells at 50ul 
were mixed with 50ul of diluted CD8+ T cells. Both conditions 
were prepared in triplicates as well. 
 
Effector and target cells were brought into close contact by 
centrifuging the plate at 250g for 4 minutes and incubated for 
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4 hours at 37°C in 5% CO2. Forty-five minutes prior to 
harvesting supernatants, wells used for Volume Correction 
Control and target cell maximum LDH release were treated 
with Lysis Solution (10X) at 10ul/well. After 4 hours 
incubation, plate was centrifuged at 250g for 4 minutes. 50ul 
aliquots from all wells were transferred to a fresh 96-well flat-
bottom (enzymatic assay) plate. Assay buffer Substrate Mix 
(Promega, USA) was thawed at 37°C shortly and added to 
each well at 50ul to detect LDH activities. The plate was then 
covered with foil and incubated for 30 minutes at room 
temperature. After incubation, 50ul of Stop Solution (Promega, 
USA) was added to each well and the sample was read at 
49nm on an Emax precision microplate reader (Molecular 
Devices, Workingham, UK) using SOFTmax software 
(Molecular Devices) immediately. The percentage of cell-
mediated cytotoxicity was calculated by the following formula: 
 
Cytotoxicity (%) = {(effector/target cell mix-spontaneous 
effector LDH release-spontaneous target LDH 
release)/(maximum target LDH release-spontaneous target 
LDH release)} x 100 
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2.8 BAL preparation  
Bronchoscopy with BAL was performed by a clinician from the 
Queen’s Medical Centre, University of Nottingham, UK. Four 
COPD patients were recruited to this research. Each of them 
was sedated with oxycodon and scopolamine hydrobromide 10 
minutes prior to the procedure. A fibreoptic bronchoscope 
(Olympus 1T 20 D, Olympus Corporation, NY, USA) was 
pushed in the subsegmental bronchus of the right middle lobe 
via the nasal route. Four 50ml aliquots of sterile, pre-warmed 
normal saline were administered and sucked into four plastic 
bottles by gentle hand suction through the bronchoscope. All 
bottles were kept in ice. The first pooled samples were discard. 
Other three samples were used for BAL cellular analysis. 
 
Before centrifugation of BAL fluid, two 50ml centrifuge tubes 
were weighted on an electronic scale. Samples were pipetted 
into the tubes and the volumes of them were noted. Filled 
tubes were re-weighted and the weight of recovered BAL fluid 
was calculated. A sterile piece of the 48um nylon gauze was 
put in a 35mm sterile funnel to pour through BAL samples, 
and then the volume and the weight of filtrate were measured 
and noted. Filtrated BAL fluid was centrifuged at 400g for 10 
minutes at 4°C. The cell pellets were washed twice with sterile 
D-PBS by centrifugation. Total cell counts were determined 
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with a haemocytometer. Cells were resuspended in RPMI 
medium supplemented with 10% FCS. To determine the cell 
populations in the BAL, extracellular staining was performed 
for these cells as described previously.  
 
2.9 Flow cytometric analysis 
Labelled cells were analyzed on an EPICS ALTRA flow 
cytometer (Beckman Coulter, Buckinghamshire, UK). For each 
test, 50000 total events were collected, unless otherwise 
stated. Data analysis was performed using WEASEL software 
version 2.3 (The Walter And Eliza Hall Institute of Medical 
Research, Melbourne, Australia). For each staining 
experiments, compensation detection was set up by using 
control tubes with single colour fluorescently conjugated 
antibody. Fluorescence minus one (FMO) tubes were also used 
for quadrant setting. Dead cells were excluded according to 
forward scatter vs side scatter characteristics. 
 
2.10 Statistical analysis 
The statistical analysis was performed with Prism software, 
version 4.0c (GraphPad).  Data that were non-normally 
distributed are expressed as median and range, unless 
otherwise stated. Normality was detected using the 
Kolmogorov–Smirnov test. Differences between the four 
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groups of participants were tested using the non-parametric 
Kruskal-Wallis test with post hoc pairwise comparisons made 
by the Dunn's Multiple Comparison test to determine which 
pair was statistically significantly different.  Differences 
between the “before and after” treatment were tested by 
parametric stuent’s t test. Confidence interval 99% was used 
to show two-tailed p values. P values of less than 0.05 or 0.01 
were considered to indicate statistical significance according to 
the size of each study group. 
 
2.11 Antibodies for flow cytometry 
Table 2.1 shows all antibodies used in whole project. FITC, PE 
and PC7 labelled antibodies were added at 5ul to cell pellets; 
ECD and PC5 were added at 2.5ul. 
 
 
 
 
 
 
 
 
 
 
 137 
Table 2.1 Antibodies for extracelluar staining and intracellular staining 
Antigen Fluorochrome Isotype Clone Source 
CD3 ECD 
PC7 
Mouse IgG1 UCHT1 Beckman Coulter, 
Luton, UK 
CD4 FICT 
PC5 
Mouse IgG1 13B8.2 Beckman Coulter, 
Luton, UK 
CD8 PC5 Mouse IgG1 B9.11 Beckman Coulter, 
Luton, UK 
CD8 ECD Mouse IgG1 SFCl21Thy2D3 Beckman Coulter, 
Luton, UK 
CD25 FITC 
PE 
Mouse IgG2a, k B1.49.9 Beckman Coulter, 
Luton, UK 
CD56 PE 
PC5 
Mouse IgG1 N901 Beckman Coulter, 
Luton, UK 
CD69 ECD 
PC5 
Mouse IgG2b TP1.55.3 Beckman Coulter, 
Luton, UK 
KIR3DL1 
(CD158e1) 
FITC Mouse IgG1, k DX9 Biolegend, San 
Diego, CA, USA 
NKG2D 
(CD314) 
PE 
Mouse IgG1 
 
ON72 
 
Beckman Coulter, 
Luton, UK 
GranzymeB 
 
FITC 
 
Mouse IgG1, k 
 
 
GB11 
 
 
BD PharmingenTM 
 
 
Perforin 
 
PE 
 
Mouse IgG2b, k 
 
 
G9 
 
 
BD PharmingenTM 
 
 
Fas-L 
(CD178) 
PE 
 
IgG Hamster 
 
4A5 
 
Beckman Coulter, 
Luton, UK 
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3.1 Activation of killer cells in peripheral blood 
in COPD patients ex vivo 
 
3.1.1 Introduction 
 
Many risk factors have been implicated in COPD, but cigarette 
smoking is still considered the common and key pathological 
driver in the development and progression of COPD (Mannino 
and Buist, 2007). Smoking cessation has shown great 
potential in control of disease development (Scanlon et al., 
2000, Tashkin and Murray, 2009).  
  
CD8+ T-lymphocytes, NKT-like cells and NK cells are the three 
main types of killer cells in the immune system and have been 
implicated in the pathogenesis of COPD (Fairclough et al., 
2008).  Abnormal numbers of CD8+ T-lymphocytes have been 
found in large airways sub-epithelium (O'Shaughnessy et al., 
1997, Lams et al., 2000), peripheral airway (Saetta et al., 
1998), parenchyma (Saetta et al., 1999), smooth muscle 
(Baraldo et al., 2004), bronchial arteries (Peinado et al., 1999, 
Saetta et al., 1999, Turato et al., 2002), peripheral blood 
(Urbanowicz et al., 2009), sputum samples (Urbanowicz et al., 
2010), and small airways such as broncheoalveolar lavage 
(BAL) (Saetta et al., 2002, Saetta et al., 2003). Abnormal 
proportions of NKT-like cells have also been detected in 
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peripheral blood (Urbanowicz et al., 2009), and induced 
sputum (Urbanowicz et al., 2010) from smokers with COPD. 
The frequency of iNKT cells is lower in peripheral blood from 
patients with exacerbations of COPD compared to stable COPD 
patients (Chi et al., 2011). Reduced numbers of NK cells and 
their phagocytic activities have been observed in peripheral 
blood from both asymptomatic smokers and COPD patients 
(Ferson et al., 1979, Prieto et al., 2001). However, NK cell 
proportion and their cytotoxicity are increased in induced 
sputum from COPD patients in contrast to healthy non-
smokers and healthy smokers (Urbanowicz et al., 2010). In 
addition, cigarette smoke treated NK cells from non-smoking 
healthy subjects have shown defective cytokine secretion 
upon poly I:C activation (Mian et al., 2008). 
 
Studies on CD4+ T cells are less extensive than CD8+ T cell 
infiltrates. CD4+ T cells have been shown to be increased in 
airways and lung parenchyma in COPD patients 
(O'Shaughnessy et al., 1997, Saetta et al., 1999), particularly 
in proximity to bronchus associated lymphoid tissue (Hogg et 
al., 2004). CD4+ helper T cells are mainly responsible for 
orchestrating downstream immune process by producing 
cytokines. They are essential for the full development of 
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adaptive immune cytotoxicity by priming and promoting the 
long-term survival of CD8+ T cells. 
 
Activation is a prerequisite for killer cells to be functional. 
Activated killer cells can cause the production of inflammatory 
cytokines, chemokines and cytotoxic molecules, such as INF-, 
TNF-, IL-8 and granzymes, which can induce pathological 
features including emphysema, mucus hypersecretion and cell 
apoptosis, and lung tissue damage in COPD (Barnes, 2004d).  
Several studies have investigated expression of activation 
markers on T-lymphocytes from peripheral blood, induced 
sputum and bronchial alveolar lavage (BAL) fluid from healthy 
smokers and COPD patients with varying results (Glader et al., 
2006b, Leckie et al., 2003), but none have looked specifically 
at CD8+ T lymphocytes, NKT-like and NK cells. CD69 and 
CD25 are cell surface markers of early and late stages of 
lymphocyte activation, respectively (Caruso et al., 1997).   
Killer cell activation involves several factors, such as 
interaction between antigen receptors and peptides presented 
by MHC class I molecules or MHC class I-related proteins. 
Human killer cells express immunoglobulin-like receptors 
(KIRs), belonging to the Ig superfamily (CD158 family), which 
bind to MHC Class I. They can be classified into two groups, 
namely, inhibitory KIRs and activating KIRs.  Inhibitory KIRs 
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possess long (L) cytoplasmic domains, such as KIR2DL or 
KIR3DL. Activating KIRs possess short cytoplasmic domains 
with an immunoreceptor tyrosine-based activation motif 
(ITAM)-bearing DAP12 adapter protein (Parham, 2005). 
NKG2D is a unique activating receptor and a type II 
transmembrane-anchored glycoprotein. It transmits signals 
through its transmembrane segment associating with adaptor 
protein DAP10. In the absence of DAP10, NKG2D is not able to 
be presented on cell surface and is retained in the cytoplasm 
(Diefenbach et al., 2002, Wu et al., 1999). Expression of 
NKG2D can be regulated by cytokines, for example, IL-15 and 
TNF- can enhance NKG2D expression whereas TGF- causes 
its downregulation (Castriconi et al., 2003, Lee et al., 2004, 
Parasa et al., 2012).  In humans, KIR3DL1 (CD158e1) and 
NKG2D are two representative signaling receptors expressed 
by CD8+ T-lymphocytes, NK cells, NKT cells and  TCR+ T 
cells (Ferrini et al., 1994, Moretta et al., 1990, Patterson et al., 
2008, Phillips et al., 1995, Wu et al., 1999). They can 
recognize MHC class I molecules and MHC class I-related 
proteins, respectively. 
 
In this chapter, the activation levels (by measurement of 
CD69 and CD25 expression) of the three main classes of 
human killer cells, namely, CD8+ T-lymphocytes, NKT-like 
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cells and NK cells in peripheral blood were investigated. 
Samples were obtained from four groups of participants 
including healthy non-smoking volunteers, current healthy 
smokers, current smokers with COPD and ex-smokers with 
COPD. To further detect the association between cell 
activation and their functional receptors in peripheral blood 
samples, we also examined the expression of the inhibitory 
receptor KIR3DL1 (CD158e1) and the activating receptor 
NKG2D in these four groups. 
 
3.1.2 Material and methods 
3.1.2.1 Study population and procedures 
The Nottingham Research Ethics Committee approved the 
study protocol (REC reference 04/Q2403/102) and written 
informed consent was obtained from all participants before 
entering the study.  Thirty-two participants were included in 
both the peripheral blood activation and the KIR study. 
Participants were diagnosed as having COPD according to the 
ATS guidelines, were either current smokers with COPD (cuS-
COPD) or ex-smokers with COPD (exS-COPD) and had accrued 
at least a 20-pack year smoking history. Healthy non-smokers 
(HNS) and current healthy smokers (HS), with an FEV1 above 
80% of predicted, were matched, as far as possible, for age, 
with participants with COPD; healthy smokers were also 
 144 
matched for smoking history. Table 3.1.1 details the 
demographic and spirometric data of the participants in this 
study. Participants were excluded as previously stated ; 
specifically, they were all non-atopic (negative skin prick test 
response to common allergen extracts including grass pollen, 
house dust mite, cat dander and dog hair) and all COPD 
patients had been free of an acute exacerbation of COPD for 
at least 6 weeks preceding the study.  In addition, none had 
received antibiotics or corticosteroids (oral and inhaled) over 
the same period. 
 
3.1.2.2 Peripheral Blood Mononuclear Cell isolation 
PBMCs were isolated from whole blood on a discontinuous 
histopaque density gradient (Sigma, Poole, UK).  Briefly, 50ml 
of whole blood were diluted 2:1 in RPMI 1640 medium (Sigma, 
Poole, UK), were diluted 2:1 in RPMI 1640 medium (Sigma, 
Poole, UK), layered over histopaque and centrifuged for 22 
minutes at 800g. The resultant mononuclear layer was 
removed and washed twice and resuspended. Cells were 
counted with a Hemocytometer using trypan blue. 
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Table 3.1.1 Demographic and spirometric values of the studied groups 
 
Healthy 
non-smokers 
Current 
healthy 
smokers 
cuS-COPD exS-
COPD 
Participants 8 8 9 7 
Age (years) 
54 
（47-66） 
53 
(45-63) 
61 
(45-77) 
62 
(49-69) 
Gender 
(M/F) 
4/4 3/5 3/6 3/4 
Packs/yrs 0 
35 
(32-40) 
56 
(30-77) 
36 
(20-51) 
Smoking 
status 
(Current/Ex) 
0 8/0 9/0 0/7 
Chronic 
bronchitis 
(Yes/No) 
0 3/5 6/3 5/2 
FEV1 (% 
pred) 
105 
(75-126) 
101 
(85-114) 
41 
(30-61) 
58 
(52-66) 
FEV1/FVC 
(%) 
104 
(67-120) 
89 
(66-101) 
48 
(29-53) 
51 
(36-65) 
∆FEV1 post 
bronch 
2.2 
(1.9-3.0) 
2.1 
(1.7-2.9) 
1.6 
(1.1-2.4) 
1.1 
(0.6-1.5) 
BMI (kg/m2) 
22.8 
(18.7-26.2) 
24.7 
(19.2-31.6) 
23.2 
(18.3-30.8) 
21.5 
(19.6-
23.1) 
Inhaled GCS 
(on/off) 
N/A N/A 3/6 4/3 
MRC 
dyspnoea 
scale 
N/A N/A 3 (2-4) 2 (1-4) 
Distance 
walked in 6 
min (m) 
N/A N/A 
308 
(50-431) 
277 
(140-
456) 
BODE Index N/A N/A 5 (2-7) 5 (1-6) 
Results are expressed as median with range in brackets. 
exS-COPD, ex-smokers with COPD; cuS-COPD, current smokers with COPD; 
FEV1, forced expiratory volume in 1 second; pre, predicted value; FVC, 
forced vital capacity; BMI, body mass index; GCS, corticosteroid; MRC, 
medical research council; BODE,  BMI, airflow Obstruction, Dyspnoea 
and Exercise capacity. 
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3.1.2.3 Flow cytometric analysis 
Cells were stained for flow cytometry as previously described .  
Briefly, cells were fixed in 3% formaldehyde in isotonic azide 
free solution (Beckman Coulter, Luton, UK) and washed before 
labelled antibodies (Table 3.1.2) were added at the 
recommended concentration.  The cells were incubated in the 
dark and excess antibody removed.  Flow cytometric analysis 
of antibody labelled cells was performed using an EPICS Altra 
(Beckman Coulter, Luton, UK).  Fifty thousand live-gated 
events were collected for each sample and isotype matched 
antibodies were used to determine binding specificity.  Data 
were analysed using WEASEL version 2.3 (WEHI).  Necrotic 
cells were excluded from analysis according to their forward 
and side scatter characteristics. 
 
3.1.2.4 Statistical analysis  
The statistical analysis was performed with Prism software, 
version 4.0c (GraphPad).  Normality was detected using the 
Kolmogorov–Smirnov test.  All data are expressed as median 
and range.  Differences between the four groups of 
participants were tested using the non-parametric Kruskal-
Wallis test with post hoc pairwise comparisons made by the 
Dunn's Multiple Comparison test to determine which pair was 
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statistically significantly different.  P values of less than 0.05 
were considered to indicate statistical significance.  
 
 
Table 3.1.2 Antibodies used for flow cytometry  
Antigen 
Fluorochro
me 
Isotype Clone Source 
CD3 ECD 
PC7 
Mouse IgG1 UCHT1 Beckman Coulter, 
Luton, UK 
CD8 PC5 
APC 
Mouse IgG1 B9.11 Beckman Coulter, 
Luton, UK 
CD8 ECD Mouse IgG1 SFCl21Thy2
D3 
Beckman Coulter, 
Luton, UK 
CD25 FITC 
PE 
Mouse IgG2a  B1.49.9 Beckman Coulter, 
Luton, UK 
CD56 PE 
PC5 
PC7 
Mouse IgG1 N901 Beckman Coulter, 
Luton, UK 
CD69 ECD 
PC5 
Mouse IgG2b TP1.55.3 Beckman Coulter, 
Luton, UK 
KIR3DL1 
(CD158e1
) 
FITC Mouse IgG1 DX9 Biolegend, San 
Diego, CA, USA 
NKG2D 
(CD314) 
PE Mouse IgG1 ON72 Beckman Coulter, 
Luton, UK 
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3.1.3 Results 
3.1.3.1 Demographic and medical characteristics of 
COPD participants, current healthy smokers and healthy 
controls 
There were no statistical difference between groups in terms 
of age (Figure 3.1.1.A) or pack years smoked (Figure 3.1.1.B) 
between ex-smokers with COPD, current smokers with COPD 
and current healthy smokers. Furthermore, there was no 
statistical difference in the inhaled corticosteroid use between 
ex-smokers with COPD and current smokers with COPD.  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
A 
Figure 3.1.1 Comparison of ages and pack year smoked 
between interested groups. There were statistical differences in 
terms of (A) ages or (B) pack year smoked between healthy non-
smokers (HNS, n=8), current healthy smokers (HS, n=9), current 
smokers with COPD (cuS-COPD, n=9) and ex-smokers with COPD 
(exS-COPD, n=7). 
B 
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3.1.3.2 Killer cell activation in peripheral blood 
All individuals had similar total mononuclear cell numbers, 
which were within the normal range (data not shown). 
Representative flow analysis dot plots of Forward Scatter (FS) 
vs Side Scatter (SS) for identification of live and dead cells 
(Figure 3.1.2.A), along with dot plots for identification of CD8+ 
T-lymphocytes (CD3+CD8+), CD4+ T-lymphocytes (CD3+CD4+) 
(Figure 3.1.2.B), NKT-like cells (CD3+CD56+), and NK cells 
(CD3-CD56+) (Figure 3.1.2C) are shown.  In addition, 
exemplar dot plots for CD69 and CD25 staining of these gated 
four cell types from peripheral blood in the four groups are 
shown in Figure 3.1.3. Cells are designated activated when 
they express one or both of the activation markers (i.e., CD69 
positive, CD69/CD25 double positive or CD25 positive). 
 
 
            
 
 
 
 
 
 
 
 
 
 
CD8+ 
T cells 
CD4+ 
T cells 
NKT cells NK cells 
A 
Figure 3.1.2 Representative dot plots gating for live/dead cells, 
identification of cell populations from current smokers with 
COPD. (A) Forward Scatter (FS) vs Side Scatter (SS) plot for 
identification of live and dead cells; (B) and (C), Identification of CD8+ 
T cells (CD3+CD8+), CD4+ T cells (CD3+CD4+), NKT-like cells 
(CD3+CD56+) and NK cells (CD3-CD56+). 
B C 
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      HNS                                                HS                                       cuS-COPD                                   exS-COPD 
 
 
 
 
 
C 
D 
Figure 3.1.3 Representative dot plots for activation of interested cell types from four groups including healthy non-
smokers (HNS), current healthy smokers (HS), current smokers with COPD (cuS-COPD) and ex-smokers with COPD 
(exS-COPD). Activation is designated by expressing either CD69 alone (lower right quadrant), CD69 and CD25 (upper right 
quadrant) or CD25 alone (upper left quadrant). (A) CD8+ T cells; (B) CD4+ T cells; (C) NKT-like cells; and (D) NK cells. 
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Significantly more CD8+ T-lymphocytes from current healthy 
smokers (41.96%, 27.2-72.8; p<0.001), current smokers with 
COPD (34.3%, 13.8-56.2; p<0.01), and ex-smokers with 
COPD (23%, 11.01-48.4; p<0.05) were activated ex vivo 
compared to healthy non-smokers (3.78%, 2.5-9.3) (Figure 
3.1.4.A). Analyses of individual markers (i.e., CD69 
positive/CD25 negative; CD69 negative/CD25 positive; or 
CD69 positive/CD25 positive) were not different between 
groups or cell types (data not shown). 
 
NKT-like cells showed a similar pattern to CD8+ T-lymphocytes, 
namely significantly more ex vivo activation from both current 
healthy smokers (40.05%, 17.7-58.7; p<0.001) and current 
smokers with COPD (33.04%, 15.7-48.8; p<0.01) compared 
to healthy non-smokers (7.3%, 4.26-16.82) (Figure 3.1.4.C).  
Also, no significant differences in NKT-like cell activation were 
observed between ex-smokers (27.05%, 12.4-48.1) and 
healthy non-smokers (7.3%, 4.26-16.82; p>0.05), current 
healthy smokers (40.05%, 17.7-58.7; p>0.05), or current 
smokers with COPD (33.04%, 15.7-48.8; p>0.05). 
 
NK (CD56+CD3-) cells from both current healthy smokers 
(39.55%, 14.78-50.1; p<0.05) and current smokers with 
COPD (44.18%, 14.2-72.8; p<0.01) were significantly more  
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A B 
C D 
Figure 3.1.4 Activation of killer cell 
types from peripheral blood ex vivo 
of four groups. Activation of CD8+ T 
cells, CD4+ T cells, NKT-like cells and NK 
cells were analysed. There was a 
significant increase in level of activation 
of CD8+ T cell (panel A), NKT-like cells 
(panel C), and NK cells (panel D) from 
current healthy smokers (HS, open 
circles) and current smokers with COPD 
(cuS-COPD, black solid circles). 
Activation of NK cells from ex-smokers 
with COPD (exS-COPD, grey solid circles) 
was also significantly increased 
compared to healthy non-smokers (HNS, 
open triangle). There was no statistical 
difference in activation of CD4+ T cells 
(panel B) between groups. : p<0.05, : 
p<0.01, : p<0.001. HNS (n=8), HS 
(n=8), cuS-COPD (n=9), and exS-COPD 
(n=7). 
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activated ex vivo than those from healthy non-smokers 
(10.1%, 1.5-22.8) (Figure 3.1.4.D). There were no significant 
differences in NK cell activation between ex-smokers with 
COPD (28.9%, 11.91-58.8; p>0.05) and other groups of 
interest. 
 
Interestingly, few CD4+ T lymphocytes were activated in 
peripheral blood from four groups (Figure 3.1.4.B) and there 
were no statistical differences between groups (all p 
value >0.05), namely, healthy non-smokers (5.17%, 0.4-
10.16), current healthy smokers (6.87%, 2.16-11.7), current 
smokers with COPD (10.46%, 3.81-14.31) and ex-smokers 
with COPD (7.81%, 4.24-15.89). 
 
3.1.3.3 Expression of CD25 on CD4+ T cells 
Although activation of CD4+ T lymphocytes was lower than 
other cell types of interest (Figure 3.1.4.B), activation markers 
including CD69 and CD25 were still detectable on their cell 
surface (Figure 3.1.3.B). Regulatory T (Treg) cells, as a subset 
of CD4+ T cells, also express CD25. Therefore, we 
hypothesised that those CD4+CD25+ T cells could be Treg cells. 
To examine this further we generated dot plots of Forward 
Scatter (FS) vs Side Scatter (SS) that showed, unlike other 
activated cell types expressing CD25 that were larger and 
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more granular (Figure 3.1.5.A, C and D), those CD4+ CD25+ T 
cells were primarily small and less granular and thus quite 
probably inactivated lymphocytes (Figure 3.1.5.B). These 
observations were seen in all groups of interest. 
 
3.1.3.4 Correlation of cell activation and number of 
cigarettes being smoked per day  
In view of our findings that current smoking increased 
numbers of activated Tc, NKT and NK cells, we looked for 
correlations between the number of cigarettes currently being 
smoked per day and level of ex vivo cell activation for these 
three cell types from both current healthy smokers and 
current smokers with COPD (Figure 3.1.6).  Cells expressing 
CD69 or CD25 alone, and expressing both activation markers 
were considered as activated cells in each cell type. In current 
smokers with COPD, NK cells showed a significant positive 
correlation between the proportion of ex vivo activation and 
number of cigarettes smoked (r=0.7615, p=0.0214) (Figures 
3.1.6.C).  No such correlation was observed for CD8+ T cells 
(r=0.2427, p=0.5206) (Figure 3.1.6.A), NKT-like cells 
(r=0.0753, p=0.8432) (Figure 3.1.6.B). Also, there was no 
significant correlation between the proportion of ex vivo 
activation and number of cigarettes smoked in these cell types 
from current healthy smokers (Figure 3.1.6). 
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A 
B 
C 
D 
Figure 3.1.5 Representative dot plots for gating cell types that express 
CD25 from current smokers with COPD. CD69 and CD25 are cell surface 
markers of early and later stages of lymphocyte activation, respectively. Unlike 
other cell types of interest, CD4+ T cells expressing CD25 was mainly 
lymphocytes (red square) but not activated cells (blue square). Regulatory T 
(Treg) cells are a subset of CD4+ T cells expressing CD25, which indicated that 
those CD4+CD25+ T cells might be Treg cells. (A) CD8+ T cell; (B) CD4+ T cells; 
(C) NKT-like cells; and (D) NK cells. 
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 Figure 3.1.6 Correlation of the proportion of cells activated 
and number of cigarettes currently smoked per day in current 
current healthy smokers (HS) and current smokers with COPD 
(cuS-COPD). Analysis was performed on peripheral blood CD8+ T 
lymphocytes (Panel A), NKT-like cells (Panel B) and NK cells (Panel 
C). A significant correlation was observed in NK cells from current 
smokers with COPD. HS, n=8; cuS-COPD, n=9. 
A 
B 
C 
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3.1.3.5 KIR (CD158e1) and NKG2D expression in 
peripheral blood 
The balance between activation receptors and inhibitory 
receptors expressed by cells is one of crucial factors 
orchestrating cell activation.  Expression of both the inhibitory 
KIR (CD158e1) and the activating receptor NKG2D by killer 
cells, including CD8+ T cells (Figure 3.1.7.A), CD4+ T cells 
(Figure 3.1.7.B), NKT cells (Figure 3.1.7.C) and NK cells 
(Figure 3.1.7.D), were measured by flow cytometry. 
Representative dot plots of KIR and NKG2D expression from 
healthy non-smokers (HNS); current healthy smokers (HS); 
current smokers with COPD (cuS-COPD); and ex-smokers with 
COPD (exS-COPD) are shown in Figure 3.1.7.  
 
CD8+ T-lymphocytes showed a significantly lower proportion of 
cells from healthy smokers (0.83%, 0.12-2.16; p < 0.001) 
and current smokers with COPD (0.66%, 0.13-3.97; p < 
0.001) expressed CD158e1 on the cell surface compared to 
healthy non-smokers (9.91%, 4.78-16.6) (Figure 3.1.8.A).   
 
The proportion of NKT-like cells expressing surface CD158e1 
was also significantly lower in current healthy smokers (2.14%, 
0.24-7.92; p < 0.001) and current smokers with COPD 
(2.24%, 1.58-6.77; p < 0.001) compared to healthy 
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Figure 3.1.7 Representative dot plots for KIR (CD158e1) and NKG2D expression of cell types of interest from four groups including 
healthy non-smokers (HNS), current healthy smokers (HS), current smokers with COPD (cuS-COPD) and ex-smokers with COPD 
(exS-COPD). NKG2D was highly expressed by CD8+ T cells, NKT-like cells and NK cells but not CD4+ T cells. (A) CD8+ T cells; (B) CD4+ T cells; (C) 
NKT-like cells; and (D) NK cells. 
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Figure 3.1.8 KIR (CD158e1) expression of cell types of interest from 
peripheral blood ex vivo of four groups. Levels of KIR expression by CD8+ T 
cell (panel A), NKT-like cells (panel C), and NK cells (panel D) were all 
significantly reduced in current healthy smokers (HS, open circles) and current 
smokers with COPD (cuS-COPD, solid circles) compared to healthy non-smokers 
(HNS, open triangles). There was no significant difference in the KIR expression 
between ex-smokers with COPD (exS-COPD, grey solid circles) and other groups. 
There was also no statistical difference in the levels of KIR expression on CD4+ T 
cells (panel B) between groups. : p<0.05, : p<0.01, : p<0.001. HNS 
(n=8), HS (n=8), cuS-COPD (n=9), and exS-COPD (n=7). 
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non- smokers (13.34%, 8.97-20.2) (Figure 3.1.8.C). 
 
Analysis of NK cells showed the proportion of these cells 
expressing surface CD158e1 was also significantly lower in 
current healthy smokers (7.7%, 3.06-13.17; p < 0.01) and 
current smokers with COPD (4.79%, 2.08-16.28; p < 0.001) 
compared to healthy non-smokers (24.22%, 18.1-29.26) 
(Figure 3.1.8.D). 
 
No differences in proportions of CD4+ T-lymphocytes (in all 
cases median levels <2.1%) expressing CD158e1 were shown 
between the four groups (Figure 3.1.8.B). 
 
Interestingly, proportions of CD4+ T lymphocytes expressing 
NKG2D were significantly lower (in all cases median levels 
<9.0%) compared to proportions of CD8+ T-lymphocytes, 
NKT-like cells and NK cells (in all cases over 95%) in each 
group. Meanwhile, there were no statistical differences on the 
proportion of each cell type expressing NKG2D between four 
groups (Figure 3.1.9). 
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Figure 3.1.9 Proportions of NKG2D expression on cell types of interest 
from peripheral blood ex vivo of four groups. NKG2D expression by CD8+ T 
cells (Tc, panel A), CD4+ T cells (Th, panel B), NKT-like (NKT, panel C) cells and 
NK cells (NK, panel D) were analysed. There were no significant differences on 
the proportion of NKG2D expression by each cell type from four groups, including 
healthy non-smokers (n=8), current healthy smokers (n=8), current smokers 
with COPD (cuS-COPD, n=9), and ex-smokers with COPD (exS-COPD, n=7). All p 
value >0.05. 
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3.1.4 Discussion 
Here we report, for the first time, that current smoking per se 
is associated with a significantly higher proportion of 
peripheral blood cytotoxic cells that are activated ex vivo and 
this is positively correlated with the number of cigarettes 
currently smoked per day.  
 
We and others have previously demonstrated the potential 
involvement of the three main classes of human killer cells, 
namely, CD8+ T-lymphocytes, NKT-like cells and NK cells in 
COPD (Paats et al., 2012, Roos-Engstrand et al., 2009, Roos-
Engstrand et al., 2010, Urbanowicz et al., 2009). These killer 
cells play key roles in inflammatory responses and activation 
of these cells can cause the production of inflammatory 
cytokines and chemokines, such as TNF- and IL-8, that can 
induce pathological features of COPD and lung tissue damage 
(Barnes, 2004c). Therefore, we hypothesized that killer cells 
are more active in COPD patients.  Here we examined the ex 
vivo activation phenotype of these cells in the peripheral blood. 
In peripheral blood, current smokers with or without COPD, 
but not ex-smokers with COPD, have the highest proportion of 
activated CD8+ T-lymphocytes, NKT-like cells and NK cells 
compared with healthy non-smokers and ex-smokers with 
COPD. This suggests that smoking per se affects systemic 
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killer cell activation. We thus examined the correlation 
between current smoking profiles and cell activation levels. 
Here we show that NK cell activation is positively correlated 
with the number of cigarettes currently smoked in COPD 
patients. No correlations between cell activation and lung 
function (FEV1 percentage of predicted) were found (data not 
shown). These data suggest that in peripheral blood, cell 
activation levels are more related to current smoking habit 
rather than disease. A previous study examining the effect of 
smoking cessation has shown in BAL fluid that CD8+ T-
lymphocytes from both smokers with normal lung function and 
COPD participants expressed high levels of CD69 and CD25 
activation markers (Roos-Engstrand et al., 2009).  Sputum T-
lymphocytes have also been shown to express higher levels of 
CD103 and CD69 than blood lymphocytes suggesting higher 
numbers of activated intraepithelial phenotype T-lymphocytes 
in the lung (Leckie et al., 2003). Furthermore, activated CD8+ 
T cells secrete more CXCR3 that lead to the accumulation of 
CD8+ T cells to the infected tissue and organs, which may 
explain why CD8+ T cells are predominant increased in COPD 
but not CD4+ T cells. Interestingly, here we also show few 
CD4+ T cells are activated in peripheral blood from the four 
groups. We further show that those CD4+CD25+ T cells may 
be regulatory T cells (not activated cells) by dot plot of 
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Forward Scatter (FS) vs Side Scatter (SS). To confirm this 
observation further studies are required. Although two studies 
have found highly activated Th1 cells in the lung of ex-
smokers with COPD and in the smalll airway wall of smokers 
with severe COPD by detecting their chemokine and cytokine 
secretion, those samples are actually from COPD patients with 
emphysema or co-suffering from cancer (Turato et al., 2002).  
 
One of the crucial factors determining cell activation is the 
signaling balance between activating receptors and inhibitory 
receptors. To investigate a possible mechanism for differences 
in activation states observed in peripheral blood, we compared 
expression of the inhibitory receptor KIR CD158e1 and the 
activating receptor NKG2D. Interestingly, in this study, the 
expression levels of the inhibitory KIR CD158e1 were lower in 
peripheral blood of current smokers with or without COPD 
compared to healthy non-smokers, which was the opposite to 
the activation levels of these killer cells including CD8+ T cells, 
NKT-like cells and NK cells.  Similar study supports this finding. 
CD94 is another inhibitory receptor expressed by NKT-like 
cells and NK cells (Lazetic et al., 1996). Decreased expression 
of CD94 on both NKT-like cells and NK cells were detected in 
PBMCs from COPD patients compared to healthy volunteers 
(Hodge et al., 2012). However, they did not detect any 
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significant differences on the cell activation levels of NKT-like 
and NK cells (only CD69 expression) between groups. 
Therefore, our findings provided the first demonstration of 
association of cell activation and KIR expression. We also 
show that activating receptor NKG2D are highly expressed by 
CD8+ T cells, NKT-like cells and NK cells but not CD4+ T cells, 
which is in accordance with previous studies that demonstrate 
NKG2D receptors are constitutively expressed and almost 
exclusively on cytotoxic cells including CD8+ T cells, NKT cells, 
NK cells and  T cells (Maasho et al., 2005). There are no 
significant differences of NKG2D expression on CD8+ T cells, 
CD4+ T cells, NKT-like cells and NK cells respectively, in the 
four groups. This further supports the proposal of increased 
peripheral blood killer cell activity in smokers due to the 
increased ratio of activating to inhibitory receptors.  
 
The present study does have some limitations that deserve 
comment. Firstly, we used CD69 and CD25 as activation 
markers.  Although other markers exist, these are generally 
accepted as representing cell activation (Marquez et al., 2010, 
McDonald et al., 2010). Secondly, CD25 is commonly used as 
a marker for T regulatory cells (Lane et al., 2010). To further 
confirm whether these CD4+CD25+ T cells are Treg cell, FOXP3 
can be used as a good marker for Treg cell indentification. 
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Also, fluorphore FITC is not particularly bright, they 
photobleach rapidly and are self-quenching at high 
concentration. Therefore, other fluorophore, such as the 
AlexaFluors, may be applied in future study to gain high 
quality analysis. Thirdly, there are many kinds of inhibitory 
and activating receptors expressed on these cells but due to 
limited cell numbers we analysed two representative receptors 
that give an indication of the killing function of these cells.  
Fourthly, it should be noted that the majority of participants 
with COPD were on inhaled corticosteroids.  However, the two 
participants who were not on inhaled corticosteroids in this 
group showed the same results in terms of activation and KIR 
expression as those on inhaled corticosteroids.   
 
Of the note, our colleague also detected, ex vivo, the 
activation levels of killer cells in sputum samples from COPD 
patients (data shown in the publication paper). Unlike 
systemic activation, lung activation is due specifically to COPD, 
irrespective of current smoking status. 
 
In summary, we have shown for the first time the activation 
levels of killer cells from peripheral blood of COPD patients. 
Also, the systemic activation is in response to smoking per se. 
We further demonstrate expression levels of inhibitory 
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receptor KIR (CD158e) in COPD groups.  These findings 
indicate that activation of killer cells in COPD participants may 
play a role in the pathogenesis of COPD.  
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3.2 Effects of cigarette smoke extract on killer 
cell activation in COPD 
 
3.2.1 Introduction 
Cigarette smoke extract (CSE) 
Cigarette smoke has been identified as the main risk factor in 
COPD development. Previous studies have demonstrated that 
cigarette smoke affects structural and functional changes in 
the respiratory ciliary epithelium (Cantin et al., 2006, Mio et 
al., 1997, Wyatt et al., 1999), lung surfactant protein and 
immune cells (Mohan, 2002a), such as lymphoctyes, alveolar 
macrophages, dendritic cells, neutrophils and NK cells. 
Therefore, accumulating data suggested that chronic 
inhalation of cigarette smoke alters a wide range of 
immunologic function, including both innate and adaptive 
immune responses.   
 
The smoke from a cigarette contains thousands chemicals 
which have various toxic, mutagenic and carcinogenic activity 
(Hoffmann and Wynder, 1986, Stedman, 1968). The 
concentrations of chemical ingredients also vary widely in the 
different cigarette brands. Studies show that various 
components of cigarette smoke can affect the immune 
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response in different cell types (Lee et al., 2007b, McCue et 
al., 2000, Ouyang et al., 2000). Two major components of 
smoke are nicotine and tar (Hoffmann and Wynder, 1986, 
Stedman, 1968).  Previous studies have shown that nicotine is 
tightly associated with increased risk of cardiovascular disease 
and cancer, particularly of lungs. Tar is an irritant. It enters 
the respiratory system as an aerosol of minute droplets that 
are deposited in the respiratory system causing excessive 
mucus production. Tar also contains carcinogens that combine 
with the affected mucus membranes. It causes lung cancer, 
chronic bronchitis and emphysema. Holt et al has investigated 
that cigarette smoke containing high levels of tar and nicotine 
is more immunosuppressive than the smoke from low-tar low-
nicotine cigarettes (Holt et al., 1976). However, effects of 
cigarette smoke on the immune system are biphasic, which is 
mainly determined by the components and duration of 
exposure. For example, unlike nicotine and tar, tobacco 
glycoprotein and metals present in cigarette smoke are 
generally immunostimulatory (Brooks et al., 1990, Francus et 
al., 1992).. 
 
Immunological features of cigarette smoke in COPD have been 
explored in human studies. In vitro activation of T cells and 
expression of granzyme B were significantly suppressed by 
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cigarette smoke, which resulted in altered immune response 
of the lymphocytes (Glader et al., 2006a). Skold et al have 
demonstrated that exposure to cigarette smoke altered the 
phenotype of human alveolar macrophages (Skold et al., 
1996). Recently, effects of cigarette smoke on DCs in COPD 
have been more explored. In vitro, the effects of cigarette 
smoke on DCs were dose-dependent. Production of cytokines 
such as IL-12 and IL-10 during DCs maturation process can 
influence DC induction of a Th1 or Th2 immune response. In 
addition to expressing high levels of antigen-presenting 
molecules and costimulatory molecules, mature DCs release 
large amounts of IL-12 that can stimulate a Th1 immune 
response. Release of IL-10, however, blocks the DC 
maturation process by interfering with up-regulation of 
costimulatory molecules and production of IL-12, 
subsequently limiting the ability of DCs to initiate a Th1 
response (Corinti et al., 2001, De Smedt et al., 1997). Early 
studies have shown that Low doses of nicotine enhanced 
human monocyte–derived DC maturation and their capacity to 
secrete IL-12 (Aicher et al., 2003). On the contrary, higher 
doses of nicotine treated DCs had low endocytic and 
phagocytic function, produced less IL-12 and more Th2 
cytokine IL-10 that promoted DCs priming Th2 cell 
differentiation more efficiently (Nouri-Shirazi and Guinet, 2003, 
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Nouri-Shirazi and Guinet, 2006). Similar results were also 
shown in Vassallo et al study.  LPS-induced DC maturation 
was suppressed by cigarette smoke, while the secretion of IL-
10 and prostaglandin E2 from these DCs were enhanced 
(Vassallo et al., 2005). Moreover, cigarette smoke impaired 
the production of TNF-, IL-6 and IFN-, whereas augmented 
the IL-8 secretion by plasmacytoid dendritic cells in response 
to Toll-like receptor (TLR)-9 (Mortaz et al., 2009). Studies on 
the effects of cigarette smoke on NK cell properties showed 
controversial findings. Some groups found that cigarette 
smoke impaired NK cell cytotoxic activities (Takeuchi et al., 
1988), whereas others showed that their killer functions were  
increased or not affected (Meliska et al., 1995, Newman et al., 
1991). However, these findings were generated from different 
disease models. Co-activation of NK cells by cigarette smoke 
and NK cell inducers have been established in Mian et al 
studies. Cigarette smoke greatly impaired the production of 
IFN- and TNF- by NK cells upon polyinosinic:polycytidylic 
acid (poly I:C) activation. The cytotoxic activities and perforin 
expression of poly I:C activated NK cells were also attenuated 
by cigarette smoke (Mian et al., 2008). Treatment of 
neutrophils with cigarette smoke extract can suppress 
neutrophil caspase-3-like activity and the phagocytic uptake 
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and intracellular digestion of staphylococci by neutrophils 
(Stringer et al., 2007).  
 
IL-2 and IL-15 
More than 30 years ago, IL-2 was shown to be a T cell growth 
factor purified from mitogen-stimulated lymphocyte culture 
(Morgan et al., 1976). Twenty years later, IL-15 was also 
identified through its ability to mimic IL-2-induced T cell 
proliferation (Bamford et al., 1996, Grabstein et al., 1994). 
Both cytokines belong to the 4--helix bundle cytokine family 
and they share several signaling pathways through their 
heterotrimeric receptors (Lin and Leonard, 1997, Lin et al., 
1995, Miyazaki et al., 1994, Fujii et al., 1995, Kawahara et al., 
1995, Waldmann and Tagaya, 1999). Receptors for IL-2 (IL-
2R) and IL-15 (IL-15R) are comprised of three subunits, 
namely, IL-2R (IL-15R for IL-15), IL-2/15R (also known as 
CD122) and common cytokine-receptor -chain (c) (Anderson 
et al., 1995, Asao et al., 2001, Cosman et al., 1995). To 
achieve high affinity form of receptor, three subunits must be 
presented together. In the absence of IL-2R or IL-15R, 
receptors for IL-2 or IL-15 will only show intermediate-affinity. 
Signal inductions are relied on and chains of receptors 
(Minami et al., 1993, Smith, 1988a, Smith, 1988b, Waldmann 
et al., 1998). IL-2R and IL-15R are two unique subunits for 
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IL-2 and IL-15 respectively with also distinct physiologic 
expression profiles. IL-2R binds to IL-2 with low-affinity 
without signal transduction, they are only detectable on 
activated lymphocytes and Treg cells (Fontenot et al., 2005, 
Rogers et al., 1997). Whereas IL-15R binds to IL-15 with 
high-affinity and recent studies have shown that IL-15R 
plays functions on intracellular signals through binding to 
tumour-necrosis factor-receptor-associated factor 2 (TRAF2) 
through its cytoplasmic tail and preventing interaction 
between IL-15R and the pro-apoptotic cascade members 
(Bulfone-Paus et al., 1999, Pereno et al., 1999, Pereno et al., 
2000). IL-15R has a wide cellular distribution. It can be 
observed in multiple tissues and cell types, such as in liver, 
heart, spleen, lung and activated vascular endothelial cells 
(Giri et al., 1995), T cells, B cells, activated monocytes, 
dendritic cells, macrophages and bone marrow stromal cell 
lines (Anderson et al., 1995). Distribution of three subunits of 
IL-2R and IL-15R, namely, -chain, -chain (CD122) and -
chain, is shown in Table 3.2.1. 
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Table 3.2.1 Expression of three units of IL-2R and IL-15R on 
immune cells 
Cell types IL-2R IL-15R IL-2/15R c 
Pre-B cells + + - + 
Mature B cells - + - + 
Mature T cells 
    Naïve 
    Effector 
    Memory 
 
- 
+ 
- 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
 
+ 
+ 
+ 
Treg cells + - + + 
NK cells - + + + 
Dendritic cells +/-  * + +/-* + 
Monocytes - + - + 
*Certain activated dendritic cells have been shown to express IL-2R and 
IL-2/15R on their surfaces (Ardavin and Shortman, 1992, Mnasria et al., 
2008). 
 
 
 
Due to common features in receptor components and signaling 
pathways, IL-2 and IL-15 have several similar functions. They 
can induce the proliferation of activated T cells, generate 
cytotoxic T cells and NK cells and facilitate B cell proliferation 
and immunoglobulin synthesis (Fehniger and Caligiuri, 2001, 
Waldmann et al., 2001, Waldmann and Tagaya, 1999). 
However, in many adaptive immune responses, significant 
differences between IL-2 and IL-15 have been identified in 
their molecular and cellular biology and functions (Thomas, 
2008, Waldmann and Tagaya, 1999). The distinct binding 
affinity and distribution of two -chains may be one reason 
contributing to distinct features of two receptors. As 
mentioned previously, IL-2 is mainly expressed by activated 
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T cells and bind IL-2 with low affinity, while IL-15 binding to 
IL-2 with high affinity is widely spread in many tissues and cell 
types. Also, in contrast to IL-2 that binds pre-formed high 
affinity heterotrimeric receptors at the cell surface (Taniguchi 
and Minami, 1993, Waldmann, 1991), IL-15 is only secreted 
at low levels and binds membrane IL-15R (Dubois et al., 
2002). Functional differences may result in distinctive roles of 
IL-2 and IL-15 in human diseases. For example, IL-2 can 
down-regulate chain expression on cycling T cells and 
dampen T cell clonal expansion through activation-induced cell 
death (AICD) (Lenardo, 1991), whereas IL-15 is an anti-
apoptosis factor and inhibits IL-2 induced AICD by facilitating 
the maintenance of CD8+ T cell survival, including self-reactive 
memory T cells (Marks-Konczalik et al., 2000). Furthermore, 
IL-2 participates in the maintenance of peripheral Treg cells 
(D'Cruz and Klein, 2005, Fontenot et al., 2005, Maloy and 
Powrie, 2005) but IL-15 has no marked effects on them 
(Fehniger and Caligiuri, 2001a). IL-2 shows ability of inhibiting 
CD8+ memory T cell proliferation but IL-15 can selectively 
stimulated the proliferation of memory CD8+ T cells and 
prolong their survival (Zhang et al., 1998). Collectively, 
although both IL-2 and IL-15 play potent roles in the 
pathogenesis of autoimmune diseases, cancers and 
inflammatory diseases, they can be either beneficial of  
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Table 3.2.2 Comparison of human IL-2 and IL-15 
Properties IL-2 IL-15 
Structure 15.5kDa; four-helix 
bundle 
14-15kDa; four-helix bundle 
Receptors IL-2R, low affinity;  
IL-2/15R; c 
IL-15R, high affinity;  
IL-2/15R; c 
Producing 
cells 
Activated T cells Monocytes, dendritic cells 
and epithelial cells* 
Function Proliferation of T cells, 
NKT cells, NK cells and B 
cells; 
Activating NK cells and 
NKT cells; 
Elimination of self-reactive 
T cells; 
Inducing AICD; 
Maintenance of Treg Cells 
Proliferation and activation 
of NKT cells and NK cells;  
Maintenance of memory 
CD8+ T cells and NK cell 
survival; 
Inhibiting IL-2-induced AICD 
 
* Epithelial cells are big producers of IL-15. Respiratory viruses such as 
respiratory syncytial virus (RSV) increased surface MIC molecules in 
respiratory epithelial cells (Zdrenghea et al., 2012). These molecules are 
ligands for NKG2D receptors on NK and T cells, playing an important role 
in the nonspecific activation of cytotoxic activity of NKG2D-positive NK and 
CD8+ T cells.  
 
 
detrimental. Their application in immune therapy may also 
differ at some points due to their unique biological features. 
Table 3.2.2 simply outlines the comparison of human IL-2 and 
IL-15. 
 
To date, IL-2 and IL-15 biological functions and their 
therapeutic applications have been well studied in cancers, 
viral infections and certain autoimmune diseases. 
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Nevertheless, their properties in smokers or COPD patients are 
still less explored. Higher IL-2 levels have been found in lung 
plasma samples from stable COPD patients compared to 
participants with rapidly progressive COPD (D'Armiento et al., 
2009). Also, corticosteroid (dexamethasone) have shown less 
inhibiton of IL-2 production in COPD patients compared to 
healthy volunteers although these numerical differences 
between groups did not reach statistical significance (Kaur et 
al., 2012). In vitro, it has shown that IL-15 stimulation by 
itself had no effect on IFN- protein expression in COPD 
patients at GOLD stages 2, 3, and 4. However, IL-15 primed 
CD8+ lung T cells to have greater cytotoxic potential by 
expressing higher levels of intracellular perforin when they 
encounter a target cells in COPD (Freeman et al., 2010). 
Furthermore, CSE treated NK cells were less activated after 
poly I:C stimulation, and this suppression was IL-15 mediated 
(Mian et al., 2009). 
 
Accumulating evidence strongly suggest CSE has markedly 
association with COPD developments. Although numbers of 
studies have shown that CSE impairs cytokine and chemokine 
productions in many cell types, for instance, macrophages, 
neutrophils, DCs or other inflammatory cells in healthy 
volunteers (Gaschler et al., 2008, Takahashi et al., 2007, 
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Takahashi et al., 2006), however, the impact of CSE on killer 
cells from COPD patients remains to be explored. Previous 
section has shown that killer cells were all significantly 
activated in vivo in current smokers with or without COPD, 
which indicates that cigarette smoking, rather than disease 
itself, may play a potent role in killer cell activation in 
peripheral blood. -CD3 is a great stimulator for CD3+ T cell 
activation. Whereas, IL-2 and IL-15 can induce NKT cells and 
NK cell stimulation. In this chapter, we have investigated, in 
vitro, the effects of CSE on unstimulated or -CD3, IL-2 or IL-
15 activated killer cells including CD8+ T cells, NKT-like cells 
and NK cells, from peripheral blood in four designed groups, 
namely, healthy non-smokers (HNS), current healthy smokers 
(HS), current smokers with COPD (cuS-COPD) and ex-
smokers with COPD (exS-COPD). 
 
 
3.2.2 Material and methods 
3.2.2.1 Study population and procedures 
The criteria of participant enrollments are the same as 
previously mentioned. Twenty participants were included in 
CSE activation study. Table 3.2.3 and Table 3.2.4 detail the 
demographic and spirometric data of the participants in  
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Table 3.2.3 Demographic and spirometric valus of the healthy non-
smoking participants in optimal concentration experiments 
Healthy 
non-
smokers 
Age 
(years) 
Gender 
(M/F) 
FEV1 
(% 
pred) 
FEV1/ 
FVC 
(%) 
∆FEV1 
post 
bronch 
BMI 
(kg/m2) 
 
 
n=4 
 
49 
(43-57) 
 
3/1 
 
110 
(89-118) 
 
99 
(82-111) 
2.3 
(2.0-
2.8) 
22.8 
(19.6-
27.7) 
 
 Table 3.2.4 Demographic and spirometric valus of the CSE 
suppression study groups 
 
Healthy  
non-smokers 
Healthy 
smokers 
cuS-COPD exS-COPD 
Participants 4 4 4 4 
Age (years) 55 （53-60） 54 (50-58) 64 (55-73) 56 (49-65) 
Gender 
(M/F) 
1/3 3/1 3/1 2/2 
Packs/yrs 0 36 (32-40) 47 (42-66) 34 (23-47) 
Smoking 
status 
(Current/Ex) 
0 4/0 4/0 0/4 
Chronic 
bronchitis 
(Yes/No) 
0 2/2 3/1 1/3 
FEV1 (% 
pred) 
103 (81-116) 98 (89-106) 43 (37-52) 59 (54-63)  
FEV1/FVC 
(%) 
94 (76-108) 83 (70-99) 36 (32-46) 52 (37-57) 
∆FEV1 post 
bronch 
2.3  
(2.0-2.6) 
2.0  
(1.9-2.4) 
1.6  
(1.5-2.2) 
1.2  
(0.9-1.3) 
BMI (kg/m2) 
23.6  
(20.7-26.0) 
26.0  
(21.8-28.5) 
25.9  
(18.9-29.8) 
21.1  
(20.0-22.7) 
Inhaled GCS 
(on/off) 
N/A N/A 1/3 1/3 
MRC 
dyspnoea 
scale 
N/A N/A 3 (2-4) 3 (2-4) 
Distance 
walked in 6 
min (m) 
N/A N/A 
268  
(102-364) 
336  
(152-428) 
BODE Index N/A N/A 5 (3-6) 4 (2-5) 
 
 
preliminary concentration experiments and CSE suppression 
study respectively. 
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Table 3.2.5 Antibodies used for flow cytometry 
Antigen 
Fluorochro
me 
Isotype Clone Source 
CD3 PC7 Mouse IgG1 UCHT1 Beckman Coulter, 
Luton, UK 
CD8 ECD Mouse IgG1 SFCl21Th
y2D3 
Beckman Coulter, 
Luton, UK 
CD25 FITC Mouse IgG2a, 
 
B1.49.9 Beckman Coulter, 
Luton, UK 
CD56 PE 
 
Mouse IgG1 N901 Beckman Coulter, 
Luton, UK 
CD69 PC5 Mouse IgG2b TP1.55.3 Beckman Coulter, 
Luton, UK 
 
 
3.2.2.2 Reagents 
Anti-CD3 was purchased from R&D system (Abingdon, UK). 
Recombined human IL-2 (rhIL-2) and recombined human IL-
15 (rhIL-15) were obtained from PeproTech EC (London, UK). 
Other monoclonal antibodies for flowcytometry were shown in 
table 3.2.5. 
 
3.2.2.3 Peripheral Blood Mononuclear Cell isolation 
PPBMCs were isolated from whole blood on a discontinuous 
histopaque density gradient (Sigma, Poole, UK).  More details 
are provided in section 2.2. 
 
3.2.2.4 Cigarette smoke extract preparation  
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CSE were freshly prepared prior to 30 minutes of cell culture 
for each experiment to avoid breakdown of substances in the 
extract and evaporation of volatile components. More details 
are provided in section 2.4. Figure 3.2.1 shows the trend of 
absobance according to CSE dilution. Thirty-six (n=36) 
cigarette were processed in this manner during the whole 
project. 
 
3.2.2.5 PBMCs culture and treatments 
In preliminary experiment to determine the optimal culture 
time and concentrations of CSE, -CD3, IL-2 or IL-15 for  
Figure 3.2.1 Absorbance of CSE at different dilutions. 
The absorbance of 0.15 is considered as 100% CSE. 
184 
 
 
Table 3.2.6 Concentrations of stimulus used for activating killer cell. 
CSE 0.2% 0.5% 1% 2% 5% 
-CD3 0.1ug/ml 0.2ug/ml 0.5ug/ml 1ug/ml 2ug/ml 
IL-2 5ng/ml 10ng/ml 20ng/ml 50ng/ml 100ng/ml 
IL-15 1ng/ml 2ng/ml 5ng/ml 10ng/ml 20ng/ml 
 
 
activation of killer cells, PBMCs isolated from healthy non-
smoking participants were resuspended in RPMI-1640 medium 
supplemented with 10% FCS at a density of 1x106 cells/ml 
and cultured at 200ul/well in 96-well flat bottom tissue culture 
plates. These cells were either untreated or treated separately 
with CSE, -CD3, IL-2 or IL-15 at various concentrations as 
indicated in Table 3.2.6. Specially, -CD3 was pre-coated in 
the plate for 90 minutes at 37°C in 5% CO2 and washed in 
cold sterile D-PBS twice to remove the unbound antibody. 
After incubation for 24 hours, 48 hours and 72 hours, cells 
were harvested at each time point and washed twice in RPMI-
1640 medium for surface marker staining to detect cell 
activation. 
 
In CSE suppression experiments, PBMCs isolated from HNS, 
HS, cuS-COPD and exS-COPD were untreated or treated with 
CSE, -CD3, IL-2 or IL-15 at each optimized concentrations 
seperately. In order to test the effects of CSE on activated 
185 
 
killer cells, cells stimulated by -CD3, IL-2 or IL-15 were also 
co-treated by CSE. For CSE suppression experiment, cells 
were incubated for 48 hours at 37°C in 5% CO2 before 
analysis. 
 
3.2.2.6 Extracellular staining 
Fluorescently conjugated antibodies used in this study for 
extracellular staining were as follows, CD3 (PC7), CD56 (PE), 
CD8 (ECD) CD25 (FITC) and CD69 (PC5), or KIR (FITC). More 
details are provided in section 2.6. 
 
3.2.2.7 Flow cytometric analysis 
Untreated or treated PBMCs were analysed by flow cytometry.  
Cells were harvested and fixed in 3% formaldehyde in isotonic 
azide free solution (Beckman Coulter, Luton, UK) and washed 
before labelled antibodies were added at the recommended 
concentration. The cells were incubated in the dark and excess 
antibody removed.  Flow cytometric analysis of antibody 
labelled cells was performed using an EPICS Altra (Beckman 
Coulter, Luton, UK). More details are provided in section 2.9. 
 
3.2.2.8 Statistical analysis  
The statistical analysis was performed with Prism software, 
version 4.0c (GraphPad). Differences between the four groups 
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of participants were tested using the parametric student’s t 
test. Confidence interval 99% was used to show two-tailed p 
values. P values of less than 0.01 were considered to indicate 
statistical significance due to the small size of each study 
group.. 
 
3.2.3 Results 
3.2.3.1 Optimal concentrations and culture time for 
killer cell activation 
To determine the optimal concentrations of interested stimulus 
and culture time, PBMCs from healthy non-smokers (n=4) 
were cultured in medium alone or in medium supplemented 
with either CSE, -CD3, IL-2 or IL-15 at increasing 
concentrations (as shown in Table 3.2.6) for 24 hours, 48 
hours and 72 hours. Cells are designated activated when they 
express one or both of the activation markers (i.e., CD69 
positive, CD69/CD25 double positive or CD25 positive).   
 
Dose- and time-dependent increases in percentages of killer 
cell activation were observed during culture with increasing 
concentrations of -CD3 (Figure 3.2.2), IL-2 (Figure 3.2.3) 
and IL-15 (Figure 3.2.4).  
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Figure 3.2.2 Activation levels of killer cells by different concentrations of -CD3. PBMCs were collected from healthy 
non-smokers (n=4). Cells were untreated or treated by -CD3 at concentrations of 0.1ug/ml, 0.2ug/ml, 0.5ug/ml, 1ug/ml 
and 2ug/ml respectively for 24 hours, 48 hours and 72 hours. 
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Figure 3.2.3 Activation levels of killer cells by different concentrations of IL-2. PBMCs were collected from healthy 
non-smokers (n=4). Cells were untreated or treated by IL-2 at concentrations of 5ng/ml, 10ng/ml, 20ng/ml, 50ng/ml and 
100ng/ml respectively for 24 hours, 48 hours and 72 hours. 
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Figure 3.2.4 Activation levels of killer cells by different concentrations of IL-15. PBMCs were collected from 
healthy non-smokers (n=4). Cells were untreated or treated by IL-15 at concentrations of 1ng/ml, 2ng/ml, 5ng/ml, 
10ng/ml and 20ng/ml respectively for 24 hours, 48 hours and 72 hours. 
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Killer cells of interest including Tc cells, NKT-like cells and NK 
cells were highly activated when increasing the concentration 
of -CD3 to 1ug/ml after incubation for 48 hours (Figure 
3.2.2). Activations of killer cells by IL-2 at selected 
concentrations were not as much activation as -CD3 treated 
cells (Figure 3.2.3). However, previous studies have shown 
that administration of high dose of IL-2 in treatment of a 
variety of diseases is associated with mortality rates of up to 
4% . Therefore, we controlled the maximal concentration of 
IL-2 at 100ng/ml. IL-15 at 20ng/ml also highly activated these 
killer cells after 48 hours incubation (Figure 3.2.4).  
 
There were no statistically significant differences on the 
activation levels of killer cells treated by CSE at different 
percentage concentrations (all p>0.05) (Figure 3.2.5). 
 
To sum up, to highly activate all killer cells of interest, the 
optimal concentration of -CD3, IL-2, IL-15 for detection of 
cell activation would be chosen at 1ug/ml, 100ng/ml, and 
20ng/ml respectively in future experiments. The dilution at 
1% of CSE would also be used for following studies. Figure 
3.2.6 showed representative dot plots of interested killer cell 
activation at optimal concentration and dilution after 48 hours 
incubation. 
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Figure 3.2.5 Activation levels of killer cells by different dilutions of CSE. PBMCs were collected from healthy non-
smokers (n=4). Cells were untreated or treated by CSE at dilutions of 0.2%, 0.5%, 1%, 2% and 5% respectively for 24 
hours, 48 hours and 72 hours. 
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 Tc cells  NKT-like cells NK cells 
A 
B 
C 
D 
E 
Figure 3.2.6 Representative dot plots for activation of Tc cells, 
NKT-like cells and NK cells in PBMCs from healthy non-smokers 
(n=4) by different stimulus at 48 hours. A) medium only; B) 1% 
CSE; C) 1ug/ml -CD3; D) 100ng/ml IL-2; and E) 20ng/ml IL-15. 
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3.2.3.2 CSE suppressed killer cell activation in response 
to different stimulus 
PBMCs collected from the four study groups were either 
untreated (control) or treated by 1% of CSE alone, or 
incubated with 1ug/ml -CD3, 100ng/ml IL-2 or 20ng/ml IL-
15 for 48 hours in the absence or presence of 1% of CSE. 
There was no significant difference on the activation of CD8+ T 
cells (Tc cells) between untreated PBMCs and CSE treated 
PBMCS in each group (Figure 3.2.7). CSE significantly reduced 
the activation levels of anti-CD3 treated Tc cells from healthy 
non-smokers (Figure 3.2.7.A, p<0.01) and current smokers 
with COPD (Figure 3.2.7.C, p<0.005). Also, IL-2 indcued Tc 
cell activation was dramatically decreased when CSE was 
added in healthy non-smokers (Figure 3.2.7.A, p<0.005), 
current smokers with COPD (Figure 3.2.7.C, p<0.001) and ex-
smokers with COPD (Figure 3.2.7.D, p<0.001). Furthermore, 
CSE markedly attenuated IL-15 stimulated T cell activation in 
all interested groups (p value was shown in Table 3.2.7).   
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A. Healthy non-smokers (HNS) 
 
B. Current Healthy smokers (HS)  
 
CSE (1%); anti-CD3 (1ug/ml) 
IL-2 (100ng/ml); IL-15 (20ng/ml) 
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Figure 3.2.7 CSE effects on activation levels of Tc cells in four 
groups. PMBCs were collected from four groups including A) HNS 
(n=4), B) HS (n=4), C) cuS-COPD (n=4), and D) exS-COPD (n=4). 
Cells were untreated or treated by different reagents at designed 
concentrations and incubated 48 hours. *, p<0.01; **, p<0.005; ***, 
p<0.001. 
 
C. current smokers with COPD (cuS-COPD) 
 
D. ex-smokers with COPD (exS-COPD) 
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Table 3.2.7 Statistical difference of before and after CSE treated cells 
 
 HNS, healthy non-smokers; HS, current healthy smokers; cuS-COPD, 
current smokers with COPD; exS-COPD, ex-smokers with COPD. 
 CSE showed significant effects on all cell types of interest upon IL-15 
stimulation in all groups. 
 
CSE effects on activated NKT cells were also investigated. 
There was no significant difference on the activation levels of 
NKT-like cells treated with or without CSE in each group 
(Figure 3.2.8). CSE significantly reduced the activation levels 
of -CD3 treated Tc cells from healthy non-smokers (Figure 
3.2.8.A, p<0.005), current smokers with COPD (Figure 
3.2.8.C, p<0.005) and ex-smokers with COPD (Figure 3.2.8.D, 
p<0.005). IL-2 indcued NKT-like cell activation was 
dramatically decreased when CSE was added in healthy non-
smokers (Figure 3.2.8.A, p<0.01), current smokers with COPD 
 Medium  
vs 
CSE 
anti-CD3 
vs 
anti-CD3+CSE 
IL-2 
vs 
IL-2+CSE 
IL-15 
vs 
IL-15+CSE 
Tc cells HNS p>0.01 p<0.01 p<0.005 p<0.005 
HS p>0.01 p>0.01 p>0.01 p<0.01 
cuS-COPD p>0.01 p<0.005 p<0.001 p<0.01 
exS-COPD p>0.01 p>0.01 p<0.01 p<0.01 
NKT-like 
cells 
HNS p>0.01 p<0.005 p<0.01 p<0.01 
HS p>0.01 p>0.01 p>0.01 p<0.005 
cuS-COPD p>0.01 p<0.005 p<0.005 p<0.01 
exS-COPD p>0.01 p<0.005 p<0.01 p<0.005 
NK cells HNS p>0.01 p<0.001 p<0.01 p<0.005 
HS p>0.01 p<0.005 p<0.005 p<0.001 
cuS-COPD p>0.01 p<0.005 p<0.005 p<0.001 
exS-COPD p>0.01 p<0.005 p<0.005 p<0.001 
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(Figure 3.2.8.C, p<0.005) and ex-smokers with COPD (Figure 
3.2.8.D, p<0.01). Furthermore, CSE markedly attenuated IL-
15 stimulated NKT-like cell activation in all groups (p value 
was shown in Table 3.2.7).  
 
When examining activated levels on NK cells, untreated cells 
compared to CSE alone had no markedly effects on NK cell 
activation in each patient group (Figure 3.2.9). Activation 
levels of NK cell in response to -CD3, IL-2 or IL-15 were all 
significangly decreased in the presence of CSE (p value was 
shown in Table 3.2.7). 
 
Absolute acitvation levels of killer cells in response to each 
stimulation were also compared between groups. There were 
no statistical differences detected (Figures are shown in 
Appendix). 
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A. Healthy non-smokers (HNS) 
 
B. Current healthy smokers (HS) 
 
CSE (1%); anti-CD3 (1ug/ml) 
IL-2 (100ng/ml); IL-15 (20ng/ml) 
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C. current smokers with COPD (cuS-COPD) 
 
D. ex-smokers with COPD (exS-COPD) 
 
Figure 3.2.8 CSE effects on activation levels of NKT cells in four 
groups. PMBCs were collected from four groups including A) HNS 
(n=4), B) HS (n=4), C) cuS-COPD (n=4), and D) exS-COPD (n=4). 
Cells were untreated or treated by different reagents at designed 
concentrations and incubated 48 hours. *, p<0.01; **, p<0.005; ***, 
p<0.001. 
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A. Healthy non-smokers (HNS) 
 
B. Current healthy smokers (HS) 
 
CSE (1%); anti-CD3 (1ug/ml) 
IL-2 (100ng/ml); IL-15 (20ng/ml) 
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C. current smokers with COPD (cuS-COPD) 
 
D. ex-smokers with COPD (exS-COPD) 
 
Figure 3.2.9 CSE effects on activation levels of NK cells in four 
groups. PMBCs were collected from four groups including A) HNS (n=4), 
B) HS (n=4), C) cuS-COPD (n=4), and D) exS-COPD (n=4). Cells were 
untreated or treated by different reagent at designed concentrations and 
incubated 48 hours. *, P<0.01; **, p<0.005; ***, p<0.001. 
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3.2.3.3 Absolute suppression levels induced by CSE on 
killer cell activation in response to different stimulation 
Since CSE dramatically suppressed most activation levels of Tc 
cells, NKT-like cells and NK cells upon different stimulation in 
each group, we further compared the absolute suppression 
levels induced by CSE on cell activation between four groups. 
The calculation fomula of absolute suppression levels was 
“Absolute suppression level = the percentage of activated cells 
of interest up on different stimulation - the percentage of 
these cells upon CSE treatment”. There were no significant 
differences on the absolute levels of CSE induced suppression 
in -CD3 treated Tc cell activatioin between four groups 
(Figure 3.2.10.A, all p>0.01). Absolute suppression level of 
CSE treated NKT cells upon -CD3 stimulation was markedly 
higher in current smokers with COPD compared to healthy 
non-smokrers (p<0.005), current healthy smokers (p<0.01) 
and ex-smokers with COPD (p<0.005) (Figure 3.2.10.B). 
Furthermore, CSE inducing absolute suppression level on NK 
cell activation upon -CD3 stimulation was markedly higher in 
current smokers with COPD compared to healthy non-smokers 
(p<0.01) and current healthy smokers (p<0.005) (Figure 
3.2.10.C). The absolute suppression level on CSE treated NK 
ce l ls  in  response  to  -CD3 was a lso  s ign i f i cant ly 
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Figure 3.2.10 Absolute suppression levels induced by CSE on 
-CD3 treated killer cell activation in four groups. A) Tc cells; 
B) NKT cells; C) NK cells. HNS (healthy non-smokers, n=4); HS 
(current healthy smokers, n=4); C) cuS-COPD (current smokers with 
COPD, n=4); exS-COPD (ex-smokers with COPD, n=4). *, P<0.01; 
**, p<0.005; ***, p<0.001. 
A 
B 
C 
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higher in healthy non-smokers (p<0.005) in contrast to 
current healthy smokers (Figure 3.2.10.C). 
 
In IL-2 treated Tc cells, absolute suppression levels induced 
by CSE were significantly higher in current smokers with COPD 
compared to healthy non-smokers (p<0.005) and current 
healthy smokers (p<0.01) (Figure 3.2.11.A).  Also, absolute 
suppression level on CSE treated NK cell activation was 
remarkably higher in current smokers with COPD compared to 
healthy non-smokrers (p<0.01), current healthy smokers 
(p<0.005) and ex-smokers with COPD (p<0.005) (Figure 
3.2.11.C). There were no significant differences on the 
absolute levels of CSE inducing suppression on Tc cell 
activation between four groups (Figure 3.2.11.B, all p>0.01).  
 
CSE did not show any statistical differences on the absolute 
suppression levels of IL-15 stimulted Tc cells between groups 
(Figure 3.2.12.A). NKT cells in response to IL-15 was 
dramatically suppressed when CSE was added in ex-smokers 
with COPD compared to healthy non-smokers (p<0.01) and 
current healthy smokers (p<0.001) (Figure 3.2.12.B). 
Moreover, the absolute suppression level induced by CSE on 
IL-15 treated NK cells was significantly higher in current 
smokers with COPD compared to other three gourps including  
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Figure 3.2.11 Absolute suppression levels induced by CSE on 
IL-2 treated killer cell activation in four groups. A) Tc cells; B) 
NKT cells; C) NK cells. HNS (healthy non-smokers, n=4); HS (current 
healthy smokers, n=4); C) cuS-COPD (current smokers with COPD, 
n=4); exS-COPD (ex-smokers with COPD, n=4). *, P<0.01; **, 
p<0.005; ***, p<0.001. 
A 
B 
C 
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Figure 3.2.12 Absolute suppression levels induced by CSE on IL-
15 treated killer cell activation in four groups. A) Tc cells; B) NKT 
cells; C) NK cells. HNS (healthy non-smokers, n=4); HS (current 
healthy smokers, n=4); C) cuS-COPD (current smokers with COPD, 
n=4); exS-COPD (ex-smokers with COPD, n=4). *, P<0.01; **, 
p<0.005; ***, p<0.001. 
C 
B 
A 
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healthy non-smokers (p<0.01), current healthy smokers 
(p<0.01) and ex-smokers with COPD (p<0.005) (Figure 
3.2.12.C). 
 
Figure 3.2.13 showed the representative dot plots of CSE 
suppressed cell activation upon different activators from a 
current smoker with COPD.  Figure1, Figure 2 and Figure 3 
from Appendix showed the comparision of absolute activation 
levels of cells of interest upon different stimulation in four 
gourps. Table 3.2.8 showed the statistical differences of 
absolute suppression induced by CSE on different cell 
activation between groups.  
 
3.2.4 Discussion 
Cigarette smoking is still the major risk factor in the 
development of COPD. Accumulating evidence has suggested 
that chronic inhalation of cigarette smoke alters a wide range 
of immunologic function, including both innate and adaptive 
immune responses (Honda et al., 1996, Mio et al., 1997, 
Mohan, 2002b, Subramaniam et al., 1996, Wyatt et al., 1999). 
The main focus of this section was to investigate the impact of 
CSE on -CD3, IL-2 or IL-15 activated killer cells including Tc 
cells, NKT-like cells and NK cells, and further compared their 
activation levels in four groups, namely, healthy non-smokers, 
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current healthy smokers, current smokers with COPD and ex-
smokers with COPD. 
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Figure 3.2.13 Representative dot plots of the activation of 
interested cells from a current smoker with COPD. PBMCs were 
stimulated by either A) meidium only; B) 1% CSE only; C) -CD3; D) -
CD3+1% CSE; E) IL-2; F) IL-2+1% CSE; G) IL-15; or H) IL-15+1% CSE; 
and incubated for 48 hours after stimulation. -CD3 significantly activated 
both Tc cells and NKT cells compared to NK cells. Whereas, IL-2 and IL-15 
showed remarkable effects on NK cell activation. 
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Table 3.2.8 Absolute suppression induced by CSE on activation of 
killer cells upon different stimulation. 
 HNS 
vs 
HS 
HNS 
vs 
cuS-COPD 
HNS 
vs 
exS-COPD 
HS 
vs 
cuS-COPD 
HS 
vs 
exS-COPD 
cuS-copd 
vs 
exS-COPD 
-CD3 treated cells 
Tc p>0.01 p>0.01 p>0.01 p>0.01 p>0.01 p>0.01 
NKT p>0.01 p<0.005 p>0.01 p<0.01 p>0.01 p<0.005 
NK p<0.01 p<0.01 p>0.01 p<0.005 p>0.01 p>0.01 
IL-2 treated cells 
Tc p>0.01 p<0.005 p>0.01 p<0.01 p>0.01 p>0.01 
NKT p>0.01 p>0.01 p>0.01 p>0.01 p>0.01 p>0.01 
NK p>0.01 p<0.01 p>0.01 p<0.005 p>0.01 p<0.005 
IL-15 treated cells 
Tc p>0.01 p>0.01 p>0.01 p>0.01 p>0.01 p>0.01 
NKT p>0.01 p>0.01 p<0.005 p>0.01 p<0.001 p>0.01 
NK p>0.01 p<0.005 p>0.01 p<0.01 p>0.01 p<0.005 
 
HNS, healthy non-smokers; HS, current healthy smokers; cuS-COPD, 
current smokers with COPD; exS-COPD, ex-smokers with COPD. 
 
 
Firstly, to achieve optimal activation of all cells of interest, we 
set up a preliminary protocol to decide the optimal 
concentrations of each activator and incubation time for cell 
culture. Tc cells, NKT-like cells and NK cells were all highly 
activated when the concentration of -CD3 increased to 
1ug/ml. CD3 is a cell surface marker for T cells including Tc 
cells, Th cells, Treg cell,  T cells and NKT cells (Call and 
Wucherpfennig, 2004). However, in preliminary experiments, 
dose-dependent increases in the activation levels of NK cells 
were also observed, although NK cells do not express 
CD3/TCR complex on their cell surface. To our knowledge, this 
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could be easily explained.  -CD3 has the capacity of 
activating CD4+ T cells, Tc cells and NKT cells that further 
release immune mediators such as IL-2 or IL-15 (Smyth et al., 
2005, Thompson et al., 1989). Furthermore, previous studies 
have shown that CSE also has effects on DCs and 
macrophages that also secret high amount of IL-15 (Carson et 
al., 1995, Jonuleit et al., 1997). Both IL-2 and IL-15 are good 
sources for NK cell activation (Waldmann, 2006).  
 
Activation of killer cells induced by IL-2 is not as great as IL-
15 treated cells in healthy non-smokers. One of the reasons is 
the biological difference on features between IL-2 and IL-15. 
Although IL-2 and IL-15 share two receptors therefore have 
certain common features in their functions, they also provide 
distinct contributions on cell activation and apoptosis (Thomas, 
2008, Waldmann and Tagaya, 1999). IL-2R is only expressed 
by pre B cells, effector T cells and DCs, whereas IL-15R is 
widely expressed on many cell types except regulatory T cells. 
Furthermore, IL-15 increases the proliferation of the CD8+ T 
cells and reduces their death by apoptosis (Ku et al., 2000, 
Zhang et al., 1998), whereas IL-2 plays a critical role in Fas-
mediated activation-induced cell death (Lenardo, 1996). 
Kanegane and Tosato has shown that in PBMCs from healthy 
volunteers, IL-2 and IL-15 can both activate memory CD4+ T 
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cells, memory CD8+ T cells and naive CD8+ T cells, but not 
naive CD4+ T cells (Kanegane and Tosato, 1996). In addition, 
IL-2 does not act on resting NKT cells or NK cells that without 
IL-2R expression (Waldmann, 2002). We controlled the 
maximal concentration of IL-2 at 100ng/ml because of the 
side effects caused by high dose IL-2 administration as 
previously mentioned.  
 
In our study, activation levels of killer cells were not 
significantly different in the absence or presence of CSE at 
increasing dilutions in healthy volunteers, without other 
stimulations. These findings were in agreement with other 
groups who detected the CSE effects on DCs or NK cells from 
healthy volunteers (Mian et al., 2009, Mortaz et al., 2009). 
Although Stringer et al showed that CSE impaired neutrophil 
caspase-3-like activity in a dilution-dependent manner (CSE 
dilution 2%-16%), they were concerned about different cell 
types and the incubation time was only for 4 hours (Stringer 
et al., 2007). According to previous studies and our detection, 
we selected 1% of CSE for further experiments because it did 
not cause any toxic effects as revealed by MMT assay (Mian et 
al., 2008, Mian et al., 2009, Stringer et al., 2007). 
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The effects of CSE on killer cells were explored not only in 
healthy volunteers but also COPD patients. Although CSE 
alone did not show any impacts on the killer cells activation in 
all interested groups, we here for the first time showed that 
CSE significantly reduced the activation levels of Tc cells, NKT 
cells and NK cells in response to -CD3, IL-2 or IL-15 in 
different groups (Table 3.2.7). Of note, three representative 
results should be pointed out. Firstly, CSE markedly 
suppressed activation levels of IL-15 treated all cell types in 
all groups. Secondly, in contrast to Tc cells and NKT cells, NK 
cells were the only cell type which activation levels upon 
different stimulation were all significantly decreased when CSE 
was added in all participant groups. Thirdly, current smokers 
with COPD were the only participant group that showed CSE 
had statistically significant effects on all killer cell type 
activation with the different stimulations. These findings were 
supported by different studies. Mian and colleague have 
shown that in PBMCs from healthy non-smokers, the 
expression of CD69, a key activation marker for NK cells, was 
significantly inhibited when PBMCs are treated by cigarette 
smoke after poly I:C activation (Mian et al., 2009). Also, the 
cigarette smoke markedly reduced NK cell cytolytic potential 
to kill K562 cancer cells which was found to be IL-15 mediated. 
Recently, Hogan et al demonstrated that CSE significantly 
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reduced the cytokine production and the ability to kill target 
cells of -GalCel activated invariant NKT cells in PBMCs from 
healthy non-smoking participants. Meanwhile, the activation 
marker of CD107, but not CD69, was decreased (Hogan et al., 
2011).  Currently there are no previous studies to show the 
CSE effects on anti-CD3 activated killer cells. 
 
Since CSE showed suppression effects on killer cells at 
different levels in each group, we further compared 
suppression levels in each cell type between healthy 
volunteers and patient groups. Due to the diverse background 
of each sample, we used absolute suppression levels to find 
out whether they have statistical differences. There were no 
significant differences of CSE suppression on Tc cells in 
response to -CD3 or IL-15 between all groups. Interestingly, 
the absolute suppression levels induced by CSE on IL-2- or IL-
15-treated NK cell activation were significantly higher in 
current smokers with COPD compared to other three groups, 
namely, healthy non-smokers, current healthy smokers and 
ex-smokers with COPD. In -CD3 stimulated NKT cells, their 
activation levels were also dramatically suppressed when CSE 
was added in current smokers with COPD compared to healthy 
pariticipants and ex-smokers with COPD. However, CSE 
remarkably reduced the activation levels of NKT cells upon IL-
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15 activation in ex-smokers with COPD, but not current 
smokers with COPD, compared to healthy non-smokers and 
current healthy smokers. 
 
Chronic exposure to cigarette smoke leads to not only cellular 
death and damage in the airways, but also failure to activate 
critical intracellular signalling mechanisms that initiate 
protective host defence. The consequence is dysfunction of 
various cell types with accompanying predisposition to 
respiratory infection (Feldman and Anderson, 2013). Although 
small sample size was studied, our findings showed that in 
different conditions, CSE indeed suppressed killer cell 
activation in either healthy groups or COPD patients, or all of 
the samples. We believe in future, more reliable and 
consistent findings will be revealed when the sample size is 
enlarged. 
 
It is important to note that cigarette smoke comprises a 
complex mixture of more than 4000 chemicals, such as 
nicotine, carbon monoxide, and tar (Hoffmann and Wynder, 
1986, Stedman, 1968). Their immune-modulation effects on 
immune cells are distinct and also dose-dependent (Holt et al., 
1976). To determine the specific component of cigarette 
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smoke that regulates killer cell activation upon IL-15 
stimulation is beyond the scope of our studies.  
 
In conclusion, we here for the first time demonstrate that 
absolute suppression levels induced by CSE on IL-2- or IL-15- 
mediated NK cell activation were significantly higher in current 
smokers with COPD patients compared to healthy non-
smokers, current healthy smokers and ex-smokers with COPD. 
These findings provide further insights on understanding the 
cellular mechanisms of COPD and may also explain why 
smokers are more susceptible to lung infections. 
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3.3 Activation and cytotoxic molecule 
expression of CD56+ cells from peripheral blood 
samples 
 
3.3.1 Introduction 
The previous chapter demonstrated that CSE significantly 
suppressed NK cell activation in IL-15 treated PBMCs, 
especially in COPD patients. Activation levels of NKT-like cells 
upon IL-15 stimulation were also markedly decreased in ex-
smokers with COPD. Collectively, these findings suggested 
that CSE had impact on IL-15 mediated CD56+ cell activation.  
 
One of the major killing mechanisms of cytotoxic cells is 
performed by killing molecules, such as granzymes and 
perforin, and Fas-Fas ligand (Fairclough et al., 2008). After 
recognition of target cells by effector cells, granules released 
from killer cells move to the immunological synapse by 
exocytosis. Their membrane then fuses with the killer cell 
plasma membrane and releases contents into target cells. 
Previous studies have shown that increased expression of 
perforin and granzyme B were detected on CD8+ T cells from 
BAL fluid in COPD patients (Hodge et al., 2006). The 
percentage of both granzyme B and perforin positive NKT-like 
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and NK cells were significantly higher in induced sputum from 
COPD patients (Urbanowicz et al., 2010), but lower in 
peripheral blood samples (Urbanowicz et al., 2009). Morissette 
and colleague found that the percentage of peripheral CD8+ T 
cells and CD56+ cells expressing perforin, granzyme B and 
Fas-ligand was not different between healthy non-smokers, 
healthy smokers and emphysematous smokers (Morissette et 
al., 2007). However, it is hard to conclude that perforin and 
granzyme B positive NKT cells are the critical difference 
between COPD and emphysematous conditions. More studies 
should be carried out to confirm it. Furthermore, up-regulated 
soluble Fas was observed in plasma from severe COPD 
patients but not mild or moderate COPD patients (Yasuda et 
al., 1998).  
 
In PBMCs, IL-15 not only stimulates NK cells or NKT cells, but 
also other immune cells, such as memory CD4+ T cells and 
CD8+ T cells, which consequently secrete more functional 
cytokines and chemokines to induce adaptive immune 
response (Anderson et al., 1995, Cosman et al., 1995). To 
confirm whether the suppression effects caused by CSE were 
directly related to IL-15 treated NKT-like cells and NK cells, in 
this section, we isolated NKT-like cells (CD3+CD56+) and NK 
cells (CD3-CD56+) from PBMCs in healthy non-smoker, current 
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healthy smokers and current smokers with COPD. Both 
activation levels and killing molecule expression were 
investigated and compared in three groups. Two types of cells 
were incubated with medium alone, CSE alone or IL-15 in the 
absence or presence of CSE, for 48 hours. Cell activation 
markers CD69 and CD25 were measured, along with killing 
molecules including perforin, granzyme B and Fas-ligand.  
 
3.3.2 Material and methods 
3.3.2.1 Study population and procedures 
The criteria of participant enrolments are the same as 
previously introduced. Nine participants were included in this 
part of the study. Table 3.3.1 shows the demographic and 
spirometric data of the participants. 
 
3.3.2.2 Reagents 
Recombined human IL-15 was obtained from PeproTech EC 
(London, UK). Other monoclonal antibodies for flowcytometry 
were shown in table 3.3.2. 
 
3.3.2.3 Cigarette smoke extract preparation 
CSE were freshly prepared prior to 30 minutes of cell culture 
for each experiment to avoid breakdown of substances in the  
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Table 3.3.1 Demographic and spirometric valus of the CSE 
suppression study groups 
 
Healthy  
non-smokers 
Current healthy 
smokers 
cuS-COPD 
Participants 3 3 3 
Age (years) 52 （50-54） 57 (54-60) 55 (52-58) 
Gender (M/F) 0/3 2/1 2/1 
Packs/yrs 0 39 (31-42) 43 (35-47) 
Smoking 
status 
(Current/Ex) 
0 3/0 3/0 
Chronic 
bronchitis 
(Yes/No) 
0 2/1 3/0 
FEV1 (% pred) 111 (102-119) 105 (98-117) 52 (46-60) 
FEV1/FVC (%) 97 (86-113) 90 (69-106) 49(45-53) 
∆FEV1 post 
bronch 
2.2  
(1.7-2.5) 
2.0  
(1.7-2.4) 
1.5  
(1.2-1.6) 
BMI (kg/m2) 25.8 (22.6-28.3) 26.7 (20.5-29.4) 
20.3  
(15.8-25.1) 
Inhaled GCS 
(on/off) 
N/A N/A 0/3 
MRC dyspnoea 
scale 
N/A N/A 3 (2-4) 
Distance 
walked in 6 
min (m) 
N/A N/A 277 (196-312) 
BODE Index N/A N/A 4 (3-6) 
 
 
extract and evaporation of volatile components. More details 
are provided in section 2.4. 
 
3.3.2.4 Separation of NKT-like cells and NK cells 
Isolated PBMCs were incubated with anti-CD56 MicroBeads 
(Miltenyi Biotech Ltd, Surrey, UK) in MACS buffer containing 
sterile D-PBS (Sigma), 1% heat-inactivated fetal calf serum 
(FCS) (QB-Perbio) and 0.4% EDTA (Sigma) for 15 minutes at 
4°C. More details are provided in section 2.3.  
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Table 3.3.2 Antibodies used for flow cytometry 
Antigen 
Fluorochro
me 
Isotype Clone Source 
CD3 PC7 Mouse IgG1 UCHT1 Beckman Coulter, 
Luton, UK 
CD25 PE Mouse IgG2a, 
 
B1.49.9 Beckman Coulter, 
Luton, UK 
CD56 PC5 
 
Mouse IgG1 N901 Beckman Coulter, 
Luton, UK 
CD69 ECD Mouse IgG2b TP1.55.3 Beckman Coulter, 
Luton, UK 
KIR3DL1 
(CD158e
1) 
FITC Mouse IgG1, k DX9 Biolegend, San 
Diego, CA, USA 
Fas-L 
(CD178) 
PE 
IgG Hamster 
 
4A5 
 
Beckman Coulter, 
Luton, UK 
Granzym
eB 
 
FITC 
 
Mouse IgG1, k 
 
 
GB11 
 
 
BD PharmingenTM 
 
 
Perforin 
 
PE 
 
Mouse IgG2b, k 
 
 
G9 
 
 
BD PharmingenTM 
 
 
 
 
 
3.3.2.5 Cell culture and treatments 
Isolated NKT-like cells and NK cells were separately 
resuspended in RPMI-1640 medium supplemented with 10% 
of FCS at a density of 1x106 cells/ml and cultured at 
200ul/well in a 96-well flat bottom tissue culture plate. These 
cells were either untreated or treated with CSE, IL-15 or IL-15 
plus CSE. All cells were cultured at 37°C in a 5% CO2 for 48 
hours before analysis. 
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3.3.2.6 Extracellular staining for CD56+ cells 
Fluorescently conjugated antibodies used for extracellular 
staining were as follows, CD3 (PC7), CD56 (PC5), CD69 (ECD) 
CD25 (PE) and Fas-L (PE), or KIR (FITC). More details are 
shown in section 2.6.  
 
3.3.2.7 Intracellular staining for CD56+ cells  
Fluorescently conjugated antibodies including perforin (PE) 
and granzyme B (FITC) were used for intracellular staining. 
Briefly, Brefeldin A (Sigma, 0.4ul for per 2×105 cells) diluted 
in RPMI medium was added to cell culture prior to 14 hours 
before harvesting cells. Cell suspension were washed with PBA, 
fixed with 3% of formaldehyde fix and incubated in the dark at 
4°C for 5 minutes. More details are shown in section 2.6. 
 
3.3.2.8 Flow cytometric analysis 
Flow cytometric analysis of antibody labelled cells was 
performed using an EPICS Altra (Beckman Coulter, Luton, UK).  
More details are provided in section 2.9. 
 
3.3.2.9 Statistical analysis  
The statistical analysis was performed with Prism software, 
version 4.0c (GraphPad). Differences between the three 
groups of participants were tested using the parametric 
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student’s t test. Confidence interval 99% was used to show 
two-tailed p values. P values of less than 0.01 were 
considered to indicate statistical significance. 
 
3.3.3 Results 
 
3.3.3.1 Demographic and medical characteristics of 
COPD participants, healthy smokers and healthy 
controls 
There were no statistical differences between groups in terms 
of age or pack years smoked between current smokers with 
COPD and current healthy smokers (Data not shown). 
 
3.3.3.2 Effects of CSE on CD56+ cell activation  
Isolated NKT-like cells and NK cells were incubated with 
medium alone, CSE (1%) alone, IL-15 (20ug/ml) in the 
absence or in the presence of CSE (1%) for 48 hours at 37°C 
before cell collection. Cells are designated activated when they 
express one or both activation markers (i.e., CD69 positive, 
CD69/CD25 double positive or CD25 positive). There were no 
significant differences on the activation levels of NKT-like cells 
(Figure 3.3.1.A) or NK cells (Figure 3.3.1.C) between medium 
and CSE alone incubation in all groups (all p>0.01). As shown 
in figure 3.3.1.B, activation levels of CSE treated NKT-like 
cells upon IL-15 stimulation were significantly suppressed 
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compared to IL-15 itself mediated cell activation in all groups 
(p<0.01). Also, CSE very markedly suppressed IL-15 
mediated NK cell activation in all groups (Figure 3.3.1.D; HNS, 
p<0.005; HS, p<0.005; cuS-COPD, p<0.001). Figure 3.3.2 
shows the representative dot plots of CSE treated NKT-like cell 
and NK cell activation upon IL-15 stimulation in current 
smokers with COPD. 
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Figure 3.3.1 CSE effects on 
activation levels of NKT-like 
cells and NK cells in different 
conditioned medium. NKT-like 
cells (panel A and B) and NK 
cells (panel C and D) were 
isolated from PBMCs in three 
groups including health non-
smokers (HNS, n=3), current 
current healthy smokers (HS, 
n=3), and current smokers with 
COPD (cuS-COPD, n=3). Cells 
were untreated or treated by 
CSE alone, IL-15 alone or IL-
15+CSE and incubated 48 
hours. Significant differences 
were considered as p 
value<0.05. *, p<0.01; **, 
p<0.005; ***, p<0.001. Cells 
are designated activated when 
they express one or both 
activation markers including 
CD69 and CD25. 
C 
B A 
D 
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3.3.3.3 Effects of CSE on killing molecule expression by 
CD56+ cells 
Killing molecules, such as granzymes and perforin, and Fas-
Fas ligand, perform major functions in cytotoxic cell mediated 
immune responses. Here we detected, in vitro, the effects of 
CSE on expression of granzyme B (Figure 3.3.3), perforin 
(Figure 3.3.4), and Fas-ligand (Figure 3.3.5) in NKT-like cells 
and NK cells upon IL-15 stimulation. There were no significant 
differences on the expression of granzyme B by either NKT 
cells or NK cells that were treated with or without CSE (Figure 
3.3.3.A and Figure 3.3.3.C). The expression of granzyme B on 
IL-15-activated NKT-like cells were significantly inhibited by 
CSE in healthy non-smokers (p<0.01) (Figure 3.3.3.B). Also, 
CSE dramatically reduced the expression of granzyme B on IL-
15-treated NK cells in both healthy non-smokers (Figure 
3.3.3.D, p<0.01) and current smokers with COPD (Figure 
3.3.3.D, p<0.001). Perforin was highly expressed in both NKT-
like cells and NK cells with or without extra stimulation in all 
groups (Figure 3.3.4). Whereas Fas-ligand expressed by NKT-
like cells and NK cells was lower in all cell incubation 
conditions in three studied groups (Figure 3.3.5). Table 3.3.3 
and table 3.3.4 showed the actual value range of expression 
levels of molecules of interest on NKT cells and NK cells. 
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medium only       1% CSE  IL-15 (20ug/ml)     IL-15+CSE 
A 
B 
 C
D
2
5
 
    CD69 
NKT 
NK 
Figure 3.3.2 Representative dot plots for activation of NKT-like cells (panel A) and NK cells (panel B) isolated from PBMCs from 
a current smoker with COPD. NKT-like cells or NK cells were either untreated or treated with CSE alone, IL-15 alone or IL-15 co-treated 
with CSE.  
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Figure 3.3.3 CSE effects 
on expression of 
granzyme B by NKT-like 
cells and NK cells. NKT-
like cells (panel A and B) 
and NK cells (panel C and 
D) were isolated from 
PBMCs in three groups 
including health non-
smokers (HNS, n=3), 
current healthy smokers 
(HS, n=3), and current 
smokers with COPD (cuS-
COPD, n=3). Cells were 
untreated or treated by CSE 
alone, IL-15 alone or IL-
15+CSE and incubated 48 
hours. *, p<0.01; **, 
p<0.005; ***, p<0.001. 
 
A B 
C D 
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A B 
C D 
Figure 3.3.4 CSE effects 
on expression of perforin 
by NKT-like cells and NK 
cells. NKT-like cells (panel A 
and B) and NK cells (panel C 
and D) were isolated from 
PBMCs in three groups 
including health non-
smokers (HNS, n=3), 
current healthy smokers 
(HS, n=3), and current 
smokers with COPD (cuS-
COPD, n=3). Cells were 
untreated or treated by CSE 
alone, IL-15 alone or IL-
15+CSE and incubated 48 
hours. *, p<0.01; **, 
p<0.005; ***, p<0.001. 
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A B 
C 
D 
Figure 3.3.5 CSE effects 
on expression of Fas-
ligand by NKT-like cells 
and NK cells. NKT-like cells 
(panel A and B) and NK cells 
(panel C and D) were 
isolated from PBMCs in three 
groups including health non-
smokers (HNS, n=3), current 
healthy smokers (HS, n=3), 
and current smokers with 
COPD (cuS-COPD, n=3). 
Cells were untreated or 
treated by CSE alone, IL-15 
alone or IL-15+CSE and 
incubated 48 hours. *, 
p<0.01; **, p<0.005; ***, 
p<0.001. 
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Table 3.3.3 Expression of molecules of interest on NKT cells with or 
without activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Granzyme B 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 48.2% 
(39.2-55.6) 
46.6% 
(43.6-52.1) 
64.7% 
(57.8-71.3) 
49.8% 
(47.6-52.9) 
HS 53.3% 
(37.8-71.6) 
55.7% 
(50.0-62.0) 
72.1% 
(69.1-77.2) 
60.1% 
(56.8-63.3) 
CuS-COPD 47.9% 
(44.0-50.0) 
49.1% 
(45.1-52.2) 
61.5% 
(55.7-66.6) 
42.1% 
(33.7-52.2) 
Perforin 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 95.8% 
(90.1-99.1) 
97.3% 
(94.2-99.2) 
94.0% 
（90.3-99.8） 
95.4% 
(91.2-98.8) 
HS 93.1% 
(92.3-94.0) 
95.1% 
(92.2-97.6) 
95.3% 
（90.3-99.0） 
95.3% 
(91.7-98.8) 
CuS-COPD 92.3% 
(87.2-99.6) 
96.2% 
(93.3-98) 
99.31% 
(98.2-99.9) 
96.7% 
(92.4-99.0) 
Fas-ligand 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 6.2% 
(3.4-8.0) 
7.9% 
(5.6-10.3) 
12.0% 
(11.0-12.7) 
9.3% 
(7.2-11.7) 
HS 8.6% 
(5.7-10.2) 
8.7% 
(6.6-11.3) 
10.9% 
(7.3-14.4) 
7.6% 
(6.3-9.1) 
CuS-COPD 7.2% 
(6.1-8.1) 
8.2% 
(6.4-11.2) 
11.5% 
(11.0-12.3) 
8.0% 
(2.1-15.1) 
KIR 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 7.9% 
(6.0-9.9) 
8.3% 
(5.1-10.1) 
9.0% 
(5.1-11.2) 
8.5% 
(7.3-9.3) 
HS 9.8% 
(7.4-12.1) 
9.3% 
(8.8-10.3) 
11.2% 
(8.2-15.2) 
7.3% 
(5.5-9.2) 
CuS-COPD 9.0% 
(8.9-9.1) 
9.7% 
(8.0-11.2) 
12.7% 
(10.3-15.1) 
6.8% 
(2.5-10.2) 
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Table 3.3.4. Expression of molecules of interest on NK cells with or 
without activation. 
 
 
 
 
 
 
 
 
Granzyme B 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 53.9% 
(44.9-60.1) 
54.2% 
(45.2-59.3) 
70.5% 
(61.1-80.3) 
51.9% 
(46.5-57.9) 
HS 55.2% 
(50.1-60.1) 
53.1% 
(49.0-56.9) 
73.3% 
(67.0-82.2) 
52.6% 
(42.0-62.1) 
CuS-COPD 50.1% 
(46.9-53.4) 
49.6% 
(46.2-52.6) 
76.9% 
(72.6-80.3) 
45.7% 
(41.2-50.2) 
Perforin 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 96.6% 
(95.5-98.7) 
92.9% 
(90.0-98.3) 
94.8% 
（90.0-97.7） 
91.9% 
(87.3-95.5) 
HS 93.2% 
(91.0-99.2) 
91.7% 
(87.9-95.9) 
91.3% 
（89.4-94.4） 
92.4% 
(88-98.9) 
CuS-COPD 92.1% 
(90.2-95.1) 
93.6% 
(90.9-97.1) 
90.6% 
(856.-95.5) 
92.1% 
(90.1-93.9) 
Fas-ligand 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 5.0% 
(3.8-7.0) 
4.1% 
(3.0-5.1) 
12.0% 
(3.4-10.2) 
9.3% 
(3.4-11.0) 
HS 5.2% 
(2.3-7.7) 
6.0% 
(2.9-9.9) 
10.9% 
(3.9-6.2) 
7.6% 
(2.4-5.9) 
CuS-COPD 3.8% 
(2.2-5.1) 
4.3% 
(2.1-7) 
11.5% 
(0.3-11.2) 
8.0% 
(3.2-5.6) 
KIR 
 Medium 
only 
CSE 
only 
IL-15 IL-15 + CSE 
HNS 5.8% 
(3.3-7.9) 
4.3% 
(0.9-9.1) 
5.0% 
(0.7-8.9) 
5.4% 
(2.5-10.2) 
HS 4.6% 
(2.1-7.2) 
3.1% 
(1.8-5.4) 
5.3% 
(2.9-7.6) 
4.3% 
(2.4-6.0) 
CuS-COPD 3.4% 
(1.5-5.7) 
2.1% 
(0.7-3.5) 
6.1% 
(0.6-10.1) 
2.6% 
(1.7-3.3) 
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CSE had no effects on the expression levels of either perforin 
or Fas-ligand. Collectively, IL-15 had the ability of inducing 
more granzyme B expression on CD56+ cells but had no 
effects on the expression of perforin and Fas-ligand. Figure 
3.3.6 shows representative dot plots of CSE effects on killing 
molecule expression by CD56+ cells from current smokers with 
COPD.  
 
3.3.3.4 Effects of CSE on KIR expression by CD56+ cells 
The effect of CSE on KIR expression was also studied (Figure 
3.3.7). Results in chapter 3.1 demonstrated that the 
expression of KIR (CD158e1), in vivo, was much more 
smoking-related than disease related (Figure 3.1.8). However, 
here, in vitro, we did not detect any statistical differences on 
KIR expression by CSE treated CD56+ cells upon IL-15 
stimulation KIR expression showed very low levels on CD56+ 
cells in each group. Due to low cell numbers of CD56+ cells, 
we did not detect the NKG2D expression. 
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Figure 3.3.6 Representative dot plots for expression of perforin, granzyme B, Fas-ligand and KIR by NKT-like cells 
(panel A and B) and NK cells (panel C and D) isolated from PBMCs from a current smoker with COPD. NKT-like cells or 
NK cells were either untreated or treated with CSE alone, IL-15 alone or IL-15 co-treated with CSE.  
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Figure 3.3.7 CSE effects 
on expression of KIR by 
NKT-like cells and NK 
cells. NKT-like cells (panel A 
and B) and NK cells (panel C 
and D) were isolated from 
PBMCs in three groups 
including health non-
smokers (HNS, n=3), current 
healthy smokers (HS, n=3), 
and current smokers with 
COPD (cuS-COPD, n=3). 
Cells were untreated or 
treated by CSE alone, IL-15 
alone or IL-15+CSE and 
incubated 48 hours. *, 
p<0.01; **, p<0.005; ***, 
p<0.001. 
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3.3.3.5 CSE suppressed cell activation 
As previously mentioned, cell activation was measured by 
expressing one or both of the activation markers including 
CD69 and CD25. CSE significantly suppressed the activation 
levels of IL-15 treated NKT-like cells and NK cells. Here we 
compared the absolute suppression induced by CSE on IL-15 
mediated NKT-like cell or NK cell activation in three groups. 
There were no statistical differences on the suppression levels 
between groups (Figure 3.3.8.A and B). The expression levels 
of granzyme B on CSE treated NKT-like cells or NK cells in 
response to IL-15 were also compared. No significant 
differences were detected on the absolute suppression of 
granzyme B expression between groups (Figure 3.3.9.A and 
B). 
 
3.3.4 Discussion 
Here we report, for the first time, in vitro, that CSE 
significantly suppresses the activation levels of IL-15 treated 
NKT-like cells and NK cells isolated from PBMCs in healthy 
non-smokers, current healthy smokers and current smokers 
with COPD. 
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Figure 3.3.8 CSE induced suppression on activation levels of IL-
15 stimulated NKT-like cells and NK cells in three groups. 
Absolute suppression levels were gained by using (% of IL-15 activated 
cells) minus (% of IL-15+CSE treated cells). All p value>0.05. HNS 
(healthy non-smokers, n=3); HS (healthy smokers, n=3); cuS-COPD 
(current smokers with COPD, n=3). 
A 
B 
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Figure 3.3.9 CSE induced suppression on expression of 
granzyme B by IL-15 stimulated NKT-like cells and NK cells 
in three groups. Absolute suppression levels were gained by using 
(% of IL-15 activated cells) minus (% of IL-15+CSE treated cells). 
All p>0.05. HNS (healthy non-smokers, n=3); HS (healthy 
smokers, n=3); cuS-COPD (current smokers with COPD, n=3). 
 
A 
B 
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IL-15 is a potent cytokine with the ability of stimulating many 
kinds of immune cells, such as memory CD4+ T cells, naive or 
memory CD8+ T cells, DCs, NKT cells and NK cells, which can 
further secrete more cytokines and chemokines to induce 
adaptive immune responses (Anderson et al., 1995, Cosman 
et al., 1995). Several studies demonstrated that cigarette 
smoke inhibited IL-12 and type-1 IFN production in activated 
PBMCs, which consequently decreased the IL-15 levels in 
healthy non-smokers (Mian et al., 2008, Mian et al., 2009). 
Also, both in vitro and in vivo, cigarette smoke significantly 
diminished IL-15 mRNA levels in poly I:C-activated PBMCs 
from healthy non-smoking participants. IL-15 production was 
markedly impaired in smoke-conditioned medium treated 
PBMCs upon poly I:C simulation. In result chapter 3.2, we 
showed that the CSE significantly reduced the activation levels 
of NKT-like cells from IL-15 treated PBMCs in healthy 
volunteers and ex-smokers with COPD. Also, CSE dramatically 
decreased the activation levels of NK cells in all groups, 
especially in COPD patients. Therefore, we examined whether 
the suppression induced by CSE on CD56+ cells is directly 
correlated with IL-15 or through other immune mediators 
secreted by other cells. We found that CSE itself did not show 
any statistical impacts on the activation levels of CD56+ cells 
compared to untreated cells. IL-15 highly activated NKT-like 
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cells and NK cells in both healthy volunteers and COPD 
patients. However, when CSE was added in the cultures, their 
activation levels were significantly reduced. This effect on NK 
cells was much more significant in current smokers with COPD.  
Interestingly, after 48 hour incubation, activation stages of 
NKT cells and NK cells showed different status (Figure 3.3.2). 
Most activated NKT cells are both CD69 and CD25 positive, 
whereas NK cells are mainly CD69 positive. This might be 
explained as followed. Cytokines released by NKT cells are 
always rapid and transient, with a peak of activity within 24 
hours. After 24 hours, productions of these cytokines, for 
example IFN-, quickly return to baseline levels (Eberl and 
MacDonald, 1998). IFN- is a good inducer for NK cell 
activation. This may explain why NKT cells were more quickly 
activated than NK cells. 
 
Our group has illustrated that the cytotoxic functions of NK 
cells and NKT cells from PBMCs were both markedly reduced 
in COPD patients compared to healthy volunteers (Urbanowicz 
et al., 2009). In vitro, the percentage of perforin /granzyme B 
double positive NK cells was significantly lower in COPD 
patients compared to controls. Furthermore, Mian et al 
demonstrated that cigarette smoke inhibited IL-15 mediated 
NK cell cytotoxic killing ability with expressing lower NK cell 
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degranulation marker CD107a in healthy non-smokers (Mian 
et al., 2009). Granzymes, perforin and Fas-Fas ligand are 
three major killing molecules that facilitate NKT-like cells and 
NK cells performing their cytotoxic functions. To evaluate 
whether CSE induced suppression was linked to NK cell 
cytotoxicity, we analysed the expression levels of above three 
cytotoxic granules on IL-15 stimulated CD56+ cells in the 
presence or in the absence of CSE. Surprisingly, CSE did not 
induce any remarkable impacts on expression levels of 
perforin and Fas-ligand in all groups. Perforin was highly 
expressed in all stimulating conditions whereas Fas-L showed 
very low levels. Of note, expression of granzyme B on IL-15 
treated NKT-like cells was markedly reduced by CSE in healthy 
non-smokers. The remarkable effects of CSE on granzyme B 
expression by NK cells were also detectable in healthy non-
smokers and current smokers with COPD. These findings were 
partially supported by other research. Morissette and 
colleague illustrated that no statistical differences were 
observed on the expression of perforin and granzyme B in 
peripheral NK cells from either healthy volunteers or smokers 
with evidence of emphysema. Protein expression of Fas-ligand 
was not detected by flow cytometry (Morissette et al., 2007). 
Although there was a markedly increase in soluble Fas in 
plasma from severe COPD patients, there were no differences 
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on its expression in mild or moderate COPD and healthy 
controls (Yasuda et al., 1998). Hodge et al also demonstrated 
that there were no significant changes in the expression levels 
of granzyme A by NK or NKT-like cells in the blood of COPD 
patients compared to controls (Hodge et al., 2013). Taken 
together, our data suggest that granzyme B, but not perforin 
and Fas-ligand, was a functional molecule attributing to the 
significant impairment NK cell killing ability in response to CSE 
in COPD patients.  
 
KIRs are inhibitory receptors expressed by cytotoxic cells. We 
early found that, in vivo, expression levels of KIR (CD158e1) 
by killer cells including CD8+ T cells and CD56+ cells were 
negatively correlated with the activation levels of these cells in 
COPD patients. In this study, KIR expression by IL-15 
incubated CD56+ cells in response to CSE was analysed and 
compared between groups. Here, in vitro, we first time 
showed that there were no significant differences on KIR 
(CD158e1) expression by CD56+ in different cell culture 
conditions. KIR expression was at very low levels in each 
group. Few studies were carried out to detect the KIRs 
expression in either healthy volunteers or COPD patients. 
However, one study reported that NKG2D expression was not 
inhibited in cigarette smoke treated PBMCs after poly I:C 
244 
 
induction (Mian et al., 2009). NKG2D is an activating receptor 
mainly expressed by killer cells and  T cells. We found, ex 
vivo, it was highly expressed in CD56+ cells (averagely over 
90%) in both healthy participants and COPD patients. 
Collectively, KIR (CD158e1) was not a functional inhibitory 
receptor for CSE induced suppression of CD56+ cells activation 
in response to IL-15. Also, KIR levels from untreated cells in 
vitro (Figure 3.3.7) were lower than that ex-vivo (Fig 3.1.8). 
These might be due to, in vitro, cell interaction during 48 hour 
incubation. Activated cells might produce inflammatory 
molecules that could affect the functional receptor expression 
levels. However, more research should be carried out to clarify 
it. 
 
Although CSE significantly suppressed CD56+ cell activation 
and their granzyme B expression in IL-15 conditioned medium, 
there were no statistical differences between groups. This 
might be due to small sample size used in this study. We 
indeed found that the activation levels of NK cells inhibited by 
CSE in COPD patients were much more significant (p<0.001). 
 
Several limitations should be considered in our study. Firstly, 
only small number of subjects in each group was recruited. 
Secondly, patient samples were only from current smokers 
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with COPD but not ex-smokers.  Moreover, there are many 
cytotoxic granules such as granzyme A and granzyme K 
related to killing mechanisms of CD56+ cells. However, 
proportions of NKT-like cells and NK cells are very low in 
PBMCs. We could just detect representative killing molecules 
(granzyme B, perforin and Fas-ligand) and one type of 
inhibitory receptors (KIR3DL, CD158e1) in our research due to 
cell numbers. The activation of CD56+ cells is regulated by 
signal balance between inhibitory receptors and activating 
receptors. We could not present any significant differences 
about KIR expression on cells between groups (Figure 3.3.7). 
In future, other inhibitory or activating receptors, such as 
NKG2D and CD94, could be detected to find out whether they 
play potent roles in CSE suppressed activation. 
 
In summary, this study showed for the first time that, CSE 
markedly suppressed IL-15 induced NKT-like cell activation 
and NK cell activation in healthy volunteers and current 
smokers with COPD. The granzyme B expression was also 
impaired on both cell types. Expression of perforin, Fas-ligand 
and KIR did not vary on CD56+ cells either in response to IL-
15 or co-stimulated CSE, in all groups. Our findings support 
the concept that cigarette smoke extract affects the cytotoxic 
functions of NKT-like and NK cell in COPD patients.  
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3.4 Cytotoxicity of CD8+CD56- T lymphocytes in 
COPD 
 
3.4.1 Introduction 
Cytotoxic T lymphocytes (Tc cells, CD3+CD8+CD56-) express 
the  T cell receptor. The predominant function of Tc cells is 
to kill infected cells via producing cytokines, such as IFN- and 
killing molecules like perforin and granzymes (Henkart, 1985, 
Zagury, 1982). Binding of Fas-ligand presented by Tc cells to 
Fas expressed by target cells can also induce apoptosis of 
infected cells (Nagata and Golstein, 1995). Abundant studies 
have shown abnormalities of Tc cells in COPD, such as in large 
airways sub-epithelium (O'Shaughnessy et al., 1997, Lams et 
al., 2000), peripheral airway (Saetta et al., 1998), 
parenchyma (Saetta et al., 1999), smooth muscle (Baraldo et 
al., 2004), bronchial arteries (Peinado et al., 1999, Saetta et 
al., 1999, Turato et al., 2002), peripheral blood (Urbanowicz 
et al., 2009), sputum samples (Urbanowicz et al., 2010), and 
small airways such as broncheoalveolar lavage (BAL) (Saetta 
et al., 2002, Saetta et al., 2003).  
 
Cell-contact-dependent cytotoxicity is the hallmark of killer 
cell function (Russell and Ley, 2002). Cytotoxic T cells kill their 
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targets by programming them to undergo apoptosis. The 
elimination of infected cells without the destruction of healthy 
tissue requires the cytotoxic mechanisms of CD8+ T cells to be 
both powerful and accurately targeted. Currently, abundant 
studies have investigated the cytotoxicity of killer cells, such 
as NK cells and CD8+ T lymphocytes, from cancer patients 
(Jewett and Tseng, 2013, Levy et al., 2013, Maher and Davies, 
2004). However, studies related to COPD are rare. Our group 
early demonstrated that cytotoxicities of NKT-like cells and NK 
cells were lower in PBMCs but higher in induced sputum from 
COPD patients compared to healthy volunteers (Urbanowicz et 
al., 2009, Urbanowicz et al., 2010). Chrysofakis et al also 
observed increased cytotoxic activity of Tc cells in induced 
sputum of COPD patients (Chrysofakis et al., 2004).  In this 
chapter, we evaluated the cytotoxic activity of blood 
CD8+CD56- T cells against the P815 cell line in four groups 
including healthy non-smokers, current healthy smokers, 
current smokers with COPD and ex-smokers with COPD. 
 
3.4.2 Material and methods 
3.4.2.1 Study population and procedures 
The criteria of participant enrolments are the same as 
previously introduced. There were thirteen participants 
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included in this study. Table 3.4.1 shows the demographic and 
spirometric data of the participants. 
 
3.4.2.2 PBMCs isolation 
PBMCs were isolated from whole blood on a discontinuous 
Histopaque density gradient (Sigma). More details are 
provided in section 2.2. 
 
3.4.2.3 CD8+CD56- T lymphocytes separation 
Isolated PBMCs were incubated with anti-CD56 MicroBeads 
(Miltenyi Biotech Ltd, Surrey, UK) in MACS buffer containing 
sterile D-PBS (Sigma), 1% heat-inactivated fetal calf serum 
(FCS) (QB-Perbio) and 0.4% EDTA (Sigma) for 15 minutes at 
4°C. CD56- cell fractions were obtained by cell suspension 
passing through a cold MS column attached to a magnet. 
Isolated CD56- fractions were washed and counted. To obtain 
CD8+CD56- T lymphocytes, cells were incubated with Multisort 
Release Reagent for 10 minutes at 4°C, washed and then 
incubated with MultiSort Stop Reagent and -CD8 microbeads 
for 15 minutes at 4°C. Finally the labelled cells were separated 
on a refrigerated LS column. Detailed protocol for cell 
separation was shown on manufacturer’s instructions. All 
isolated fractions were washed, counted and purity confirmed 
by flow cytometry (≥90%).  
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Table 3.4.1 Demographic and spirometric valus of the CSE 
suppression study groups 
 
Healthy 
non-smokers 
Current 
healthy 
smokers 
cuS-COPD exS-
COPD 
Participants 4 4 3 2 
Age (years) 55 （50-60） 54 (51-60) 55 (52-58) 
49  
(46-52) 
Gender (M/F) 1/3 2/2 2/1 0/2 
Packs/yrs 0 39 (33-42) 43 (35-47) 
44  
(39-49) 
Smoking 
status 
(Current/Ex) 
0 4/0 3/0 
 
0/2 
Chronic 
bronchitis 
(Yes/No) 
0 3/1 3/0 
 
2/0 
FEV1 (% pred) 
117 
(102-128) 
103 
(92-117) 
52 
(46-60) 
57 
(54-60) 
FEV1/FVC (%) 97 (86-116) 87 (66-106) 49(45-53) 
47 (39-
56) 
∆FEV1 post 
bronch 
2.4 
(1.7-2.9) 
1.8 
(1.5-2.4) 
1.5 
(1.2-1.6) 
1.4 
(1.3-1.6) 
BMI (kg/m2) 
26.6 (22.6-
28.3) 
25.2 (19.7-
29.4) 
20.3 
(15.8-25.1) 
20.1 
(18.7-
21.5) 
Inhaled GCS 
(on/off) 
N/A N/A 0/3 
1/1 
MRC dyspnoea 
scale 
N/A N/A 3 (2-4) 
3 (2-4) 
Distance 
walked in 6 
min (m) 
N/A N/A 
277 
(196-312) 
302 
(218-386) 
 
BODE Index N/A N/A 4 (3-6) 5 (4-7) 
exS-COPD, ex-smokers with COPD; cuS-COPD, current smokers with COPD; 
FEV1, forced expiratory volume in 1 second; pre, predicted value; FVC, 
forced vital capacity; BMI, body mass index; GCS, corticosteroid; MRC, 
medical research council; BODE,  BMI, airflow Obstruction, Dyspnoea 
and Exercise capacity. 
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3.4.2.4 Cell culture 
For cytotoxicity assay, isolated CD8+CD56- T cells were 
incubated for 24 hours at 37°C in 5% CO2. Before cell 
incubation, the plate was coated with 2µg/ml anti-CD3 (in 
50ul D-PBS solution each well) for a minimum of 2 hours at 
37°C in 5% CO2. Target cells (P815 cells) were grown in 
RPMI-1640 medium supplemented with 10% FCS at 37°C in 
5% CO2 and ready for use when they reached confluence. 
 
3.4.2.5 CD8+CD56- T lymphocytes Redirected 
Cytotoxicity Assay 
The cytotoxicity of CD8+CD56- T lymphocyte was measured 
with colorimetric quantification of lactate dehydrogenase LDH 
released from lysed target cells (cell line P815). More details 
are provided in section 2.7. 
 
3.4.2.6 Flow cytometric analysis 
Flow cytometric analysis of antibody labelled cells was 
performed using an EPICS Altra (Beckman Coulter, Luton, UK).  
More details are provided in section 2.9. 
 
3.4.2.7 Statistical analysis  
The statistical analysis was performed with Prism software, 
version 4.0c (GraphPad).  Data were non-normally distributed 
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all are expressed as median and range, unless otherwise 
stated.  Differences between the four groups of participants 
were tested using paramatric student’s t test. Confidence 
interval 99% was selected to show two-tailed p values. P 
values of less than 0.01 were considered to indicate statistical 
significance. 
 
3.4.3 Results 
3.4.3.1 Purity of Tc lymphocytes 
The purity of isolated CD8+CD56- T lymphocytes was 
determined by flow cytometry. Figure 3.4.1.A showed the 
representative dot plots of the proportion of CD3+CD8+CD56- 
T cells in each group, namely, healthy non-smokers (HNS, A i), 
current healthy smokers (HS, A ii), current smokers with 
COPD (cuS-COPD, A iii) and ex-smokers with COPD (exS-
COPD, A iv). The purity of the immunomagnetically selected 
CD3+CD8+ T lymphocytes in isolated CD8+CD56- fractions was 
over 90% (Figure 3.4.1.B). 
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Figure 3.4.1 Purity of immunomagnetically separated 
CD8+CD56- T lymphocytes from the peripheral blood of the 
studied groups.  CD8+CD56- T cells were isolated from PBMCs in four 
groups including health non-smokers (HNS, n=4), current healthy 
smokers (HS, n=4), current smokers with COPD (cuS-COPD, n=3), 
and ex-smokers with COPD (exS-COPD, n=2). (A) Representative dot 
plots of the purified CD3+CD8+CD56- T cells from PBMCs in each 
group, namely, i, NHS; ii, HS; iii, cuS-COPD; iv, exS-COPD. 
Percentage of purity was shown. (B) Purity of immunomagnetically 
separated CD8+CD56- T lymphocytes in each group. 
A 
iii iv 
B 
i ii 
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3.4.3.2 Cytotoxicity of CD8+CD56- T lymphocytes in 
COPD 
To test the cytotoxic activity of the immunomagnetically-
purified CD8+CD56- T cells, a non-radioactive colorimetric 
quantification of LDH released assay was performed (LDH is a 
stable cytosolic enzyme released upon cell lysis). In vitro, we 
compared the killing ability of CD8+CD56- T cells against the 
P815 cell line at different ratios in the four participant groups. 
As shown in Figure 3.4.2, a dose dependent reduction was 
displayed on the cytotoxic ability of CD8+CD56- T cells against 
P815 cells in each group. At ratio 40:1 (Figure 3.4.3.A), the 
cytotoxicity of CD8+CD56- T cells was  significantly less in both 
current smokers with COPD (21.6% ± 2.4%, p<0.005) and 
ex-smokers with COPD (27.57% ± 3.6%, p<0.005) compared 
to healthy non-smokers (63.47% ± 6.6%). The lysis ability of 
CD8+CD56- T cells were also dramatically decreased in 
current smokers with COPD (21.6% ± 2.4%, p<0.005) and 
ex-smokers with COPD (27.57% ±3.6%, p<0.01) compared 
to current healthy smokers (56.81% ± 9.7%) (Figure 3.4.3.A). 
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Figure 3.4.2 Cytotoxic activity of CD8+CD56- T cells towards 
P815 cells in studied groups. CD8+CD56- T cells were isolated from 
PBMCs of four interested groups, namely, health non-smokers (HNS, 
n=4), healthy smokers (HS, n=4), current smokers with COPD (cuS-
COPD, n=3), and ex-smokers with COPD (exS-COPD, n=2). Purified 
CD8+CD56- T cells were incubated with 2ug/ml of anti-CD3 for 24 hours 
before havesting. Cytotoxicity was assessed after 4 hours at the 
indicated effector to target (E:T) ratio. Data are mean ± standard 
deviation of different groups.  
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Figure 3.4.3 Cytotoxic activity of CD8+CD56- T cells against 
P815 cells at the effector to target ratio of 40:1 (panel A) and 
20:1 (panel B).  Cytotoxicity detection for ratios 40:1 and 20:1 was 
performed in the same experiment in each sample. CD8+CD56- T cells 
were immunomagnetically isolated from PBMCs of health non-smokers 
(HNS, n=4), current healthy smokers (HS, n=4), current smokers 
with COPD (cuS-COPD, n=3), and ex-smokers with COPD (exS-COPD, 
n=2). Significant differences were considered as p value<0.05 
(*,p<0.01; **,p<0.005; ***,p<0.001). 
A 
B 
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Similar findings were also observed at ratio 20:1 (Figure 
3.4.3.B). There were remarkable decreases on the cytotoxicity 
of CD8+CD56- T cells from current smokers with COPD (12.1% 
± 1.9%) compared to those from healthy non-smokers 
(34.0% ± 10.0%, p<0.01) and current healthy smokers 
(26.7% ± 5.1%, p<0.005). There were no significant 
differences on the lysis ability of Tc cells between healthy non-
smokers and current healthy smokers at each ratio. 
 
3.4.4 Discussion 
Here we demonstrated that CD8+CD56- T lymphocytes from 
PBMCs showed significantly less cytotoxic activity against 
P815 cells in COPD patents compared to healthy non-smokers 
and healthy smokers. Also, dose dependent reductions were 
exhibited on the cytotoxicity of CD8+CD56- T cells in each 
group. These findings were in accordance with an earlier study 
that showed the cytotoxicity of NK cells and NKT-like cells  
from PMBCs was significantly lower in COPD patients in 
contrast to healthy volunteers (Urbanowicz et al., 2009). 
 
Target-cell death induced by CD8+CD56- T cells can be 
initiated by various signals (Plataki et al., 2006). For example, 
when cytotoxic T cells are mixed with target cells and rapidly 
brought into contact by centrifugation, they can program 
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antigen-specific target cells to die by secretion of preformed 
effector molecules and cytokines, such as perforin, granzymes 
and INF-. K562 cell line was previously selected as the target 
cells in this research. However, no remarkable findings were 
observed between COPD patients and healthly groups. 
Previous studies have shown that K562 cells do not express 
HLA-A, B, C, or HLA-DR on their surface that are recognized 
by CD8+ T cells to induce cell cytotoxicity (Garson et al., 1985, 
Maziarz et al., 1990). Here we used P815 cell line as target 
cells. The lysis ability of CD8+ T cells against P815 cells was 
significantly reduced in COPD groups compared to healthy 
volunteers. This was supported by other studies that showed 
CD56- T cells, which were NKG2D-positive, were not cytotoxic 
against K562 cells (Karimi et al., 2005, Trinchieri, 2003, 
Verneris et al., 2004). NKG2D might account for this reason. 
Besides MHC class I molecule dependant pathway, cytotoxic T 
cells also induce activating signal by MHC-unrestricted and 
TCR-independent pathway (Schmidt-Wolf et al., 1993). 
NKG2D is a representative MHC-unrestricted activation 
receptor expressed by human NK cells, CD8+ T cells and  T 
cells. Multiple studies illustrate that NKG2D ligation leads to 
different functional outcomes on killer cells (Diefenbach et al., 
2000, Groh et al., 2001, Jamieson et al., 2002, Pende et al., 
2001). Groh et al showed that NKG2D augmented cytotoxicity 
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of CD8+ T cells only when cytotoxic T cells and target cells 
were MHC matched (Groh et al., 2001). Another research also 
confirmed that NKG2D-blocking antibodies dramatically 
attenuated the cytolysis of CD8+ T cells in tumor targets 
(Verneris et al., 2004). 
 
DAP10 and DAP12 are two well-identified adapter proteins 
associated with NKG2D in human cytotoxic cells (Rosen et al., 
2004). Studies confirm that NKG2D, together with the DAP10 
and DAP12 molecules, has been shown to play a unique role in 
the mechanism of cytotoxicity of T cells (Karimi et al., 2005, 
Trinchieri, 2003, Verneris et al., 2004). Double knockdown of 
DAP10 and DAP12 reduced much of the killing ability of 
activated CD8+ T cells in PBMCs from healthy volunteers 
(Kakimi et al., 2000). However, DAP10 and DAP12 were 
associated with not only NKG2D receptor but also other 
receptors such as KIRs and CD94-NKG2C receptors (Lanier, 
2009). DAP12-associated KIR has been indentified on the 
subsets of human effector T cells in mice (Feng et al., 2005). 
Defining the DAP12-related KIRs in human are beyond our 
study, however, in future, the relationship between KIRs 
expression and cytotoxicity of killer cells may be another 
prospective study in COPD. Indeed, in an earler section we 
showed that ex vivo expression of KIRs, but not NKG2D, on 
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CD8+ T cells were highly reduced in current smokers with 
COPD (Figure 3.1.8).  
 
The relatively low participant numbers, especially the number 
of ex-smokers with COPD, should be pointed out. We did not 
find out any differences on the cytotoxic ability of CD8+CD56- 
T cells between current smokers with COPD and ex-smokers 
with COPD. However, the significant differences between 
healthy and patient groups could partially explain the finding 
that the cytotoxicity of CD8+ CD56- T cells was disease-related 
rather than smoking per se.  
 
In summary, this study has shown that the cytotoxicity of 
CD8+CD56- T cells was significantly reduced in the peripheral 
blood of COPD subjects (both current and ex) compared to 
healthy non-smokers and healthy current smokers. 
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3.5 Killer cell activation in bronchoalveolar 
lavage fluid from COPD 
 
3.5.1 Introduction 
In the last decade, there have been many studies performed 
on bronchial biopsies, lung parenchyma and peripheral blood 
obtained from COPD patients compared with healthy non-
smokers and smokers with normal lung function. 
Bronchoscopy with bronchoalveolar lavage (BAL) is an 
important research tool for assessing airway inflammation in a 
variety of inflammatory lung diseases. Increased numbers of 
neutrophils (Battaglia et al., 2007), CD1a+ immature DCs 
(Casolaro et al., 1988, Soler et al., 1989), macrophages 
(Barnes, 2004d, Saetta et al., 1993, Saetta et al., 1997, 
Wallace et al., 1992), eosinophils (Saetta et al., 1996, Saetta 
et al., 1994), CD8+ T cells (Saetta et al., 2002, Saetta et al., 
2003), / T cells (Ekberg-Jansson et al., 2000, Pons et al., 
2005) and regulatory T cells (Smyth et al., 2007) were 
detected in the BAL fluid from either current healthy smokers 
or current smokers with COPD. However, the number of iNKT 
cells from BAL was significantly decreased (less than 2% of 
total CD3+ T cells) in subjects with stable or exacerbated 
COPD (Vijayanand et al., 2007). Besides immune cells, 
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abnormal levels of immune molecules were also detected in 
BAL from COPD patients. The concentration of CXCL1 (Traves 
et al., 2002), CXCL5 (Tanino et al., 2002), CCL2 (Capelli et al., 
1999, de Boer et al., 2000, Traves et al., 2002), GM-CSF 
(Balbi et al., 1997), ET-1 (Bacakoglu et al., 2003, Chalmers et 
al., 1999), histamine (Kalenderian et al., 1988) and tryptase 
(Bessa et al., 2008, Kalenderian et al., 1988) were all 
significantly increased in BAL fluid from COPD patients. Levels 
of both IL-4 released by CD8+ T cells and IFN- released by 
CD4+ T cells were also elevated in the BAL fluid from COPD 
patients (Barczyk et al., 2006). Increased xanthine/xanthine 
oxidase activity has been observed in BAL fluid from COPD 
patients (Pinamonti et al., 1998). The expression of perforin 
and granzyme B on CD8+ T cells from BAL fluid were also 
significantly increased in COPD patients and healthy smokers 
compared non-smokers (Hodge et al., 2006).  
 
To date, the study on the killer cell activation from BAL in 
COPD is rare. In this chapter, we aim to examine the 
activation levels of killer cells including CD8+ T cells, NKT-like 
cells and NK cells from BAL in COPD patients. 
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3.5.2 Material and Methods 
3.5.2.1 Study population and procedures 
The criteria of participant enrolments are the same as 
previously introduced. There were only four current smokers 
with COP included in this study. Table 3.5.1 shows the 
demographic and spirometric data of the participants. 
 
3.5.2.2 BAL collection 
Bronchoscopy with BAL was performed by a clinician from the 
Queen’s Medical Centre. More details are provided in Section 
2.8. 
 
 
 
 
Table 3.5.1 Demographic and spirometric valus of the BAL study 
Current 
smokers 
with COPD 
Age 
(years) 
Gender 
(M/F) 
Packs/ 
year 
Chronic 
bronchitis 
(Yes/ 
No) 
n=4 49 
(43-57) 
2/2 41 
(38-46) 
4/0 
 
FEV1 (% pred) FEV1/ 
FVC (%) 
∆FEV1 post 
bronch 
BMI 
(kg/m2) 
61 
(50-72) 
37 
(31-44) 
1.6 
(1.4-1.9) 
19.7 
(16.6-22.5) 
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3.5.2.3 BAL cell collection 
Before centrifugation of BAL fluid, two 50ml centrifuge tubes 
were weighted on an electronic scale. Samples were pipetted 
into the tubes and volumes of them were noted. Filled tubes 
were reweighted and the weight of recovered BAL fluid was 
calculated. More details are provided in Section 2.8. 
 
3.5.2.4 Extracellular staining 
To determine the cell populations in the BAL, extracellular 
staining for these cells were performed as described 
previously. Cells were labeled with fluorescently conjugated 
antibodies including CD3 (PC7), CD8 (ECD) and CD56 (PE) to 
identify the proportion of cell population of interest. CD25 
(FITC) and CD69 (PC5) were also added to detect the 
activation of interested cell types. All samples were analysed 
by flow cytomentry. 
 
3.5.2.5 Flow cytometric analysis 
Flow cytometric analysis of antibody labelled cells was 
performed using an EPICS Altra (Beckman Coulter, Luton, UK).  
More details are provided in Section 2.9. 
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3.5.2.6 Statistical analysis  
The statistical analysis was performed with Prism software, 
version 4.0c (GraphPad). Differences between four cell types 
including CD8+ T cells, CD4+ T cells, NKT cells and NK cells 
from COPD smokers were tested using the parametric 
student’s t test. Confidence interval 99% was used to show 
two-tailed p values. P values of less than 0.01 were 
considered to indicate statistical significance. 
 
3.5.3 Results 
Killer cell activation in BAL from COPD patients ex vivo 
All individuals had similar total mononuclear cell numbers, 
which were within the normal range (data not shown).  
Representative flow analysis dot plots showed Forward Scatter 
(FS) vs Side Scatter (SS) for identification of live and dead 
cells (Figure 3.5.1.A), along with dot plots for identification of 
CD8+ T-lymphocytes (CD3+CD8+), CD4+ T-lymphocytes 
(CD3+CD4+), NKT-like cells (CD3+CD56+), and NK cells (CD3-
CD56+) (Figure 3.5.1.B).  In addition dot plots for CD69 and 
CD25 staining of these four cell types from BAL of a COPD 
patient ar presented in Figure 3.5.2. Cells are designated 
activated when they express one or both of the activation 
markers (i.e., CD69 positive, CD69/CD25 double positive or 
CD25 positive). CD8+ T cells (92.0%, 89.1-97.1; p<0.001),  
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B 
NKT-like 
cells 
NK cells 
Figure 3.5.1 Representative dot plots gating for live/dead cells and 
identification cell populations from current smokers with COPD. (A) 
Forward Scatter (FS) vs Side Scatter (SS) plot for indentification of live 
and dead cells; (B) Indentification of CD8+ T cells (CD3+CD8+), CD4+ T 
cells (CD3+CD4+), NKT-like cells (CD3+CD56+) and NK cells (CD3-CD56+). 
 
A 
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 Figure 3.5.2 Representative dot plots for identification of 
activation of cells of interst from a current smoker with 
COPD. Activation is designated by expressing either CD69 alone 
(lower right quadrant), CD69 and CD25 (upper right quadrant) or 
CD25 alone (upper left quadrant).  
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NKT-like cells (96.5%, 87.7-99.2; p<0.001) and NK cells 
(94.5%, 88.7-97.3; p<0.001) were all highly and significantly 
activated in compared to CD4+ T cells (46.9%, 40.2-68.5) in 
COPD patients (Figure 3.5.3). CD69 and CD25 represent early 
and late activation markers for cell activation respectively. As 
shown in Figure 3.5.4, activated CD8+ T cells and NK cells 
primarily express CD69, whereas the major proportion of 
activated NKT-like cells is CD69 and CD25 double positive. All 
cells analysed expressed low level of CD25. 
 
 
 
 
 
 
Figure 3.5.3 Activation of cells of interest including CD8+ 
T cells (Tc), CD4+ T cells (Th), NKT-like cells and NK cells 
from BAL fluid of current smokers with COPD (n=4). Tc, 
NKT-like and NK cells were all significantly activated compared 
Th cells from BAL of current smokers with COPD (p<0.001). 
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3.5.4 Discussion 
Bronchoscopy with BAL is an important research tool for 
assessing airway inflammation in a variety of inflammatory 
lung diseases. Many studies have shown the abnormal 
numbers of immune cells and molecules from BAL in COPD. 
Here we showed that killer cells including CD8+ T cells, NKT-
like cells and NK cells were all highly activated compared to 
CD4+ T cells from BAL of current smokers with COPD. This 
finding was supported by other studies. CD8+ T-lymphocytes 
from BAL fluid of smokers with or without COPD were 
significantly activated compared to healthy non-smoking 
Figure 3.5.4 Activation stages of cells of interest including 
CD8+ T cells (Tc), CD4+ T cells (Th), NKT-like cells and NK 
cells from BAL fluid of current smokers with COPD (n=4). 
Tc, NKT-like and NK cells were all significantly activated 
compared Th cells from BAL of current smokers with COPD. 
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volunteers (Roos-Engstrand et al., 2009). Also, increased 
proportion of CD8+ T cells expressing CD69 was observed in 
the lung tissue of COPD patients compared to non-smokers 
(Freeman et al., 2010). However, in our study we could not 
conclude that high levels of killer cell activation were disease 
specific due to lack of healthy controls. 
 
CD69 and CD25 represent early and late activation markers 
respectively for cell activation. Interestingly, we found that the 
major proportion of activated NKT-like cells was CD69 and 
CD25 double positive in BAL of current smokers with COPD, 
whereas CD8+ T cells and NK cells mainly express CD69 (early 
activation marker) ex vivo. This finding was partially 
supported by Freeman et al study. They found increased 
proportion of CD8+ T cells expressing CD69 in the lung tissue 
of COPD patients compared to non-smokers (Freeman et al., 
2010). NKT cells, a subset of T lymphocytes but also express 
NK cell surface markers, exhibit both pro-inflammatory and 
immuregulatory characteristics. Cytokines released by NKT 
cells are always rapid and transient, with a peak of activity 
within 24 hours. After 24 hours, productions of these 
cytokines, for example IFN-, quickly return to baseline levels 
(Eberl and MacDonald, 1998). This may explain why NKT cells 
were more quickly activated than CD8+ T cells and NK cells.  
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Here we also showed the activation level of CD4+ T cells was 
lower compared to interested killer cells in COPD patients. This 
is consistant with our findings in PBMCs and sputum that both 
showed low level activation of Th cells in both healthy groups 
and COPD subjects. However, there were no control groups in 
BAL study. In future, we could compare the expression of 
avtivatioin markers of CD69 and CD25 between healthy 
volunteers and patient groups. Also, to identify whether those 
CD4+ T cells were regulatory T cells, FoxP3 staining could be 
applied. 
 
Overactivation of killer cells can induce hypersecretion of 
inflammatory cytokines and chemokines that consequently 
cause other types of cell activation, and finally contribute to 
the lung tissue damage in the COPD patients. Although here 
we could not conclude these highly activated cells were 
disease related because of no control samples, in future, it 
may be worth investigating the killer cells activation and their 
functional receptor expression in BAL fluid from both healthy 
volunteers and COPD patients, which provide new insights on 
the role of killer cells and contributing to a better knowledge 
of the pathogenesis of COPD. 
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Discussion 
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COPD is characterised by poorly reversible airflow obstruction 
and airway inflammation with high morbidity and mortality 
(Celli and MacNee, 2004). As an inflammatory disease, both 
innate and adaptive immune system show abnormal features 
in COPD (O'Shaughnessy et al., 1997, Saetta et al., 1998, 
Baraldo et al., 2004, Barnes, 2004b, Demedts et al., 2007, 
Urbanowicz et al., 2009) that eventually lead to chronic 
obstructive bronchiolitis, emphysema and mucus 
hypersecretion.  
 
Activated neutrophils (Damiano et al., 1986, Galdston et al., 
1977), macropahges (Molet et al., 2005, Montano et al., 
2004), DCs (Demedts et al., 2007) and CD8+ T lymphocytes 
(Roos-Engstrand et al., 2009) have been reported in airways 
or sputum of COPD patients compared to normal non-smokers. 
However, studies on the activation levels of killer cells 
including CD8+ T cells, NKT-like cells and NK cells from PBMCs 
are unexplored. Previous studies also demonstrated the 
potential involvement of the three main classes of human 
killer cells, namely, CD8+ T-lymphocytes, NKT-like cells and 
NK cells in COPD (Paats et al., 2012, Roos-Engstrand et al., 
2009, Roos-Engstrand et al., 2010, Urbanowicz et al., 2009) 
that play key roles in inflammatory responses. 
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Here we showed, ex vivo, for the first time that activation 
phenotype of these cells in the peripheral blood. Activation 
levels CD8+ T-lymphocytes, NKT-like cells and NK cells were 
significantly higher in current smokers with or without COPD in 
comparison with healthy non-smokers and ex-smokers with 
COPD. This finding indicated a systemic influence of smoking 
on killer cell activation, irrespective of the presence of airflow 
limitation. We also found that NK cell activation was positively 
correlated with the number of cigarettes currently smoked in 
COPD patients. No correlations between cell activation and 
lung function (FEV1 percentage of predicted) were found. 
These data indicate that in peripheral blood, cell activation 
levels are more related to current smoking habit rather than 
disease. A previous study examining the effect of smoking 
cessation has shown that CD8+ T-lymphocytes from BAL fluid 
of smokers with or without COPD expressed high levels of 
CD69 and CD25 activation markers (Roos-Engstrand et al., 
2009). Also, an increased proportion of CD8+ T cells 
expressing CD69 was observed in the lung tissue of COPD 
patients compared to non-smokers (Freeman et al., 2010). 
Sputum T-lymphocytes have been shown to express higher 
levels of CD103 and CD69 than blood lymphocytes suggesting 
higher numbers of activated intraepithelial phenotype T-
lymphocytes in the lung of COPD patients (Leckie et al., 2003).  
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Also, in our study, CD4+ T cells expressed very low levels of 
activation markers, namely, CD69 and CD25, in all groups. 
CD25 is also a cell marker for regulatory T cells. Therefore, we 
hypothesised those CD4+CD25+ T cells might mainly be 
regulatory cells rather than activated cells. To examine this 
further we generated Forward Scatter (FS) vs Side Scatter (SS) 
plots that showed, unlike other activated cell types expressing 
CD25 that were larger and more granular, those CD4+CD25+ T 
cells were primarily small and less granular and thus quite 
probably inactivated lymphocytes. However, to confirm this 
observation further studies are required, such as staining for 
FoxP3. Although two studies have found highly activated Th1 
cells in the lung of ex-smokers with COPD and in the smalll 
airway wall of smokers with severe COPD by detecting their 
chemokine and cytokine secretion, those samples are actually 
from COPD patients with emphysema or co-suffering from 
cancer (Turato et al., 2002).  
 
KIR (CD158e1) expression by killer cells was significantly 
lower in peripheral blood of current smokers with or without 
COPD compared to healthy non-smokers. This finding was 
opposite to the activation levels of these killer cells. Signalling 
balance between activating receptors and inhibitory receptors 
is one of the crucial factors determining cell activation. Similar 
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finding was shown in Hodge et al study. CD94 is another 
inhibitory receptor expressed by NKT-like cells and NK cells 
(Lazetic et al., 1996). Decreased expression of CD94 on both 
NKT-like cells and NK cells were detected in PBMCs from COPD 
patients compared to healthy volunteers (Hodge et al., 2012). 
However, they did not detect any significant differences on the 
cell activation levels of NKT-like and NK cells (only CD69 
expression) between groups. Therefore, our findings provided 
the first demonstration of association of cell activation and KIR 
expression.  
 
We also showed that activating receptor NKG2D was highly 
expressed by CD8+ T cells, NKT-like cells and NK cells but not 
CD4+ T cells, which was in accordance with previous studies 
that demonstrate NKG2D receptors are constitutively 
expressed and almost exclusively on cytotoxic cells including 
CD8+ T cells, NKT cells, NK cells and T cells (Maasho et al., 
2005). There were no significant differences of NKG2D 
expression on CD8+ T cells, CD4+ T cells, NKT-like cells and 
NK cells respectively, in the four groups. This further supports 
the proposal of increased peripheral blood killer cell activity in 
smokers due to the increased ratio of activating to inhibitory 
receptors.  
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Of note, our group has published data showing, ex vivo, the 
activation levels of killer cells in sputum samples from COPD 
patients are elevated (Wang et al., 2013). Unlike systemic 
activation, lung activation is due specifically to COPD, 
irrespective of current smoking status. 
 
In this study, activation levels of cells from BAL of COPD 
patients were examined. CD8+ T cells, NKT-like cells and NK 
cells were all highly activated compared to CD4+ T cells in BAL 
fuild from COPD patients ex vivo. This finding was similar to 
those we observed in PBMCs from current smokers with COPD. 
Moreover, CD8+ T cells and NK cells showed early activation 
stage (mainly expressing CD69), whereas the main proportion 
of activated NKT-like cells were CD69 and CD25 double 
positive. However, it was hard to conclude whether it was 
COPD specific due to no control samples from healthy 
participants. This is because the procedure of taking BAL 
samples is indeed very uncomfortable for those volunteers. 
 
Cytotoxicity of CD8+ T cells was also investigated in our study. 
We demonstrated that CD8+CD56- T lymphocytes from PBMCs 
showed significantly less cytotoxic activity against P815 cells 
in COPD patents compared to healthy non-smokers and 
healthy smokers. Also, dose dependent reductions were 
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exhibited on the cytotoxicity of CD8+CD56- T cells in each 
group. This finding was in accordance with previous research 
on lysis ability of CD56+ cells. The cytotoxicity of CD56+ cells, 
including NK cells and NKT-like cells, from PMBCs against 
K562 cell line was significantly lower in COPD patients in 
contrast to healthy volunteers (Urbanowicz et al., 2009).  
 
Of note, K562 cell line was previously selected as target cells 
in this research. However, no remarkable findings were 
observed between COPD patients and health groups. Here we 
used P815 cell line as target cells. Interestingly, the lysis 
ability of CD8+ T cells against P815 cells was significantly 
reduced in COPD groups including both current and ex-
smokers with COPD compared to healthy volunteers. Anti-CD3 
monoclonal antibody induces cytolysis by cross-linking CD3+ 
effector and IgG-FcR+ target cells.  After coating with P815 
cells, anti-CD3 can induce P815 cells bearing the relevant IgG-
FcR and further perform as antigen presenting cells to activate 
CD8+ T cells (van de Griend et al., 1987). Furthermore, other 
studies that showed NKG2D-positive CD56- T cells were not 
cytotoxic against K562 cells (Karimi et al., 2005, Trinchieri, 
2003, Verneris et al., 2004). Besides MHC class I molecule 
dependant pathway, cytotoxic T cells also induce activating 
signal by MHC-unrestricted and TCR-independent pathway 
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(Schmidt-Wolf et al., 1993). Groh et al showed that NKG2D 
augmented cytotoxicity of CD8+ T cells only when cytotoxic T 
cells and target cells were MHC matched (Groh et al., 2001). 
Another research also confirmed that NKG2D-blocking 
antibodies dramatically attenuated the cytolysis of CD8+ T 
cells in tumor targets (Verneris et al., 2004).  
 
We did not find any differences on the cytotoxic ability of 
CD8+CD56- T cells between current smokers with COPD and 
ex-smokers with COPD. However, the significant differences 
between healthy and patient groups could partially reveal the 
finding that the cytotoxic of CD8+ CD56- T cells was disease-
related rather than smoking per se.  
 
Cigarette smoking, as the major risk factor in the 
development of COPD, affects structural and functional 
changes in the respiratory ciliary epithelium (Cantin et al., 
2006, Mio et al., 1997, Wyatt et al., 1999), lung surfactant 
protein (Honda et al., 1996, Subramaniam et al., 1996) and 
immune cells (Mohan, 2002a).  
 
Here we investigate the impact of cigarette smoke extract 
(CSE) on -CD3, IL-2 or IL-15 activated killer cells including 
Tc cells, NKT-like cells and NK cells, and further compared the 
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absolute suppression levels induced by CSE on those cells 
upon different activation between four groups, namely, 
healthy non-smokers, current healthy smokers, current 
smokers with COPD and ex-smokers with COPD. 
 
Optimal concentration of each activator and incubation time 
for cell culture was achieved by a preliminary protocol. Tc cells, 
NKT-like cells and NK cells were all highly activated when the 
concentration of -CD3 increased to 1ug/ml. However, in 
preliminary experiments, dose-dependent increases in the 
activation levels of NK cells were also observed, although NK 
cells do no express CD3/TCR complex on their cell surface. To 
our knowledge, this could be easily explained.  -CD3 has the 
capacity of activating CD4+ T cells, Tc cells and NKT cells that 
further release immune mediators such as IL-2 or IL-15 
(Smyth et al., 2005, Thompson et al., 1989). Furthermore, 
CSE also has effects on DCs and macrophages that also secret 
high amount of IL-15 (Carson et al., 1995, Jonuleit et al., 
1997). Both IL-2 and IL-15 are good sources for NK cell 
activation (Waldmann, 2006).  
 
In our study, activation levels of killer cells were not 
significantly different in the absence or presence of CSE at 
increasing dilutions in healthy volunteers, without other 
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stimulations. These findings were in agreement with other 
groups who detected the CSE effects on DCs or NK cells from 
healthy volunteers (Mian et al., 2009, Mortaz et al., 2009). 
According to previous studies and our detection, we selected 
1% of CSE for further experiments because it did not cause 
any toxic effects as revealed by MMT assay (Mian et al., 2008, 
Mian et al., 2009, Stringer et al., 2007). 
 
The effects of CSE on killer cells were explored not only in 
healthy volunteers but also COPD patients in our study. Three 
significant results should be highlighted. Firstly, CSE markedly 
suppressed activation levels of IL-15 treated cells for all cell 
types in all groups. Secondly, in contrast to Tc cells and NKT 
cells, NK cells were the only cell type which activation levels 
upon different stimulation were all significantly decreased 
when CSE was added in all groups. Thirdly, current smokers 
with COPD were the only group that showed CSE had 
statistically significant effects on all interested cell types 
activation upon different stimulation. All above research were 
carried out in whole PBMCs. These findings were partially 
supported by different studies. Mian and colleague have 
shown that in PBMCs from healthy non-smokers, the 
expression of CD69, a key activation marker for NK cells, was 
significantly inhibited when PBMCs was treated by cigarette 
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smoke after poly I:C activation (Mian et al., 2009). Hogan et 
al demonstrated that CSE significantly reduced the cytokine 
production and the ability to kill target cells of -GalCel 
activated invariant NKT cells in PBMCs from healthy non-
smoking participants. Meanwhile, the activation marker of 
CD107, but not CD69, was decreased (Hogan et al., 2011).   
 
CSE suppression effects on isolated NKT-like cells (CD3+CD56+) 
and NK cells (CD3-CD56+) in response to IL-15 were also 
compared between groups. We found that, in vitro, CSE 
significantly suppresses the activation levels of IL-15 treated 
NKT-like cells and NK cells isolated from PBMCs in healthy 
non-smokers and smokes with or without COPD. However, this 
effect on NK cells was much more significant in cuurent 
smokers with COPD. Previous study has shown that cigarette 
smoke inhibited IL-12 and type-1 IFN production in activated 
PBMCs, which consequently decreased the IL-15 levels in 
healthy non-smokers (Mian et al., 2008, Mian et al., 2009). 
Also, both in vitro and in vivo, cigarette smoke significantly 
diminished IL-15 mRNA levels in poly I:C-activated PBMCs 
from healthy non-smoking participants. IL-15 production was 
markedly impaired in smoke-conditioned medium treated 
PBMCs upon poly I:C simulation.  
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Granzymes, perforin and Fas-Fas ligand are three major killing 
molecules that facilitate NKT-like cells and NK cells performing 
their cytotoxic functions. We found that expression of 
granzyme B on IL-15 treated NKT-like cells and NK cells were 
markedly reduced by CSE in PBMCs from healthy non-smokers. 
Also, CSE significantly suppressed granzyme B expression by 
NK cells in response to IL-15 in current smokers with COPD. 
Surprisingly, CSE did not induce any remarkable impacts on 
expression levels of perforin and Fas-ligand in all groups. 
Perforin was highly expressed in all stimulating conditions 
whereas Fas-L showed very low levels. These findings were 
partially supported by other research. Morissette and 
colleague illustrated that no statistical differences were 
observed on the expression of perforin and granzyme B in 
peripheral NK cells from either healthy volunteers or smokers 
with evidence of emphysema. Protein expression of Fas-ligand 
was not detected by flow cytometry (Morissette et al., 2007). 
The cytotoxicities of NK cells and NKT cells from PBMCs were 
both markedly reduced in COPD patients compared to healthy 
volunteers (Urbanowicz et al., 2009). In vitro, the percentage 
of perforin /granzyme B double positive NK cells was 
significantly lower in COPD patients compared to controls. 
Although there was a markedly increase in soluble Fas in 
plasma from severe COPD patients, there were no differences 
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on its expression in mild or moderate COPD and healthy 
controls (Yasuda et al., 1998). Hodge et al also demonstrated 
that there were no significant changes in the expression levels 
of granzyme A by NK or NKT-like cells in the blood of COPD 
patients compared to controls (Hodge et al., 2013). Taken 
together, our data suggest that granzyme B, but not perforin 
and Fas-ligand, was a functional molecule attributing to the 
significant impairment of NK cell killing ability in response to 
CSE in COPD patients. The action of granzyme B against 
target cells can be either perforin dependent (Bossi and 
Griffiths, 2005, Monks et al., 1998) or perforin-independent 
(Froelich et al., 1996, Metkar et al., 2002, Shi et al., 1997). 
No matter which action is undertaken, granzyme B mediated 
apoptosis is caspase-dependent (Talanian et al., 1997, Yang 
et al., 1998). 
 
We also showed, in vitro, there were no significant differences 
on KIR (CD158e1) expression by CD56+ with or without CSE 
treatment. KIR expression was at a very low level in each 
group. Few studies were carried out to detect the KIRs 
expression in either healthy volunteers or COPD patients. 
However, one study reported that NKG2D expression was not 
inhibited in cigarette smoke treated PBMCs after poly I:C 
induction (Mian et al., 2009). Therefore, KIR (CD158e1) was 
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not a functional inhibitory receptor for CSE induced 
suppression of CD56+ cells activation in response to IL-15. 
 
Although CSE significantly suppressed the isolated CD56+ cell 
activation and their granzyme B expression in IL-15 
conditioned medium in both healthy non-smokers and current 
smokers with COPD, there were no statistical differences on 
the absolute suppression levels between groups, which were 
different from our early findings that showed in un-isolated NK 
CD56+ cells, absolute suppression levels induced by CSE on 
IL-15 mediated NK cell activation was significantly higher in 
current smokers with COPD compared to healthy non-smokers 
and current healthy smokers. Two reasons might be 
accounted for that. Firstly, small sample size was used in this 
study. In figure 3.3.7, the absolute suppreesion level induced 
by CSE on NK cell activation was higher than other two 
healthy groups, although no statistical differences were 
presented. Secondly, IL-15 is a potent cytokine with the ability 
of stimulating many kinds of immune cells, such as memory 
CD4+ T cells, naive or memory CD8+ T cells, DCs, NKT cells 
and NK cells, which can further secrete more cytokines and 
chemokines to induce adaptive immune responses (Anderson 
et al., 1995, Cosman et al., 1995). Therefore, in whole PBMCs 
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sample, IL-15 can further induce other immune response on 
un-isolated CD56+ cells. 
 
It is important to note that cigarette smoke comprises a 
complex mixture of more than 4000 chemicals, such as 
nicotine, carbon monoxide, and tar (Hoffmann and Wynder, 
1986, Stedman, 1968). Their immune-modulation effects on 
immune cells are distinct and also dose-dependent (Holt et al., 
1976). To determine the specific component of cigarette 
smoke that regulates killer cell activation upon different 
stimulation is beyond the scope of our studies.  
 
Several limitations should be considered in the whole project. 
Firstly, in the ex vivo study, there are many kinds of inhibitory 
and activating receptors expressed on killer cells but due to 
limited cell numbers we analyse two representative receptors 
that give an indication of the killing function of these cells.  
Secondly, we could not obtain healthy samples in our BAL 
study. Thirdly, in vitro, only small numbers of subjects were 
recruited. Moreover, there are many cytotoxic granules such 
as granzyme A and granzyme K related to killing mechanisms 
of CD56+ cells. However, proportions of NKT-like cells and NK 
cells are very low in PBMCs. We could just detect 
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representative killing molecules in our research due to cell 
numbers.  
 
In conclusion, five important findings have been illustrated in 
this study. Firstly, we showed for the first time that, ex vivo, 
killer cells, including CD8+ T cells, NKT-like cells and NK cells, 
were significantly activated in current smokers with or without 
COPD compared to healthy non-smokers. Secondly, KIR 
(CD158e1) expression by all killer cell types was dramatically 
lower in smokers with or without COPD in comparison with 
healthy non-smokers. Thirdly, the cytotoxicity of CD8+ T cells 
from COPD patients were significantly less than that in healthy 
volunteers. Forthly, in vitro, CSE markedly decreased IL-15 
treated NK cell activation in current smokers with COPD 
compared to other three groups. Finally, the expression of 
granzyme B, but not perforin and Fas-L, was also significantly 
inhibited on IL-15 stimulated NK cells when CSE was added. 
 
Over activation of killer cells provide more understanding on 
the pathology of COPD development. Abnormal expression of 
KIR also suggests the potential use of KIRs therapy in COPD. 
Less cytotoxicity of CD8+ T cells may explain why lung tissue 
is susceptible to infection in COPD patients. Suppression 
effects induced by CSE on NK cell activation and killing 
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molecule expression indicate that chronic exposure to 
cigarette smoke leads to not only cellular death and damage 
in the airways, but also failure to activate critical intracellular 
signalling mechanisms that initiate protective host defence. 
The consequence is dysfunction of various cell types with 
accompanying predisposition to respiratory infection. 
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Figure 1. Comparison of absolute activation levels of CD8+ T 
cells upon different stimulation in four groups including 
healthy non-smokers (HNS, n=4), current healthy smokers 
(HS, n=4), current smokers with COPD (cuS-COPD, n=4) and 
ex-smokers with COPD (exS-COPD, n=4). PBMCs were 
collected and incubated with different reagents for 48 hours.  
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Figure 2. Comparison of absolute activation levels of NKT-
like cells upon different stimulation in four groups including 
healthy non-smokers (HNS, n=4), current healthy smokers 
(HS, n=4), current smokers with COPD (cuS-COPD, n=4) and 
ex-smokers with COPD (exS-COPD, n=4). PBMCs were 
collected and incubated with different reagents for 48 hours.  
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Figure 3. Comparison of absolute activation levels of NK 
cells upon different stimulation in four groups including 
healthy non-smokers (HNS, n=4), current healthy smokers 
(HS, n=4), current smokers with COPD (cuS-COPD, n=4) and 
ex-smokers with COPD (exS-COPD, n=4). PBMCs were 
collected and incubated with different reagents for 48 hours.  
